

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp255

Request ID: cder_mpl1r_wp255_nsdv_v01

Request Description: In this report we characterized dispensing and administration patterns of 28¹ New Molecular Entities (NMEs) approved from January 1, 2021 to June 30, 2021, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 12.1.2.

Data Source: We distributed this request to 12 Sentinel Data Partners on September 21, 2023. The study period included data from January 1, 2021 to most recent data available. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals initiating any of the 28 NMEs drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.²

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2021 and June 30, 2021, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse³ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request, Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Overview for Request: cder_mpl1r_wp255

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

¹The list of NMEs found on FDA's website includes 27 NMEs that were approved from January through June of 2021 , however this query looked at 28 NMEs. One of the NMEs is co-packaged as cabotegravir and rilpivirine. Cabotegravir was approved on its own in 2021 while rilpivirine was approved on its own in 2011, and thus we separated the NME into two scenarios: 1) cabotegravir on its own, and 2) co-packaged cabotegravir and rilpivirine. Additionally, there were two proprietary drugs approved under the non-proprietary name, pegcetacoplan: 1) Empaveli was approved in May 2021, and 2) Syfovre was approved in 2023. Therefore, this query on NMEs approved in the first half of 2021 will only include Empaveli.

²For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>)

³Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
Table 1a	Aggregated Characteristics of Vericiguat in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1b	Aggregated Characteristics of Cabotegravir and Rilpivirine (co-packaged) in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1c	Aggregated Characteristics of Voclosporin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1d	Aggregated Characteristics of Tepotinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1e	Aggregated Characteristics of Umbralisib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1f	Aggregated Characteristics of Evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1g	Aggregated Characteristics of Trilaciclib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1h	Aggregated Characteristics of Casimersen in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1i	Aggregated Characteristics of Fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1j	Aggregated Characteristics of Melphalan Flufenamide in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1k	Aggregated Characteristics of Tivozanib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1l	Aggregated Characteristics of Ponesimod in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1m	Aggregated Characteristics of Dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1n	Aggregated Characteristics of Viloxazine in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1o	Aggregated Characteristics of Drospirenone and Estetrol in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1p	Aggregated Characteristics of dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1q	Aggregated Characteristics of Loncastuximab Tesirine-lpyl in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1r	Aggregated Characteristics of Serdexmethylphenidate and Dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1s	Aggregated Characteristics of Pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1t	Aggregated Characteristics of Amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1u	Aggregated Characteristics of Piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1v	Aggregated Characteristics of Sotorasib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1w	Aggregated Characteristics of Infigratinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
Table 1x	Aggregated Characteristics of Olanzapine and Samidorphan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table of Contents

Table 1y Aggregated Characteristics of Ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 1z Aggregated Characteristics of Aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 1aa Aggregated Characteristics of Asparaginase Erwinia Chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 1ab Aggregated Characteristics of Cabotegravir in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 2a Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 2b Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 2c Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Table 2d Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Table 2e Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Table 2f Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Table 3a Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 3b Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 3c Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Table 3d Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Table 3e Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Table 3f Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Table 4a Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 4b Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 4c Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Table 4d Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Table 4e Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Table 4f Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Table 5a Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table 5b Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table of Contents

<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Figure 1a</u>	Patient Entry into Study by Month for Vericiguat in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Figure 1b</u>	Patient Entry into Study by Month for Cabotegravir and Rilpivirine (co-packaged) in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Figure 1c</u>	Patient Entry into Study by Month for Voclosporin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Figure 1d</u>	Patient Entry into Study by Month for Tepotinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Figure 1e</u>	Patient Entry into Study by Month for Umbrisib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023
<u>Figure 1f</u>	Patient Entry into Study by Month for Evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Table of Contents

Figure 1g Patient Entry into Study by Month for Trilaciclib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1h Patient Entry into Study by Month for Casimersen in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1i Patient Entry into Study by Month for Fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1j Patient Entry into Study by Month for Melphalan Flufenamide in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1k Patient Entry into Study by Month for Tivozanib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1l Patient Entry into Study by Month for Ponesimod in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1m Patient Entry into Study by Month for Dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1n Patient Entry into Study by Month for Viloxazine in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1o Patient Entry into Study by Month for Drospirenone and Estetrol in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1p Patient Entry into Study by Month for dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1q Patient Entry into Study by Month for Loncastuximab Tesirine-lpyl in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1r Patient Entry into Study by Month for Serdexmethylphenidate and Dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1s Patient Entry into Study by Month for Pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1t Patient Entry into Study by Month for Amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1u Patient Entry into Study by Month for Piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1v Patient Entry into Study by Month for Sotorasib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1w Patient Entry into Study by Month for Infigratinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1x Patient Entry into Study by Month for Olanzapine and Samidorphan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1y Patient Entry into Study by Month for Ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1z Patient Entry into Study by Month for Aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1aa Patient Entry into Study by Month for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Figure 1ab Patient Entry into Study by Month for Cabotegravir in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 21, 2023)

Appendix B List of Proprietary and Non-proprietary Names of Medical Products Used to Define Exposures in this Request

Table of Contents

- Appendix C** List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request
- Appendix D** List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request
- Appendix E** List of Proprietary and Non-proprietary Names of Medical Products Used to Define Characteristics in this Request
- Appendix F** Specifications Defining Parameters for Baseline Characteristics in this Request
- Appendix G** Baseline Characteristics for this Request
- Appendix H** Query Design Diagram for this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Vericiguat in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	3,212	N/A
Demographic Characteristics		
Age (years)	73.7	11.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	607	18.9%
≥ 65 years	2,566	79.9%
Sex		
Female	1,108	34.5%
Male	2,104	65.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	142	4.4%
Black or African American	365	11.4%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	666	20.7%
White	2,027	63.1%
Hispanic origin		
Yes	95	3.0%
No	2,404	74.8%
Unknown	713	22.2%
Year		
2021	897	27.9%
2022	2,224	69.2%
2023	91	2.8%
Health Characteristics		
Acute Myocardial Infarction	275	8.6%
Alzheimer's Disease and related conditions	313	9.7%
Atrial Fibrillation	1,615	50.3%
Diabetes Mellitus	1,682	52.4%
Heart Failure	3,067	95.5%
Hyperlipidemia	2,368	73.7%
Hypertension	2,799	87.1%
Depression	683	21.3%

Table 1a. Aggregated Characteristics of Vericiguat in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	2,566	79.9%
Rheumatoid Arthritis/Osteoarthritis	716	22.3%
Stroke/TIA	226	7.0%
Breast Cancer	87	2.7%
Colorectal Cancer	34	1.1%
Prostate Cancer	138	4.3%
Lung Cancer	53	1.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	682	21.2%
Anemia	1,480	46.1%
Asthma	231	7.2%
Benign Prostatic Hyperplasia	482	15.0%
Chronic Kidney Disease	1,709	53.2%
COPD and Bronchiectasis	883	27.5%
Glaucoma	389	12.1%
Osteoporosis	157	4.9%
Obesity procedures	1,008	31.4%
Obesity NDCs	42	1.3%
Overweight	424	13.2%
Smoking procedures	404	12.6%
Smoking NDCs	15	0.5%
Alcohol Abuse or Dependence	84	2.6%
Drug Abuse or Dependence	128	4.0%
History of Cardiac Arrest	34	1.1%
History of Coronary Angioplasty or Bypass	1,222	38.0%

Table 1a. Aggregated Characteristics of Vericiguat in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.9	15.2
Mean number of emergency room encounters	0.8	1.8
Mean number of inpatient hospital encounters	0.8	1.1
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	9.7	12.9
Mean number of filled prescriptions	33.9	23.9
Mean number of generics dispensed	13.4	5.8
Mean number of unique drug classes dispensed	12.4	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1b. Aggregated Characteristics of Cabotegravir and Rilpivirine (co-packaged) in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,910	N/A
Demographic Characteristics		
Age (years)	55.2	11.8
Age		
0-17 years	0	0.0%
18-24 years	16	0.8%
25-40 years	274	14.3%
41-64 years	1,145	59.9%
≥ 65 years	475	24.9%
Sex		
Female	454	23.8%
Male	1,456	76.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	644	33.7%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	447	23.4%
White	797	41.7%
Hispanic origin		
Yes	116	6.1%
No	1,347	70.5%
Unknown	447	23.4%
Year		
2021	391	20.5%
2022	1,436	75.2%
2023	83	4.3%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	25	1.3%
Atrial Fibrillation	50	2.6%
Diabetes Mellitus	338	17.7%
Heart Failure	136	7.1%
Hyperlipidemia	664	34.8%
Hypertension	741	38.8%
Depression	681	35.7%

Table 1b. Aggregated Characteristics of Cabotegravir and Rilpivirine (co-packaged) in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	248	13.0%
Rheumatoid Arthritis/Osteoarthritis	264	13.8%
Stroke/TIA	27	1.4%
Breast Cancer	*****	*****
Colorectal Cancer	21	1.1%
Prostate Cancer	29	1.5%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	91	4.8%
Anemia	331	17.3%
Asthma	124	6.5%
Benign Prostatic Hyperplasia	129	6.8%
Chronic Kidney Disease	304	15.9%
COPD and Bronchiectasis	170	8.9%
Glaucoma	116	6.1%
Osteoporosis	52	2.7%
Obesity procedures	395	20.7%
Obesity NDCs	18	0.9%
Overweight	189	9.9%
Smoking procedures	357	18.7%
Smoking NDCs	41	2.1%
Alcohol Abuse or Dependence	109	5.7%
Drug Abuse or Dependence	277	14.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	60	3.1%

Table 1b. Aggregated Characteristics of Cabotegravir and Rilpivirine (co-packaged) in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.2	16.9
Mean number of emergency room encounters	0.5	1.4
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.0	6.4
Mean number of filled prescriptions	29.7	24.2
Mean number of generics dispensed	9.4	6.0
Mean number of unique drug classes dispensed	8.6	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1c. Aggregated Characteristics of Voclosporin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	324	N/A
Demographic Characteristics		
Age (years)	40.9	12.5
Age		
0-17 years	*****	*****
18-24 years	34	10.5%
25-40 years	140	43.2%
41-64 years	134	41.4%
≥ 65 years	*****	*****
Sex		
Female	261	80.6%
Male	63	19.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	67	20.7%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	190	58.6%
White	54	16.7%
Hispanic origin		
Yes	22	6.8%
No	108	33.3%
Unknown	194	59.9%
Year		
2021	128	39.5%
2022	173	53.4%
2023	23	7.1%

Table 1c. Aggregated Characteristics of Voclosporin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer’s Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	32	9.9%
Heart Failure	44	13.6%
Hyperlipidemia	87	26.9%
Hypertension	192	59.3%
Depression	67	20.7%
Ischemic Heart Disease	38	11.7%
Rheumatoid Arthritis/Osteoarthritis	62	19.1%
Stroke/TIA	15	4.6%
Breast Cancer	0	0.0%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	35	10.8%
Anemia	176	54.3%
Asthma	14	4.3%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	293	90.4%
COPD and Bronchiectasis	13	4.0%
Glaucoma	16	4.9%
Osteoporosis	*****	*****
Obesity procedures	79	24.4%
Obesity NDCs	*****	*****
Overweight	38	11.7%
Smoking procedures	24	7.4%
Smoking NDCs	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	12	3.7%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.4	10.6

Table 1c. Aggregated Characteristics of Voclosporin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	1.5
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.4	14.4
Mean number of filled prescriptions	24.4	17.3
Mean number of generics dispensed	10.0	5.9
Mean number of unique drug classes dispensed	9.5	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1d. Aggregated Characteristics of Tepotinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	141	N/A
Demographic Characteristics		
Age (years)	74.8	9.3
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	125	88.7%
Sex		
Female	92	65.2%
Male	49	34.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	43	30.5%
White	77	54.6%
Hispanic origin		
Yes	0	0.0%
No	92	65.2%
Unknown	49	34.8%
Year		
2021	*****	*****
2022	81	57.4%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	16	11.3%
Diabetes Mellitus	24	17.0%
Heart Failure	24	17.0%
Hyperlipidemia	65	46.1%
Hypertension	90	63.8%
Depression	27	19.1%

Table 1d. Aggregated Characteristics of Tepotinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	48	34.0%
Rheumatoid Arthritis/Osteoarthritis	30	21.3%
Stroke/TIA	*****	*****
Breast Cancer	17	12.1%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	139	98.6%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	19	13.5%
Anemia	63	44.7%
Asthma	*****	*****
Benign Prostatic Hyperplasia	16	11.3%
Chronic Kidney Disease	32	22.7%
COPD and Bronchiectasis	25	17.7%
Glaucoma	14	9.9%
Osteoporosis	19	13.5%
Obesity procedures	15	10.6%
Obesity NDCs	0	0.0%
Overweight	16	11.3%
Smoking procedures	14	9.9%
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1d. Aggregated Characteristics of Tepotinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.7	13.2
Mean number of emergency room encounters	0.5	0.9
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	10.5	11.5
Mean number of filled prescriptions	23.6	12.5
Mean number of generics dispensed	10.7	5.3
Mean number of unique drug classes dispensed	9.8	4.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1e. Aggregated Characteristics of Umbralisib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	76	N/A
Demographic Characteristics		
Age (years)	74.8	8.2
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	36	47.4%
Male	40	52.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	62	81.6%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	49	64.5%
2022	27	35.5%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	12	15.8%
Heart Failure	*****	*****
Hyperlipidemia	25	32.9%
Hypertension	35	46.1%
Depression	17	22.4%

Table 1e. Aggregated Characteristics of Umbralisib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	16	21.1%
Rheumatoid Arthritis/Osteoarthritis	11	14.5%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	46	60.5%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	22	28.9%
COPD and Bronchiectasis	11	14.5%
Glaucoma	12	15.8%
Osteoporosis	*****	*****
Obesity procedures	*****	*****
Obesity NDCs	0	0.0%
Overweight	*****	*****
Smoking procedures	*****	*****
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1e. Aggregated Characteristics of Umbralisib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.3	17.4
Mean number of emergency room encounters	0.5	0.9
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	11.1	12.9
Mean number of filled prescriptions	20.5	12.0
Mean number of generics dispensed	9.7	5.3
Mean number of unique drug classes dispensed	9.0	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1f. Aggregated Characteristics of Evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	49	N/A
Demographic Characteristics		
Age (years)	56.9	12.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	22	44.9%
≥ 65 years	*****	*****
Sex		
Female	37	75.5%
Male	12	24.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	24	49.0%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	23	46.9%
Unknown	*****	*****
Year		
2021	23	46.9%
2022	26	53.1%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	11	22.4%
Hyperlipidemia	48	98.0%
Hypertension	21	42.9%
Depression	*****	*****

Table 1f. Aggregated Characteristics of Evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	38	77.6%
Rheumatoid Arthritis/Osteoarthritis	12	24.5%
Stroke/TIA	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity procedures	14	28.6%
Obesity NDCs	0	0.0%
Overweight	*****	*****
Smoking procedures	*****	*****
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	18	36.7%

Table 1f. Aggregated Characteristics of Evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.1	12.8
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.3	5.9
Mean number of filled prescriptions	23.1	21.1
Mean number of generics dispensed	9.2	6.2
Mean number of unique drug classes dispensed	8.8	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1g. Aggregated Characteristics of Trilaciclib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

*****Data are not presented in this table due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Table 1h. Aggregated Characteristics of Casimersen in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	30	N/A
Demographic Characteristics		
Age (years)	16.9	7.2
Age		
0-17 years	18	60.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	0	0.0%
Male	30	100.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	19	63.3%
2022	11	36.7%
2023	0	0.0%

Table 1h. Aggregated Characteristics of Casimersen in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer’s Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	12	40.0%
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity procedures	*****	*****
Obesity NDCs	0	0.0%
Overweight	*****	*****
Smoking procedures	0	0.0%
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.6	13.3

Table 1h. Aggregated Characteristics of Casimersen in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.2	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	16.9	34.4
Mean number of filled prescriptions	14.5	16.1
Mean number of generics dispensed	4.6	4.4
Mean number of unique drug classes dispensed	4.2	3.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1i. Aggregated Characteristics of Fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2021	.	.
2022	.	.
2023	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

Table 1i. Aggregated Characteristics of Fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity procedures	.	.
Obesity NDCs	.	.
Overweight	.	.
Smoking procedures	.	.
Smoking NDCs	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.

Table 1i. Aggregated Characteristics of Fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Data presented by a dash or period is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

Table 1j. Aggregated Characteristics of Melphalan Flufenamide in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	87	N/A
Demographic Characteristics		
Age (years)	73.3	6.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	45	51.7%
Male	42	48.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	11	12.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	*****	*****
White	64	73.6%
Hispanic origin		
Yes	*****	*****
No	71	81.6%
Unknown	*****	*****
Year		
2021	87	100.0%
2022	0	0.0%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	16	18.4%
Diabetes Mellitus	23	26.4%
Heart Failure	27	31.0%
Hyperlipidemia	36	41.4%
Hypertension	53	60.9%
Depression	12	13.8%

Table 1j. Aggregated Characteristics of Melphalan Flufenamide in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	24	27.6%
Rheumatoid Arthritis/Osteoarthritis	21	24.1%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	16	18.4%
Anemia	63	72.4%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	29	33.3%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity procedures	14	16.1%
Obesity NDCs	0	0.0%
Overweight	17	19.5%
Smoking procedures	*****	*****
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1j. Aggregated Characteristics of Melphalan Flufenamide in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	39.4	19.1
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.6	1.1
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	13.1	17.5
Mean number of filled prescriptions	28.4	16.8
Mean number of generics dispensed	12.7	5.1
Mean number of unique drug classes dispensed	11.8	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1k. Aggregated Characteristics of Tivozanib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	632	N/A
Demographic Characteristics		
Age (years)	69.9	8.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	490	77.5%
Sex		
Female	162	25.6%
Male	470	74.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	23	3.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	126	19.9%
White	470	74.4%
Hispanic origin		
Yes	16	2.5%
No	488	77.2%
Unknown	128	20.3%
Year		
2021	233	36.9%
2022	382	60.4%
2023	17	2.7%
Health Characteristics		
Acute Myocardial Infarction	13	2.1%
Alzheimer's Disease and related conditions	17	2.7%
Atrial Fibrillation	87	13.8%
Diabetes Mellitus	182	28.8%
Heart Failure	98	15.5%
Hyperlipidemia	271	42.9%
Hypertension	476	75.3%
Depression	143	22.6%

Table 1k. Aggregated Characteristics of Tivozanib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	187	29.6%
Rheumatoid Arthritis/Osteoarthritis	120	19.0%
Stroke/TIA	30	4.7%
Breast Cancer	12	1.9%
Colorectal Cancer	*****	*****
Prostate Cancer	28	4.4%
Lung Cancer	57	9.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	318	50.3%
Anemia	353	55.9%
Asthma	30	4.7%
Benign Prostatic Hyperplasia	80	12.7%
Chronic Kidney Disease	624	98.7%
COPD and Bronchiectasis	68	10.8%
Glaucoma	42	6.6%
Osteoporosis	18	2.8%
Obesity procedures	112	17.7%
Obesity NDCs	*****	*****
Overweight	70	11.1%
Smoking procedures	49	7.8%
Smoking NDCs	*****	*****
Alcohol Abuse or Dependence	11	1.7%
Drug Abuse or Dependence	31	4.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	62	9.8%

Table 1k. Aggregated Characteristics of Tivozanib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.6	15.5
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.6	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.6	11.2
Mean number of filled prescriptions	29.4	18.4
Mean number of generics dispensed	12.2	5.6
Mean number of unique drug classes dispensed	11.2	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1I. Aggregated Characteristics of Ponesimod in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	106	N/A
Demographic Characteristics		
Age (years)	49.8	10.4
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	26	24.5%
41-64 years	66	62.3%
≥ 65 years	*****	*****
Sex		
Female	83	78.3%
Male	23	21.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	63	59.4%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	68	64.2%
Year		
2021	27	25.5%
2022	68	64.2%
2023	11	10.4%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	19	17.9%
Hypertension	23	21.7%
Depression	32	30.2%

Table 1I. Aggregated Characteristics of Ponesimod in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	13	12.3%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	13	12.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity procedures	22	20.8%
Obesity NDCs	*****	*****
Overweight	*****	*****
Smoking procedures	*****	*****
Smoking NDCs	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1I. Aggregated Characteristics of Ponesimod in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.8	8.9
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.2	7.5
Mean number of filled prescriptions	15.2	17.2
Mean number of generics dispensed	6.4	4.7
Mean number of unique drug classes dispensed	6.1	4.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1m. Aggregated Characteristics of Dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	736	N/A
Demographic Characteristics		
Age (years)	43.3	17.3
Age		
0-17 years	108	14.7%
18-24 years	75	10.2%
25-40 years	149	20.2%
41-64 years	288	39.1%
≥ 65 years	116	15.8%
Sex		
Female	379	51.5%
Male	357	48.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	605	82.2%
White	112	15.2%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	609	82.7%
Year		
2021	121	16.4%
2022	595	80.8%
2023	20	2.7%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	12	1.6%
Atrial Fibrillation	25	3.4%
Diabetes Mellitus	666	90.5%
Heart Failure	51	6.9%
Hyperlipidemia	273	37.1%
Hypertension	247	33.6%
Depression	133	18.1%

Table 1m. Aggregated Characteristics of Dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	100	13.6%
Rheumatoid Arthritis/Osteoarthritis	69	9.4%
Stroke/TIA	20	2.7%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	110	14.9%
Anemia	105	14.3%
Asthma	25	3.4%
Benign Prostatic Hyperplasia	18	2.4%
Chronic Kidney Disease	150	20.4%
COPD and Bronchiectasis	17	2.3%
Glaucoma	35	4.8%
Osteoporosis	15	2.0%
Obesity procedures	174	23.6%
Obesity NDCs	*****	*****
Overweight	80	10.9%
Smoking procedures	37	5.0%
Smoking NDCs	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	15	2.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	38	5.2%

Table 1m. Aggregated Characteristics of Dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.4	16.4
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.5	8.3
Mean number of filled prescriptions	19.4	20.6
Mean number of generics dispensed	7.7	6.0
Mean number of unique drug classes dispensed	6.7	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1n. Aggregated Characteristics of Viloxazine in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	7,859	N/A
Demographic Characteristics		
Age (years)	20.9	13.4
Age		
0-17 years	4,952	63.0%
18-24 years	807	10.3%
25-40 years	1,119	14.2%
41-64 years	881	11.2%
≥ 65 years	100	1.3%
Sex		
Female	3,394	43.2%
Male	4,465	56.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	60	0.8%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	6,408	81.5%
White	1,339	17.0%
Hispanic origin		
Yes	72	0.9%
No	428	5.4%
Unknown	7,359	93.6%
Year		
2021	1,176	15.0%
2022	5,293	67.3%
2023	1,390	17.7%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	21	0.3%
Atrial Fibrillation	18	0.2%
Diabetes Mellitus	158	2.0%
Heart Failure	42	0.5%
Hyperlipidemia	288	3.7%
Hypertension	334	4.2%
Depression	2,627	33.4%

Table 1n. Aggregated Characteristics of Viloxazine in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	66	0.8%
Rheumatoid Arthritis/Osteoarthritis	178	2.3%
Stroke/TIA	11	0.1%
Breast Cancer	12	0.2%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	161	2.0%
Anemia	236	3.0%
Asthma	230	2.9%
Benign Prostatic Hyperplasia	19	0.2%
Chronic Kidney Disease	63	0.8%
COPD and Bronchiectasis	57	0.7%
Glaucoma	50	0.6%
Osteoporosis	19	0.2%
Obesity procedures	580	7.4%
Obesity NDCs	25	0.3%
Overweight	216	2.7%
Smoking procedures	288	3.7%
Smoking NDCs	44	0.6%
Alcohol Abuse or Dependence	184	2.3%
Drug Abuse or Dependence	400	5.1%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	14	0.2%

Table 1n. Aggregated Characteristics of Viloxazine in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.8	13.3
Mean number of emergency room encounters	0.2	0.8
Mean number of inpatient hospital encounters encounters	0.0 0.0	0.3 0.2
Mean number of other ambulatory encounters	2.2	6.1
Mean number of filled prescriptions	11.0	12.0
Mean number of generics dispensed	4.2	4.0
Mean number of unique drug classes dispensed	4.0	3.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Aggregated Characteristics of Drospirenone and Estetrol in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	3,472	N/A
Demographic Characteristics		
Age (years)	28.9	9.8
Age		
0-17 years	*****	*****
18-24 years	1,125	32.4%
25-40 years	1,463	42.1%
41-64 years	481	13.9%
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	62	1.8%
Black or African American	*****	*****
Islander	*****	*****
Unknown	2,930	84.4%
White	430	12.4%
Hispanic origin		
Yes	101	2.9%
No	21	0.6%
Unknown	3,350	96.5%
Year		
2021	361	10.4%
2022	2,502	72.1%
2023	609	17.5%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
conditions	*****	*****
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	33	1.0%
Heart Failure	0	0.0%
Hyperlipidemia	62	1.8%
Hypertension	55	1.6%
Depression	526	15.1%

Table 1o. Aggregated Characteristics of Drospirenone and Estetrol in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	45	1.3%
Stroke/TIA	*****	*****
Breast Cancer	12	0.3%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	90	2.6%
Anemia	228	6.6%
Asthma	79	2.3%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	11	0.3%
COPD and Bronchiectasis	*****	*****
Glaucoma	28	0.8%
Osteoporosis	*****	*****
Obesity procedures	316	9.1%
Obesity NDCs	17	0.5%
Overweight	171	4.9%
Smoking procedures	41	1.2%
Smoking NDCs	*****	*****
Alcohol Abuse or Dependence	23	0.7%
Drug Abuse or Dependence	31	0.9%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1o. Aggregated Characteristics of Drospirenone and Estetrol in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.1	8.9
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	1.6	3.1
Mean number of filled prescriptions	6.2	7.5
Mean number of generics dispensed	3.2	3.2
Mean number of unique drug classes dispensed	3.1	3.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1p. Aggregated Characteristics of dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	99	N/A
Demographic Characteristics		
Age (years)	68.9	9.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	73	73.7%
Sex		
Female	69	69.7%
Male	30	30.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	27	27.3%
White	58	58.6%
Hispanic origin		
Yes	*****	*****
No	62	62.6%
Unknown	*****	*****
Year		
2021	*****	*****
2022	78	78.8%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	23	23.2%
Heart Failure	*****	*****
Hyperlipidemia	39	39.4%
Hypertension	56	56.6%
Depression	19	19.2%

Table 1p. Aggregated Characteristics of dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	21	21.2%
Rheumatoid Arthritis/Osteoarthritis	18	18.2%
Stroke/TIA	*****	*****
Breast Cancer	11	11.1%
Colorectal Cancer	39	39.4%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	50	50.5%
Acquired Hypothyroidism	13	13.1%
Anemia	52	52.5%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	24	24.2%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity procedures	22	22.2%
Obesity NDCs	0	0.0%
Overweight	11	11.1%
Smoking procedures	*****	*****
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****

Table 1p. Aggregated Characteristics of dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.4	13.5
Mean number of emergency room encounters	0.6	1.0
Mean number of inpatient hospital encounters	0.5	0.8
encounters	0.1	0.2
Mean number of other ambulatory encounters	7.5	7.5
Mean number of filled prescriptions	16.2	13.1
Mean number of generics dispensed	7.9	5.0
Mean number of unique drug classes dispensed	7.3	4.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1q. Aggregated Characteristics of Loncastuximab Tesirine-Ipyl in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	338	N/A
Demographic Characteristics		
Age (years)	75.2	10.3
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	299	88.5%
Sex		
Female	135	39.9%
Male	203	60.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	60	17.8%
White	255	75.4%
Hispanic origin		
Yes	*****	*****
No	253	74.9%
Unknown	*****	*****
Year		
2021	*****	*****
2022	264	78.1%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	19	5.6%
Atrial Fibrillation	87	25.7%
Diabetes Mellitus	83	24.6%
Heart Failure	80	23.7%
Hyperlipidemia	154	45.6%
Hypertension	205	60.7%
Depression	71	21.0%

Table 1q. Aggregated Characteristics of Loncastuximab Tesirine-Ipyl in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	120	35.5%
Rheumatoid Arthritis/Osteoarthritis	57	16.9%
Stroke/TIA	13	3.8%
Breast Cancer	13	3.8%
Colorectal Cancer	*****	*****
Prostate Cancer	23	6.8%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	59	17.5%
Anemia	246	72.8%
Asthma	27	8.0%
Benign Prostatic Hyperplasia	43	12.7%
Chronic Kidney Disease	120	35.5%
COPD and Bronchiectasis	48	14.2%
Glaucoma	27	8.0%
Osteoporosis	21	6.2%
Obesity procedures	53	15.7%
Obesity NDCs	0	0.0%
Overweight	26	7.7%
Smoking procedures	18	5.3%
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	12	3.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	42	12.4%

Table 1q. Aggregated Characteristics of Loncastuximab Tesirine-Ipyl in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	35.1	16.9
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	1.1	1.5
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	12.9	14.3
Mean number of filled prescriptions	25.7	16.7
Mean number of generics dispensed	12.2	6.3
Mean number of unique drug classes dispensed	11.2	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1r. Aggregated Characteristics of Serdexmethylphenidate and Dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	5,031	N/A
Demographic Characteristics		
Age (years)	22.6	14.2
Age		
0-17 years	2,839	56.4%
18-24 years	561	11.2%
25-40 years	896	17.8%
41-64 years	697	13.9%
≥ 65 years	38	0.8%
Sex		
Female	2,260	44.9%
Male	2,771	55.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	34	0.7%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	4,154	82.6%
White	818	16.3%
Hispanic origin		
Yes	56	1.1%
No	80	1.6%
Unknown	4,895	97.3%
Year		
2021	174	3.5%
2022	3,186	63.3%
2023	1,671	33.2%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	77	1.5%
Heart Failure	*****	*****
Hyperlipidemia	144	2.9%
Hypertension	147	2.9%
Depression	1,404	27.9%

Table 1r. Aggregated Characteristics of Serdexmethylphenidate and Dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	27	0.5%
Rheumatoid Arthritis/Osteoarthritis	77	1.5%
Stroke/TIA	*****	*****
Breast Cancer	11	0.2%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	82	1.6%
Anemia	122	2.4%
Asthma	104	2.1%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	30	0.6%
COPD and Bronchiectasis	*****	*****
Glaucoma	31	0.6%
Osteoporosis	*****	*****
Obesity procedures	331	6.6%
Obesity NDCs	23	0.5%
Overweight	134	2.7%
Smoking procedures	75	1.5%
Smoking NDCs	15	0.3%
Alcohol Abuse or Dependence	73	1.5%
Drug Abuse or Dependence	94	1.9%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1r. Aggregated Characteristics of Serdexmethylphenidate and Dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.5	10.3
Mean number of emergency room encounters	0.1	0.4
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.5	4.2
Mean number of filled prescriptions	10.1	10.4
Mean number of generics dispensed	3.9	3.6
Mean number of unique drug classes dispensed	3.8	3.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1s. Aggregated Characteristics of Pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	65	N/A
Demographic Characteristics		
Age (years)	57.0	14.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	24	36.9%
≥ 65 years	26	40.0%
Sex		
Female	31	47.7%
Male	34	52.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	33	50.8%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	31	47.7%
Unknown	34	52.3%
Year		
2021	33	50.8%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	11	16.9%
Hypertension	17	26.2%
Depression	18	27.7%

Table 1s. Aggregated Characteristics of Pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	65	100.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	12	18.5%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity procedures	*****	*****
Obesity NDCs	0	0.0%
Overweight	*****	*****
Smoking procedures	*****	*****
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1s. Aggregated Characteristics of Pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	24.9	20.4
Mean number of emergency room encounters	0.5	1.0
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	6.4	10.0
Mean number of filled prescriptions	14.2	14.3
Mean number of generics dispensed	5.8	4.3
Mean number of unique drug classes dispensed	5.5	4.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1t. Aggregated Characteristics of Amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	303	N/A
Demographic Characteristics		
Age (years)	70.4	8.4
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	243	80.2%
Sex		
Female	213	70.3%
Male	90	29.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	26	8.6%
Black or African American	12	4.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	87	28.7%
White	178	58.7%
Hispanic origin		
Yes	*****	*****
No	199	65.7%
Unknown	*****	*****
Year		
2021	*****	*****
2022	221	72.9%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	27	8.9%
Diabetes Mellitus	52	17.2%
Heart Failure	32	10.6%
Hyperlipidemia	98	32.3%
Hypertension	145	47.9%
Depression	72	23.8%

Table 1t. Aggregated Characteristics of Amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	53	17.5%
Rheumatoid Arthritis/Osteoarthritis	51	16.8%
Stroke/TIA	23	7.6%
Breast Cancer	18	5.9%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	288	95.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	53	17.5%
Anemia	136	44.9%
Asthma	21	6.9%
Benign Prostatic Hyperplasia	14	4.6%
Chronic Kidney Disease	71	23.4%
COPD and Bronchiectasis	37	12.2%
Glaucoma	29	9.6%
Osteoporosis	25	8.3%
Obesity procedures	32	10.6%
Obesity NDCs	0	0.0%
Overweight	34	11.2%
Smoking procedures	14	4.6%
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****

Table 1t. Aggregated Characteristics of Amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	30.3	13.1
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.8	9.8
Mean number of filled prescriptions	20.7	17.3
Mean number of generics dispensed	9.7	5.6
Mean number of unique drug classes dispensed	9.0	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1u. Aggregated Characteristics of Piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	43,225	N/A
Demographic Characteristics		
Age (years)	74.3	7.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	40,000	92.5%
Sex		
Female	73	0.2%
Male	43,152	99.8%
Race ²		
American Indian or Alaska Native	49	0.1%
Asian	473	1.1%
Black or African American	3,814	8.8%
Native Hawaiian or Other Pacific Islander	79	0.2%
Unknown	8,343	19.3%
White	30,467	70.5%
Hispanic origin		
Yes	361	0.8%
No	31,800	73.6%
Unknown	11,064	25.6%
Year		
2021	0	0.0%
2022	40,586	93.9%
2023	2,639	6.1%
Health Characteristics		
Acute Myocardial Infarction	207	0.5%
Alzheimer's Disease and related conditions	1,171	2.7%
Atrial Fibrillation	4,708	10.9%
Diabetes Mellitus	9,242	21.4%
Heart Failure	3,873	9.0%
Hyperlipidemia	18,180	42.1%
Hypertension	21,963	50.8%
Depression	4,296	9.9%

Table 1u. Aggregated Characteristics of Piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	11,311	26.2%
Rheumatoid Arthritis/Osteoarthritis	6,269	14.5%
Stroke/TIA	904	2.1%
Breast Cancer	1,356	3.1%
Colorectal Cancer	521	1.2%
Prostate Cancer	39,698	91.8%
Lung Cancer	381	0.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	2,832	6.6%
Anemia	8,904	20.6%
Asthma	1,005	2.3%
Benign Prostatic Hyperplasia	8,753	20.2%
Chronic Kidney Disease	6,762	15.6%
COPD and Bronchiectasis	2,424	5.6%
Glaucoma	5,309	12.3%
Osteoporosis	961	2.2%
Obesity procedures	7,653	17.7%
Obesity NDCs	129	0.3%
Overweight	4,745	11.0%
Smoking procedures	2,550	5.9%
Smoking NDCs	80	0.2%
Alcohol Abuse or Dependence	841	1.9%
Drug Abuse or Dependence	654	1.5%
History of Cardiac Arrest	57	0.1%
History of Coronary Angioplasty or Bypass	3,438	8.0%

Table 1u. Aggregated Characteristics of Piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.2	11.9
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.6	5.4
Mean number of filled prescriptions	12.5	11.0
Mean number of generics dispensed	6.1	4.2
Mean number of unique drug classes dispensed	5.8	3.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1v. Aggregated Characteristics of Sotorasib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,296	N/A
Demographic Characteristics		
Age (years)	71.3	8.3
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,013	78.2%
Sex		
Female	790	61.0%
Male	506	39.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	107	8.3%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	254	19.6%
White	919	70.9%
Hispanic origin		
Yes	11	0.8%
No	973	75.1%
Unknown	312	24.1%
Year		
2021	506	39.0%
2022	753	58.1%
2023	37	2.9%
Health Characteristics		
Acute Myocardial Infarction	26	2.0%
Alzheimer's Disease and related conditions	64	4.9%
Atrial Fibrillation	181	14.0%
Diabetes Mellitus	289	22.3%
Heart Failure	223	17.2%
Hyperlipidemia	610	47.1%
Hypertension	785	60.6%
Depression	359	27.7%

Table 1v. Aggregated Characteristics of Sotorasib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	445	34.3%
Rheumatoid Arthritis/Osteoarthritis	286	22.1%
Stroke/TIA	83	6.4%
Breast Cancer	90	6.9%
Colorectal Cancer	78	6.0%
Prostate Cancer	59	4.6%
Lung Cancer	1,232	95.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	299	23.1%
Anemia	691	53.3%
Asthma	55	4.2%
Benign Prostatic Hyperplasia	94	7.3%
Chronic Kidney Disease	326	25.2%
COPD and Bronchiectasis	553	42.7%
Glaucoma	95	7.3%
Osteoporosis	91	7.0%
Obesity procedures	219	16.9%
Obesity NDCs	*****	*****
Overweight	147	11.3%
Smoking procedures	351	27.1%
Smoking NDCs	29	2.2%
Alcohol Abuse or Dependence	52	4.0%
Drug Abuse or Dependence	74	5.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	113	8.7%

Table 1v. Aggregated Characteristics of Sotorasib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.1	13.1
Mean number of emergency room encounters	0.8	1.6
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.3	11.4
Mean number of filled prescriptions	26.0	17.7
Mean number of generics dispensed	11.7	6.1
Mean number of unique drug classes dispensed	10.6	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1w. Aggregated Characteristics of Infigratinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	32	N/A
Demographic Characteristics		
Age (years)	66.2	13.2
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	19	59.4%
Male	13	40.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	11	34.4%
2022	21	65.6%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	15	46.9%
Hypertension	20	62.5%
Depression	*****	*****
Ischemic Heart Disease	*****	*****

Table 1w. Aggregated Characteristics of Infigratinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	21	65.6%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	11	34.4%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity procedures	*****	*****
Obesity NDCs	0	0.0%
Overweight	*****	*****
Smoking procedures	*****	*****
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1w. Aggregated Characteristics of Infigratinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.6	14.2
Mean number of emergency room encounters	0.5	0.8
Mean number of inpatient hospital encounters	0.6	1.1
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	12.3	12.9
Mean number of filled prescriptions	18.1	10.3
Mean number of generics dispensed	9.1	4.9
Mean number of unique drug classes dispensed	8.3	4.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1x. Aggregated Characteristics of Olanzapine and Samidorphan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	4,064	N/A
Demographic Characteristics		
Age (years)	45.9	14.0
Age		
0-17 years	24	0.6%
18-24 years	266	6.5%
25-40 years	1,291	31.8%
41-64 years	2,072	51.0%
≥ 65 years	411	10.1%
Sex		
Female	2,257	55.5%
Male	1,807	44.5%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	64	1.6%
Black or African American	429	10.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,266	31.2%
White	2,264	55.7%
Hispanic origin		
Yes	162	4.0%
No	2,550	62.7%
Unknown	1,352	33.3%
Year		
2021	499	12.3%
2022	3,362	82.7%
2023	203	5.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	161	4.0%
Atrial Fibrillation	44	1.1%
Diabetes Mellitus	774	19.0%
Heart Failure	164	4.0%
Hyperlipidemia	964	23.7%
Hypertension	1,145	28.2%
Depression	2,726	67.1%

Table 1x. Aggregated Characteristics of Olanzapine and Samidorphan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	242	6.0%
Rheumatoid Arthritis/Osteoarthritis	348	8.6%
Stroke/TIA	42	1.0%
Breast Cancer	37	0.9%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	507	12.5%
Anemia	501	12.3%
Asthma	279	6.9%
Benign Prostatic Hyperplasia	63	1.6%
Chronic Kidney Disease	223	5.5%
COPD and Bronchiectasis	282	6.9%
Glaucoma	158	3.9%
Osteoporosis	40	1.0%
Obesity procedures	1,457	35.9%
Obesity NDCs	55	1.4%
Overweight	262	6.4%
Smoking procedures	895	22.0%
Smoking NDCs	63	1.6%
Alcohol Abuse or Dependence	390	9.6%
Drug Abuse or Dependence	604	14.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	31	0.8%

Table 1x. Aggregated Characteristics of Olanzapine and Samidorphan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.9	15.2
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.2	0.6
Mean number of other ambulatory encounters	6.1	11.4
Mean number of filled prescriptions	36.4	27.6
Mean number of generics dispensed	10.1	5.9
Mean number of unique drug classes dispensed	9.4	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1y. Aggregated Characteristics of Ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,569	N/A
Demographic Characteristics		
Age (years)	37.8	11.8
Age		
0-17 years	*****	*****
18-24 years	242	15.4%
25-40 years	723	46.1%
41-64 years	577	36.8%
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	26	1.7%
Black or African American	38	2.4%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,344	85.7%
White	161	10.3%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	1,528	97.4%
Year		
2021	246	15.7%
2022	1,155	73.6%
2023	168	10.7%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	108	6.9%
Heart Failure	*****	*****
Hyperlipidemia	126	8.0%
Hypertension	125	8.0%
Depression	271	17.3%
Ischemic Heart Disease	15	1.0%

Table 1y. Aggregated Characteristics of Ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Rheumatoid Arthritis/Osteoarthritis	59	3.8%
Stroke/TIA	*****	*****
Breast Cancer	15	1.0%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	76	4.8%
Anemia	159	10.1%
Asthma	56	3.6%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	11	0.7%
COPD and Bronchiectasis	14	0.9%
Glaucoma	30	1.9%
Osteoporosis	*****	*****
Obesity procedures	228	14.5%
Obesity NDCs	23	1.5%
Overweight	118	7.5%
Smoking procedures	34	2.2%
Smoking NDCs	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	16	1.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1y. Aggregated Characteristics of Ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.8	10.1
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.9	4.2
Mean number of filled prescriptions	13.3	13.3
Mean number of generics dispensed	6.7	5.1
Mean number of unique drug classes dispensed	6.4	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1z. Aggregated Characteristics of Aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	348	N/A
Demographic Characteristics		
Age (years)	74.7	5.7
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	186	53.4%
Male	162	46.6%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	307	88.2%
Hispanic origin		
Yes	*****	*****
No	307	88.2%
Unknown	*****	*****
Year		
2021	0	0.0%
2022	348	100.0%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	333	95.7%
Atrial Fibrillation	20	5.7%
Diabetes Mellitus	53	15.2%
Heart Failure	16	4.6%
Hyperlipidemia	153	44.0%
Hypertension	151	43.4%
Depression	92	26.4%

Table 1z. Aggregated Characteristics of Aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	60	17.2%
Rheumatoid Arthritis/Osteoarthritis	57	16.4%
Stroke/TIA	17	4.9%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	15	4.3%
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	39	11.2%
Anemia	64	18.4%
Asthma	*****	*****
Benign Prostatic Hyperplasia	27	7.8%
Chronic Kidney Disease	40	11.5%
COPD and Bronchiectasis	12	3.4%
Glaucoma	44	12.6%
Osteoporosis	14	4.0%
Obesity procedures	39	11.2%
Obesity NDCs	*****	*****
Overweight	52	14.9%
Smoking procedures	*****	*****
Smoking NDCs	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	15	4.3%

Table 1z. Aggregated Characteristics of Aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.1	10.1
Mean number of emergency room encounters	0.2	0.6
Mean number of urgent care encounters	0.0	0.3
Mean number of hospital encounters	0.0	0.1
Mean number of office encounters	3.3	2.9
Mean number of filled prescriptions	14.2	9.9
Mean number of generics dispensed	6.7	4.3
Mean number of brand name dispensed	6.5	4.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1aa. Aggregated Characteristics of Asparaginase Erwinia Chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	67	N/A
Demographic Characteristics		
Age (years)	17.0	16.8
Age		
0-17 years	50	74.6%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	21	31.3%
Male	46	68.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	51	76.1%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	0	0.0%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	23	34.3%
Depression	*****	*****

Table 1aa. Aggregated Characteristics of Asparaginase Erwinia Chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	65	97.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	11	16.4%
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity procedures	*****	*****
Obesity NDCs	0	0.0%
Overweight	0	0.0%
Smoking procedures	*****	*****
Smoking NDCs	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1aa. Aggregated Characteristics of Asparaginase Erwinia Chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	33.2	18.0
Mean number of emergency room encounters	1.3	1.6
Mean number of inpatient hospital encounters	3.4	2.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	11.6	21.5
Mean number of filled prescriptions	23.3	14.2
Mean number of generics dispensed	11.6	5.8
Mean number of unique drug classes dispensed	10.8	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

NaN: Not a Number

Table 1ab. Aggregated Characteristics of Cabotegravir in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	741	N/A
Demographic Characteristics		
Age (years)	42.4	12.0
Age		
0-17 years	0	0.0%
18-24 years	52	7.0%
25-40 years	345	46.6%
41-64 years	271	36.6%
≥ 65 years	73	9.9%
Sex		
Female	55	7.4%
Male	686	92.6%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	530	71.5%
White	157	21.2%
Hispanic origin		
Yes	34	4.6%
No	127	17.1%
Unknown	580	78.3%
Year		
2021	0	0.0%
2022	596	80.4%
2023	145	19.6%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	56	7.6%
Heart Failure	*****	*****
Hyperlipidemia	112	15.1%
Hypertension	146	19.7%
Depression	189	25.5%

Table 1ab. Aggregated Characteristics of Cabotegravir in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	32	4.3%
Rheumatoid Arthritis/Osteoarthritis	46	6.2%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	14	1.9%
Anemia	67	9.0%
Asthma	18	2.4%
Benign Prostatic Hyperplasia	25	3.4%
Chronic Kidney Disease	46	6.2%
COPD and Bronchiectasis	*****	*****
Glaucoma	19	2.6%
Osteoporosis	*****	*****
Obesity procedures	117	15.8%
Obesity NDCs	*****	*****
Overweight	82	11.1%
Smoking procedures	56	7.6%
Smoking NDCs	12	1.6%
Alcohol Abuse or Dependence	27	3.6%
Drug Abuse or Dependence	38	5.1%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1ab. Aggregated Characteristics of Cabotegravir in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.6	10.0
Mean number of emergency room encounters	0.3	1.1
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.4	5.1
Mean number of filled prescriptions	12.3	14.6
Mean number of generics dispensed	5.1	4.8
Mean number of unique drug classes dispensed	4.9	4.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Vericiguat</i>	13,282	10,597	79.8%	529	4.0%	2,145	16.1%	11	0.1%
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	9,079	6,768	74.5%	2,300	25.3%	*****	*****	*****	*****
<i>Voclosporin</i>	1,794	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Tepotinib</i>	616	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Umbralisib</i>	264	264	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Evinacumab-dgnb</i>	400	388	97.0%	12	3.0%	0	0.0%	0	0.0%
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	702	702	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	199	199	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tivozanib</i>	2,525	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ponesimod</i>	605	566	93.6%	*****	*****	25	4.1%	*****	*****
<i>Dasiglucagon</i>	1,151	1,071	93.0%	34	3.0%	46	4.0%	0	0.0%
<i>Viloxazine</i>	25,135	23,299	92.7%	589	2.3%	1,231	4.9%	16	0.1%
<i>Drospirenone and Estetrol</i>	10,879	7,627	70.1%	*****	*****	2,786	25.6%	*****	*****
<i>dostarlimab-gxly</i>	438	438	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Loncastuximab Tesirine-lpyl</i>	1,225	1,225	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	13,881	13,801	99.4%	38	0.3%	42	0.3%	0	0.0%
<i>Pegcetacoplan</i>	727	727	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Amivantamab-vmjw</i>	3,189	3,189	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Piflufolastat F 18</i>	45,606	45,606	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Sotorasib</i>	5,641	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Infigratinib</i>	109	109	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Olanzapine and Samidorphan</i>	17,404	16,852	96.8%	315	1.8%	*****	*****	*****	*****
<i>Ibrexafungerp</i>	2,352	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Aducanumab-avwa</i>	1,297	1,297	100.0%	0	0.0%	0	0.0%	0	0.0%

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	1,014	1,014	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Cabotegravir</i>	2,068	1,817	87.9%	****	****	****	****	0	0.0%

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Vericiguat</i>	13,282	1	30	30	30	120	37.0	23.9
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	9,079	1	28	30	33	219	34.4	14.5
<i>Voclosporin</i>	1,794	1	30	30	30	86	28.7	5.1
<i>Tepotinib</i>	616	1	30	30	30	60	28.7	5.3
<i>Umbrisib</i>	264	3	30	30	30	30	29.3	3.5
<i>Evinacumab-dgnb</i>	400	1	1	1	1	56	4.6	11.2
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	702	1	1	1	7	28	4.9	7.8
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	199	1	1	1	1	28	2.5	6.2
<i>Tivozanib</i>	2,525	1	28	28	28	39	26.6	4.6
<i>Ponesimod</i>	605	2	30	30	30	180	30.7	15.4
<i>Dasiglucagon</i>	1,151	1	1	10	30	90	17.7	20.2
<i>Viloxazine</i>	25,135	1	30	30	30	180	30.9	15.1
<i>Drospirenone and Estetrol</i>	10,879	1	28	28	63	132	41.1	25.4
<i>dostarlimab-gxly</i>	438	1	1	1	1	21	1.2	2.1
<i>Loncastuximab Tesirine-lpyl</i>	1,225	1	1	1	1	21	1.5	3.2
<i>Serdexmethylphenidate and Dexamethylphenidate</i>	13,881	1	30	30	30	90	26.8	8.2
<i>Pegcetacoplan</i>	727	1	28	28	28	30	27.0	4.7
<i>Amivantamab-vmjw</i>	3,189	1	1	1	1	28	1.3	2.7
<i>Piflufolastat F 18</i>	45,606	1	1	1	1	1	1.0	0.0
<i>Sotorasib</i>	5,641	1	30	30	30	90	28.6	5.2
<i>Infigratinib</i>	109	8	28	28	28	28	27.2	3.1
<i>Olanzapine and Samidorphan</i>	17,404	1	30	30	30	180	28.0	10.2
<i>Ibrexafungerp</i>	2,352	1	1	1	1	52	1.8	4.3
<i>Aducanumab-avwa</i>	1,297	1	1	1	1	30	1.2	2.1
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	1,014	1	1	1	1	1	1.0	0.0
<i>Cabotegravir</i>	2,068	1	1	1	30	90	16.4	19.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Vericiguat	13,282	10,597	100.0%	529	100.0%	2,145	100.0%	11	100.0%
Female	4,790	3,928	37.1%	170	32.1%	*****	*****	*****	*****
Male	8,492	6,669	62.9%	359	67.9%	*****	*****	*****	*****
Cabotegravir and Rilpivirine (co-packaged)	9,079	6,768	100.0%	2,300	100.0%	*****	*****	*****	*****
Female	1,996	1,502	22.2%	*****	*****	*****	*****	0	0.0%
Male	7,083	5,266	77.8%	*****	*****	*****	*****	*****	*****
Voclosporin	1,794	*****	*****	0	NaN	*****	*****	0	NaN
Female	1,382	*****	*****	0	NaN	*****	*****	0	NaN
Male	412	*****	*****	0	NaN	*****	*****	0	NaN
Tepotinib	616	*****	*****	*****	*****	0	NaN	0	NaN
Female	389	*****	*****	*****	*****	0	NaN	0	NaN
Male	227	*****	*****	*****	*****	0	NaN	0	NaN
Umbrisib	264	264	100.0%	0	NaN	0	NaN	0	NaN
Female	131	131	49.6%	0	NaN	0	NaN	0	NaN
Male	133	133	50.4%	0	NaN	0	NaN	0	NaN
Evinacumab-dgnb	400	388	100.0%	12	100.0%	0	NaN	0	NaN
Female	284	272	70.1%	12	100.0%	0	NaN	0	NaN
Male	116	116	29.9%	0	0.0%	0	NaN	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	702	702	100.0%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN
Male	702	702	100.0%	0	NaN	0	NaN	0	NaN
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	199	199	100.0%	0	NaN	0	NaN	0	NaN
Female	99	99	49.7%	0	NaN	0	NaN	0	NaN
Male	100	100	50.3%	0	NaN	0	NaN	0	NaN
Tivozanib	2,525	*****	*****	*****	*****	0	NaN	0	NaN
Female	622	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,903	*****	*****	*****	*****	0	NaN	0	NaN
Ponesimod	605	566	100.0%	12	100.0%	*****	*****	*****	*****
Female	445	*****	*****	*****	*****	*****	*****	*****	*****
Male	160	*****	*****	*****	*****	*****	*****	0	0.0%
Dasiglucagon	1,151	1,071	100.0%	34	100.0%	46	100.0%	0	NaN
Female	599	560	52.3%	17	50.0%	22	47.8%	0	NaN
Male	552	511	47.7%	17	50.0%	24	52.2%	0	NaN
Viloxazine	25,135	23,299	100.0%	589	100.0%	1,231	100.0%	16	100.0%
Female	9,639	8,997	38.6%	*****	*****	436	35.4%	*****	*****
Male	15,496	14,302	61.4%	*****	*****	795	64.6%	*****	*****
Drospirenone and Estetrol	10,879	7,627	100.0%	*****	*****	2,786	100.0%	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	0	0.0%

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
dostarlimab-gxly	438	438	100.0%	0	NaN	0	NaN	0	NaN
Female	302	302	68.9%	0	NaN	0	NaN	0	NaN
Male	136	136	31.1%	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	1,225	1,225	100.0%	0	NaN	0	NaN	0	NaN
Female	476	476	38.9%	0	NaN	0	NaN	0	NaN
Male	749	749	61.1%	0	NaN	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	13,881	13,801	100.0%	38	100.0%	42	100.0%	0	NaN
Female	5,735	5,707	41.4%	*****	*****	*****	*****	0	NaN
Male	8,146	8,094	58.6%	*****	*****	*****	*****	0	NaN
Pegcetacoplan	727	727	100.0%	0	NaN	0	NaN	0	NaN
Female	369	369	50.8%	0	NaN	0	NaN	0	NaN
Male	358	358	49.2%	0	NaN	0	NaN	0	NaN
Amivantamab-vmjw	3,189	3,189	100.0%	0	NaN	0	NaN	0	NaN
Female	2,375	2,375	74.5%	0	NaN	0	NaN	0	NaN
Male	814	814	25.5%	0	NaN	0	NaN	0	NaN
Piflufolastat F 18	45,606	45,606	100.0%	0	NaN	0	NaN	0	NaN
Female	73	73	0.2%	0	NaN	0	NaN	0	NaN
Male	45,533	45,533	99.8%	0	NaN	0	NaN	0	NaN
Sotorasib	5,641	*****	*****	*****	*****	*****	*****	0	NaN
Female	3,443	*****	*****	*****	*****	*****	*****	0	NaN
Male	2,198	*****	*****	*****	*****	*****	*****	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Infigratinib	109	109	100.0%	0	NaN	0	NaN	0	NaN
Female	57	57	52.3%	0	NaN	0	NaN	0	NaN
Male	52	52	47.7%	0	NaN	0	NaN	0	NaN
Olanzapine and Samidorphan	17,404	16,852	100.0%	315	100.0%	*****	*****	*****	*****
Female	9,133	8,874	52.7%	138	43.8%	*****	*****	*****	*****
Male	8,271	7,978	47.3%	177	56.2%	*****	*****	*****	*****
Ibexafungerp	2,352	*****	*****	*****	*****	0	NaN	0	NaN
Female	2,330	*****	*****	*****	*****	0	NaN	0	NaN
Male	22	*****	*****	*****	*****	0	NaN	0	NaN
Aducanumab-avwa	1,297	1,297	100.0%	0	NaN	0	NaN	0	NaN
Female	665	665	51.3%	0	NaN	0	NaN	0	NaN
Male	632	632	48.7%	0	NaN	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	1,014	1,014	100.0%	0	NaN	0	NaN	0	NaN
Female	320	320	31.6%	0	NaN	0	NaN	0	NaN
Male	694	694	68.4%	0	NaN	0	NaN	0	NaN
Cabotegravir	2,068	1,817	100.0%	*****	*****	*****	*****	0	NaN
Female	135	114	6.3%	*****	*****	*****	*****	0	NaN
Male	1,933	1,703	93.7%	*****	*****	*****	*****	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	13,282	1	30	30	30	120	37.0	23.9
Female	4,790	1	28	30	30	104	35.4	23.1
Male	8,492	1	30	30	30	120	37.9	24.3
Cabotegravir and Rilpivirine (co-packaged)	9,079	1	28	30	33	219	34.4	14.5
Female	1,996	1	28	30	30	84	33.9	14.2
Male	7,083	1	28	30	34	219	34.5	14.6
Voclosporin	1,794	1	30	30	30	86	28.7	5.1
Female	1,382	1	30	30	30	86	28.7	5.2
Male	412	1	30	30	30	30	28.8	4.8
Tepotinib	616	1	30	30	30	60	28.7	5.3
Female	389	1	30	30	30	60	28.4	5.5
Male	227	4	30	30	30	60	29.2	4.8
Umbrisib	264	3	30	30	30	30	29.3	3.5
Female	131	17	30	30	30	30	29.7	1.7
Male	133	3	30	30	30	30	28.9	4.6
Evinacumab-dgnb	400	1	1	1	1	56	4.6	11.2
Female	284	1	1	1	1	56	6.0	13.0
Male	116	1	1	1	1	30	1.3	2.7
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	702	1	1	1	7	28	4.9	7.8
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	702	1	1	1	7	28	4.9	7.8
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	199	1	1	1	1	28	2.5	6.2
Female	99	1	1	1	1	28	2.9	7.0
Male	100	1	1	1	1	28	2.1	5.3
Tivozanib	2,525	1	28	28	28	39	26.6	4.6
Female	622	2	28	28	28	31	26.8	4.1
Male	1,903	1	28	28	28	39	26.5	4.7
Ponesimod	605	2	30	30	30	180	30.7	15.4

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	445	2	30	30	30	180	31.1	16.6
Male	160	7	30	30	30	90	29.6	11.1
Dasiglucagon	1,151	1	1	10	30	90	17.7	20.2
Female	599	1	1	10	30	90	17.4	19.7
Male	552	1	1	10	30	90	18.1	20.7
Viloxazine	25,135	1	30	30	30	180	30.9	15.1
Female	9,639	1	30	30	30	180	30.4	14.7
Male	15,496	1	30	30	30	180	31.3	15.4
Drospirenone and Estetrol	10,879	1	28	28	63	132	41.1	25.4
Female	*****	1	28	28	63	132	41.1	25.4
Male	*****	13	28	45	84	84	54.7	29.3
dostarlimab-gxly	438	1	1	1	1	21	1.2	2.1
Female	302	1	1	1	1	1	1.0	0.0
Male	136	1	1	1	1	21	1.8	3.7
Loncastuximab Tesirine-lpyl	1,225	1	1	1	1	21	1.5	3.2
Female	476	1	1	1	1	21	1.6	3.5
Male	749	1	1	1	1	21	1.5	2.9
Serdexmethylphenidate and Dexmethylphenidate	13,881	1	30	30	30	90	26.8	8.2
Female	5,735	1	30	30	30	90	26.6	8.4
Male	8,146	1	30	30	30	90	27.0	8.1
Pegcetacoplan	727	1	28	28	28	30	27.0	4.7
Female	369	2	28	28	28	30	27.1	4.5
Male	358	1	28	28	28	30	26.8	4.9
Amivantamab-vmjw	3,189	1	1	1	1	28	1.3	2.7
Female	2,375	1	1	1	1	28	1.3	2.6
Male	814	1	1	1	1	28	1.4	3.0
Piflufolastat F 18	45,606	1	1	1	1	1	1.0	0.0
Female	73	1	1	1	1	1	1.0	0.0
Male	45,533	1	1	1	1	1	1.0	0.0
Sotorasib	5,641	1	30	30	30	90	28.6	5.2
Female	3,443	1	30	30	30	60	28.6	4.9
Male	2,198	1	30	30	30	90	28.4	5.6
Infigratinib	109	8	28	28	28	28	27.2	3.1

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	57	8	28	28	28	28	26.7	4.1
Male	52	21	28	28	28	28	27.8	1.0
Olanzapine and Samidorphan	17,404	1	30	30	30	180	28.0	10.2
Female	9,133	1	30	30	30	180	28.2	10.1
Male	8,271	1	30	30	30	90	27.9	10.3
Ibexafungerp	2,352	1	1	1	1	52	1.8	4.3
Female	2,330	1	1	1	1	52	1.8	4.2
Male	22	1	1	2	7	30	6.7	10.0
Aducanumab-avwa	1,297	1	1	1	1	30	1.2	2.1
Female	665	1	1	1	1	30	1.3	3.0
Male	632	1	1	1	1	1	1.0	0.0
Asparaginase Erwinia Chrysanthemii (recombinant)-rywn	1,014	1	1	1	1	1	1.0	0.0
Female	320	1	1	1	1	1	1.0	0.0
Male	694	1	1	1	1	1	1.0	0.0
Cabotegravir	2,068	1	1	1	30	90	16.4	19.2
Female	135	1	1	5	30	60	18.6	20.6
Male	1,933	1	1	1	30	90	16.3	19.1

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Vericiguat	13,282	10,597	100.0%	529	100.0%	2,145	100.0%	11	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	2,631	2,148	20.3%	*****	*****	390	18.2%	*****	*****
≥ 65 years	10,513	8,330	78.6%	*****	*****	1,742	81.2%	*****	*****
Cabotegravir and Rilpivirine (co-	9,079	6,768	100.0%	2,300	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	59	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	1,318	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	5,571	4,104	60.6%	*****	*****	*****	*****	0	0.0%
≥ 65 years	2,131	1,569	23.2%	*****	*****	*****	*****	*****	*****
Voclosporin	1,794	*****	*****	0	NaN	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN
18-24 years	228	228	*****	0	NaN	0	0.0%	0	NaN
25-40 years	760	760	*****	0	NaN	0	0.0%	0	NaN
41-64 years	*****	*****	*****	0	NaN	*****	*****	0	NaN
≥ 65 years	60	60	*****	0	NaN	0	0.0%	0	NaN
Tepotinib	616	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	92	92	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
Umbrisib	264	264	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	28	28	10.6%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	236	236	89.4%	0	NaN	0	NaN	0	NaN
Evinacumab-dgnb	400	388	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	20	20	5.2%	0	0.0%	0	NaN	0	NaN
18-24 years	14	14	3.6%	0	0.0%	0	NaN	0	NaN
25-40 years	54	54	13.9%	0	0.0%	0	NaN	0	NaN
41-64 years	205	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	107	*****	*****	*****	*****	0	NaN	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	702	702	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	406	406	57.8%	0	NaN	0	NaN	0	NaN
18-24 years	145	145	20.7%	0	NaN	0	NaN	0	NaN
25-40 years	151	151	21.5%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	199	199	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	20	20	10.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	179	179	89.9%	0	NaN	0	NaN	0	NaN
Tivozanib	2,525	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	552	552	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
Ponesimod	605	566	100.0%	*****	*****	25	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	12	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	145	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	391	364	64.3%	*****	*****	*****	*****	*****	*****
≥ 65 years	57	*****	*****	0	0.0%	*****	*****	0	0.0%
Dasiglucagon	1,151	1,071	100.0%	34	100.0%	46	100.0%	0	NaN
0-17 years	206	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	126	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	222	203	19.0%	*****	*****	*****	*****	0	NaN
41-64 years	461	422	39.4%	16	47.1%	23	50.0%	0	NaN
≥ 65 years	136	*****	*****	*****	*****	*****	*****	0	NaN
Viloxazine	25,135	23,299	100.0%	589	100.0%	1,231	100.0%	16	100.0%
0-17 years	18,786	17,335	74.4%	427	72.5%	1,010	82.0%	14	87.5%
18-24 years	1,913	1,783	7.7%	45	7.6%	85	6.9%	0	0.0%
25-40 years	2,383	2,257	9.7%	58	9.8%	*****	*****	*****	*****
41-64 years	1,868	1,751	7.5%	*****	*****	63	5.1%	*****	*****
≥ 65 years	185	173	0.7%	*****	*****	*****	*****	0	0.0%
Drospirenone and Estetrol	10,879	7,627	100.0%	462	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	45	9.7%	*****	*****	0	0.0%
18-24 years	3,581	2,511	32.9%	*****	*****	898	*****	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	4,310	2,982	39.1%	*****	*****	1,138	*****	*****	*****
41-64 years	1,604	1,150	15.1%	*****	*****	395	*****	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
dostarlimab-gxly	438	438	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	325	325	74.2%	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	1,225	1,225	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	115	115	9.4%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,089	1,089	88.9%	0	NaN	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	13,881	13,801	100.0%	38	100.0%	42	100.0%	0	NaN
0-17 years	8,654	8,613	62.4%	20	52.6%	21	50.0%	0	NaN
18-24 years	1,384	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	2,093	2,077	15.0%	*****	*****	*****	*****	0	NaN
41-64 years	1,664	1,653	12.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	86	*****	*****	0	0.0%	*****	*****	0	NaN
Pegcetacoplan	727	727	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	28	28	3.9%	0	NaN	0	NaN	0	NaN
25-40 years	123	123	16.9%	0	NaN	0	NaN	0	NaN
41-64 years	262	262	36.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	314	314	43.2%	0	NaN	0	NaN	0	NaN
Amivantamab-vmjw	3,189	3,189	100.0%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	19	19	0.6%	0	NaN	0	NaN	0	NaN
41-64 years	582	582	18.3%	0	NaN	0	NaN	0	NaN
≥ 65 years	2,588	2,588	81.2%	0	NaN	0	NaN	0	NaN
Piflufolastat F 18	45,606	45,606	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	42,212	42,212	92.6%	0	NaN	0	NaN	0	NaN
Sotorasib	5,641	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	1,259	1,259	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN
Infigratinib	109	109	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	21	21	19.3%	0	NaN	0	NaN	0	NaN
41-64 years	27	27	24.8%	0	NaN	0	NaN	0	NaN
≥ 65 years	61	61	56.0%	0	NaN	0	NaN	0	NaN
Olanzapine and Samidorphan	17,404	16,852	100.0%	315	100.0%	*****	*****	*****	*****
0-17 years	69	*****	*****	0	0.0%	*****	*****	0	0.0%
18-24 years	1,035	*****	*****	19	6.0%	*****	*****	*****	*****
25-40 years	5,733	5,530	32.8%	135	42.9%	68	*****	0	0.0%
41-64 years	9,103	8,850	52.5%	130	41.3%	123	*****	0	0.0%
≥ 65 years	1,464	1,407	8.3%	31	9.8%	26	*****	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
lbrefaxungerp	2,352	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	338	338	*****	0	0.0%	0	NaN	0	NaN
25-40 years	1,115	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	856	856	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Aducanumab-avwa	1,297	1,297	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	37	37	2.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,260	1,260	97.1%	0	NaN	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	1,014	1,014	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	804	804	79.3%	0	NaN	0	NaN	0	NaN
18-24 years	64	64	6.3%	0	NaN	0	NaN	0	NaN
25-40 years	113	113	11.1%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
Cabotegravir	2,068	1,817	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	151	124	6.8%	*****	*****	*****	*****	0	NaN
25-40 years	888	803	44.2%	85	*****	0	0.0%	0	NaN
41-64 years	780	682	37.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	249	208	11.4%	41	*****	0	0.0%	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	13,282	1	30	30	30	120	37.0	23.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	57	84	84	57.0	38.2
25-40 years	*****	1	28	30	30	90	32.6	19.6
41-64 years	2,631	1	30	30	30	118	36.2	22.9
≥ 65 years	10,513	1	30	30	30	120	37.3	24.2
Cabotegravir and Rilpivirine (co-packaged)	9,079	1	28	30	33	219	34.4	14.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	59	3	28	30	30	60	31.5	12.8
25-40 years	1,318	1	28	30	30	60	33.2	12.8
41-64 years	5,571	1	28	30	40	90	34.5	14.4
≥ 65 years	2,131	1	28	30	41	219	34.6	15.6
Voclosporin	1,794	1	30	30	30	86	28.7	5.1
0-17 years	11	13	30	30	30	30	28.5	5.1
18-24 years	228	8	30	30	30	30	29.6	2.4
25-40 years	760	1	30	30	30	30	28.6	5.1
41-64 years	735	1	30	30	30	86	28.6	5.6
≥ 65 years	60	3	30	30	30	30	28.2	5.5
Tepotinib	616	1	30	30	30	60	28.7	5.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	3	30	30	30	30	28.7	5.0
≥ 65 years	523	1	30	30	30	60	28.7	5.3
Umbrisib	264	3	30	30	30	30	29.3	3.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	28	3	30	30	30	30	28.8	5.2
≥ 65 years	236	3	30	30	30	30	29.4	3.2
Evinacumab-dgnb	400	1	1	1	1	56	4.6	11.2
0-17 years	20	1	1	1	1	1	1.0	0.0
18-24 years	14	1	1	1	1	1	1.0	0.0
25-40 years	54	1	1	1	1	30	1.5	3.9
41-64 years	205	1	1	1	1	56	5.0	10.0
≥ 65 years	107	1	1	1	1	56	6.4	16.3
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	702	1	1	1	7	28	4.9	7.8
0-17 years	406	1	1	1	1	28	2.6	6.3

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	145	1	1	1	28	28	8.2	11.9
25-40 years	151	1	7	7	7	14	7.8	2.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	199	1	1	1	1	28	2.5	6.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	20	1	1	1	1	1	1.0	0.0
≥ 65 years	179	1	1	1	1	28	2.7	6.5
Tivozanib	2,525	1	28	28	28	39	26.6	4.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	10	18	27	28	28	23.0	8.7
41-64 years	*****	1	28	28	28	28	26.7	4.6
≥ 65 years	1,969	1	28	28	28	39	26.6	4.5
Ponesimod	605	2	30	30	30	180	30.7	15.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	29	30	30	30	39	30.7	2.6
25-40 years	145	2	30	30	30	90	29.1	12.5
41-64 years	391	2	30	30	30	180	31.2	16.4
≥ 65 years	57	2	30	30	30	90	31.4	16.6
Dasiglucagon	1,151	1	1	10	30	90	17.7	20.2
0-17 years	206	1	1	2	30	90	13.4	18.0
18-24 years	126	1	1	15	30	90	17.1	16.6
25-40 years	222	1	1	15	30	90	19.1	21.4
41-64 years	461	1	1	15	30	90	18.9	21.3
≥ 65 years	136	1	2	18	30	90	18.9	19.8
Viloxazine	25,135	1	30	30	30	180	30.9	15.1
0-17 years	18,786	1	30	30	30	180	31.5	15.5
18-24 years	1,913	1	30	30	30	90	30.3	14.6
25-40 years	2,383	1	29	30	30	158	28.3	13.0
41-64 years	1,868	1	30	30	30	108	28.8	13.8
≥ 65 years	185	2	30	30	30	90	28.9	13.8
Drospirenone and Estetrol	10,879	1	28	28	63	132	41.1	25.4
0-17 years	*****	1	28	28	65	90	41.1	25.4
18-24 years	3,581	1	28	28	61	132	40.9	25.3
25-40 years	4,310	1	28	28	69	118	41.4	25.6
41-64 years	1,604	1	28	28	59	91	40.6	24.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	*****	6	28	28	84	84	43.0	32.9
dostarlimab-gxly	438	1	1	1	1	21	1.2	2.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	325	1	1	1	1	21	1.3	2.4
Loncastuximab Tesirine-lpyl	1,225	1	1	1	1	21	1.5	3.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	115	1	1	1	1	21	3.9	7.0
≥ 65 years	1,089	1	1	1	1	21	1.3	2.3
Serdexmethylphenidate and Dexmethylphenidate	13,881	1	30	30	30	90	26.8	8.2
0-17 years	8,654	1	30	30	30	90	27.0	7.9
18-24 years	1,384	1	30	30	30	90	26.6	8.7
25-40 years	2,093	1	28	30	30	90	26.3	8.8
41-64 years	1,664	1	30	30	30	90	26.6	8.6
≥ 65 years	86	1	25	30	30	90	26.3	10.7
Pegcetacoplan	727	1	28	28	28	30	27.0	4.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	28	5	28	28	28	28	26.3	5.2
25-40 years	123	1	28	28	28	28	26.7	5.0
41-64 years	262	2	28	28	28	30	27.1	4.7
≥ 65 years	314	2	28	28	28	30	27.0	4.6
Amivantamab-vmjw	3,189	1	1	1	1	28	1.3	2.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	19	1	1	1	1	1	1.0	0.0
41-64 years	582	1	1	1	1	28	1.1	1.1
≥ 65 years	2,588	1	1	1	1	28	1.3	3.0
Piflufolastat F 18	45,606	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	42,212	1	1	1	1	1	1.0	0.0
Sotorasib	5,641	1	30	30	30	90	28.6	5.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	18	30	30	30	30	30	30.0	0.0
41-64 years	1,259	1	30	30	30	30	28.4	5.0
≥ 65 years	4,364	1	30	30	30	90	28.6	5.2

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Infigratinib	109	8	28	28	28	28	27.2	3.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	21	27	28	28	28	28	28.0	0.2
41-64 years	27	28	28	28	28	28	28.0	0.0
≥ 65 years	61	8	28	28	28	28	26.7	4.1
Olanzapine and Samidorphan	17,404	1	30	30	30	180	28.0	10.2
0-17 years	69	6	30	30	30	90	30.5	12.1
18-24 years	1,035	1	30	30	30	180	28.6	11.3
25-40 years	5,733	1	30	30	30	90	27.7	10.1
41-64 years	9,103	1	30	30	30	90	28.1	10.1
≥ 65 years	1,464	1	30	30	30	90	28.7	10.9
Ibexafungerp	2,352	1	1	1	1	52	1.8	4.3
0-17 years	*****	1	1	1	1	2	1.1	0.3
18-24 years	338	1	1	1	1	30	1.8	4.1
25-40 years	1,115	1	1	1	1	52	1.9	4.3
41-64 years	856	1	1	1	1	30	1.7	3.9
≥ 65 years	*****	1	1	1	1	28	5.7	10.2
Aducanumab-avwa	1,297	1	1	1	1	30	1.2	2.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	37	1	1	1	1	1	1.0	0.0
≥ 65 years	1,260	1	1	1	1	30	1.2	2.2
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	1,014	1	1	1	1	1	1.0	0.0
0-17 years	804	1	1	1	1	1	1.0	0.0
18-24 years	64	1	1	1	1	1	1.0	0.0
25-40 years	113	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Cabotegravir	2,068	1	1	1	30	90	16.4	19.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	151	1	1	1	30	75	18.6	21.6
25-40 years	888	1	1	1	30	60	12.9	18.2
41-64 years	780	1	1	1	30	90	16.3	19.3
≥ 65 years	249	1	27	30	30	60	27.8	16.4

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Vericiguat</i>	3,212	664	20.7%	861	26.8%	1,364	42.5%	*****	*****	*****	*****
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	1,910	306	16.0%	435	22.8%	992	51.9%	177	9.3%	0	0.0%
<i>Voclosporin</i>	324	77	23.8%	72	22.2%	141	43.5%	34	10.5%	0	0.0%
<i>Tepotinib</i>	141	44	31.2%	*****	*****	50	35.5%	*****	*****	0	0.0%
<i>Umbrisib</i>	76	19	25.0%	26	34.2%	31	40.8%	0	0.0%	0	0.0%
<i>Evinacumab-dgnb</i>	49	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	30	18	60.0%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	87	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tivozanib</i>	632	159	25.2%	235	37.2%	213	33.7%	25	4.0%	0	0.0%
<i>Ponesimod</i>	106	12	11.3%	26	24.5%	55	51.9%	13	12.3%	0	0.0%
<i>Dasiglucagon</i>	736	553	75.1%	153	20.8%	30	4.1%	0	0.0%	0	0.0%
<i>Viloxazine</i>	7,859	3,004	38.2%	2,248	28.6%	2,318	29.5%	289	3.7%	0	0.0%
<i>Drospirenone and Estetrol</i>	3,472	632	18.2%	1,170	33.7%	1,522	43.8%	148	4.3%	0	0.0%
<i>dostarlimab-gxly</i>	99	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Loncastuximab Tesirine-lpyl</i>	338	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	5,031	2,142	42.6%	1,621	32.2%	1,229	24.4%	39	0.8%	0	0.0%
<i>Pegcetacoplan</i>	65	*****	*****	*****	*****	28	43.1%	25	38.5%	0	0.0%
<i>Amivantamab-vmjw</i>	303	292	96.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Piflufolastat F 18</i>	43,225	43,225	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Sotorasib</i>	1,296	324	25.0%	428	33.0%	478	36.9%	66	5.1%	0	0.0%
<i>Infigratinib</i>	32	*****	*****	15	46.9%	*****	*****	0	0.0%	0	0.0%
<i>Olanzapine and Samidorphan</i>	4,064	1,200	29.5%	1,069	26.3%	1,642	40.4%	153	3.8%	0	0.0%
<i>Ibexafungerp</i>	1,569	1,544	98.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Aducanumab-avwa</i>	348	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	67	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
<i>Cabotegravir</i>	741	484	65.3%	112	15.1%	145	19.6%	0	0.0%	0	0.0%

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Vericiguat</i>	3,212	1	46	104	221	768	153.0	136.7
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	1,910	1	60	131	234	612	163.3	131.4
<i>Voclosporin</i>	324	2	35	119	240	628	159.1	143.5
<i>Tepotinib</i>	141	3	30	90	180	639	125.4	129.4
<i>Umbrisib</i>	76	3	39	89	150	330	101.8	73.2
<i>Evinacumab-dgnb</i>	49	1	3	7	15	592	37.5	112.4
<i>Trilaciclib</i>	*****	*****	*****	*****	*	*****	*****	*****
<i>Casimersen</i>	30	1	17	27	139	606	113.9	169.8
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	87	1	1	2	3	140	5.7	17.7
<i>Tivozanib</i>	632	2	30	83	132	679	106.3	103.8
<i>Ponesimod</i>	106	14	74	126	270	612	175.4	144.2
<i>Dasiglucagon</i>	736	1	2	25	30	346	27.7	37.2
<i>Viloxazine</i>	7,859	1	30	60	131	625	98.9	103.5
<i>Drospirenone and Estetrol</i>	3,472	1	54	84	176	635	128.8	107.3
<i>dostarlimab-gxly</i>	99	1	2	4	6	72	5.5	8.1
<i>Loncastuximab Tesirine-lpyl</i>	338	1	1	3	5	349	5.5	22.7
<i>Serdexmethylphenidate and Dexamethylphenidate</i>	5,031	1	30	48	92	575	74.0	72.3
<i>Pegcetacoplan</i>	65	5	140	300	479	684	301.5	190.7
<i>Amivantamab-vmjw</i>	303	1	5	8	16	224	13.5	22.4
<i>Piflufolastat F 18</i>	43,225	1	1	1	1	5	1.1	0.3
<i>Sotorasib</i>	1,296	1	31	90	162	647	124.3	116.8
<i>Infigratinib</i>	32	18	53	84	112	363	92.8	67.7
<i>Olanzapine and Samidorphan</i>	4,064	1	30	86	180	506	120.0	106.3
<i>Ibrexafungerp</i>	1,569	1	1	1	2	167	2.8	8.4
<i>Aducanumab-avwa</i>	348	1	1	3	5	215	4.3	11.7
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	67	1	6	12	23	90	15.1	14.1
<i>Cabotegravir</i>	741	1	2	5	71	334	45.7	66.6

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Vericiguat	3,212	664	100.0%	861	100.0%	1,364	100.0%	*****	*****	*****	*****
Female	1,108	211	31.8%	314	36.5%	474	34.8%	*****	*****	*****	*****
Male	2,104	453	68.2%	547	63.5%	890	65.2%	*****	*****	*****	*****
Cabotegravir and Rilpivirine (co-packaged)	1,910	306	100.0%	435	100.0%	992	100.0%	177	100.0%	0	NaN
Female	454	85	27.8%	119	27.4%	220	22.2%	30	16.9%	0	NaN
Male	1,456	221	72.2%	316	72.6%	772	77.8%	147	83.1%	0	NaN
Voclosporin	324	77	100.0%	72	100.0%	141	100.0%	34	100.0%	0	NaN
Female	261	64	83.1%	*****	*****	109	77.3%	*****	*****	0	NaN
Male	63	13	16.9%	*****	*****	32	22.7%	*****	*****	0	NaN
Tepotinib	141	44	100.0%	*****	*****	50	100.0%	*****	*****	0	NaN
Female	92	33	75.0%	*****	*****	27	54.0%	*****	*****	0	NaN
Male	49	11	25.0%	*****	*****	23	46.0%	*****	*****	0	NaN
Umbrisib	76	19	100.0%	26	100.0%	31	100.0%	0	NaN	0	NaN
Female	36	*****	*****	*****	*****	15	48.4%	0	NaN	0	NaN
Male	40	*****	*****	*****	*****	16	51.6%	0	NaN	0	NaN
Evinacumab-dgnb	49	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Female	37	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Male	12	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	30	18	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	0	0	0.0%	*****	*****	*****	*****	*****	*****	0	NaN
Male	30	18	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	87	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	45	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	42	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tivozanib	632	159	100.0%	235	100.0%	213	100.0%	25	100.0%	0	NaN
Female	162	41	25.8%	60	25.5%	*****	*****	*****	*****	0	NaN
Male	470	118	74.2%	175	74.5%	*****	*****	*****	*****	0	NaN
Ponesimod	106	12	100.0%	26	100.0%	55	100.0%	13	100.0%	0	NaN
Female	83	*****	*****	*****	*****	42	76.4%	*****	*****	0	NaN
Male	23	*****	*****	*****	*****	13	23.6%	*****	*****	0	NaN
Dasiglucagon	736	553	100.0%	153	100.0%	30	100.0%	0	NaN	0	NaN
Female	379	282	51.0%	81	52.9%	16	53.3%	0	NaN	0	NaN
Male	357	271	49.0%	72	47.1%	14	46.7%	0	NaN	0	NaN
Viloxazine	7,859	3,004	100.0%	2,248	100.0%	2,318	100.0%	289	100.0%	0	NaN
Female	3,394	1,434	47.7%	993	44.2%	889	38.4%	78	27.0%	0	NaN
Male	4,465	1,570	52.3%	1,255	55.8%	1,429	61.6%	211	73.0%	0	NaN
Drospirenone and Estetrol	3,472	632	100.0%	1,170	100.0%	1,522	100.0%	148	100.0%	0	NaN
Female	*****	*****	*****	*****	*****	1,522	100.0%	*****	*****	0	NaN
Male	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
dostarlimab-gxly	99	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	69	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	30	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	338	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	135	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Male	203	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	5,031	2,142	100.0%	1,621	100.0%	1,229	100.0%	39	100.0%	0	NaN
Female	2,260	1,047	48.9%	723	44.6%	477	38.8%	13	33.3%	0	NaN
Male	2,771	1,095	51.1%	898	55.4%	752	61.2%	26	66.7%	0	NaN
Pegcetacoplan	65	*****	*****	*****	*****	28	100.0%	25	100.0%	0	NaN
Female	31	*****	*****	*****	*****	14	50.0%	*****	*****	0	NaN
Male	34	*****	*****	*****	*****	14	50.0%	*****	*****	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Amivantamab-vmjw	303	292	100.0%	****	****	****	****	0	NaN	0	NaN
Female	213	****	****	****	****	****	****	0	NaN	0	NaN
Male	90	****	****	****	****	****	****	0	NaN	0	NaN
Piflufolastat F 18	43,225	43,225	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	73	73	0.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	43,152	43,152	99.8%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	1,296	324	100.0%	428	100.0%	478	100.0%	66	100.0%	0	NaN
Female	790	202	62.3%	270	63.1%	271	56.7%	47	71.2%	0	NaN
Male	506	122	37.7%	158	36.9%	207	43.3%	19	28.8%	0	NaN
Infigratinib	32	****	****	15	100.0%	****	****	0	NaN	0	NaN
Female	19	****	****	****	****	****	****	0	NaN	0	NaN
Male	13	****	****	****	****	****	****	0	NaN	0	NaN
Olanzapine and Samidorphan	4,064	1,200	100.0%	1,069	100.0%	1,642	100.0%	153	100.0%	0	NaN
Female	2,257	704	58.7%	622	58.2%	849	51.7%	82	53.6%	0	NaN
Male	1,807	496	41.3%	447	41.8%	793	48.3%	71	46.4%	0	NaN
Ibexafungerp	1,569	1,544	100.0%	****	****	****	****	0	NaN	0	NaN
Female	****	****	****	****	****	****	****	0	NaN	0	NaN
Male	****	****	****	****	****	****	****	0	NaN	0	NaN
Aducanumab-avwa	348	****	****	0	NaN	****	****	0	NaN	0	NaN
Female	186	****	****	0	NaN	****	****	0	NaN	0	NaN
Male	162	****	****	0	NaN	****	****	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Asparaginase Erwinia Chrysanthemi (recombinant)-ryw	67	****	****	****	****	0	NaN	0	NaN	0	NaN
Female	21	****	****	****	****	0	NaN	0	NaN	0	NaN
Male	46	****	****	****	****	0	NaN	0	NaN	0	NaN
Cabotegravir	741	484	100.0%	112	100.0%	145	100.0%	0	NaN	0	NaN
Female	55	39	8.1%	****	****	****	****	0	NaN	0	NaN
Male	686	445	91.9%	****	****	****	****	0	NaN	0	NaN

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,212	1	46	104	221	768	153.0	136.7
Female	1,108	1	50	103	223	768	153.2	136.3
Male	2,104	1	44	104	217	653	152.9	136.9
Cabotegravir and Rilpivirine (co-packaged)	1,910	1	60	131	234	612	163.3	131.4
Female	454	1	55	115	220	584	149.2	125.1
Male	1,456	1	60	139	240	612	167.7	133.1
Voclosporin	324	2	35	119	240	628	159.1	143.5
Female	261	2	32	106	222	628	152.0	140.2
Male	63	3	60	150	279	589	188.3	154.2
Tepotinib	141	3	30	90	180	639	125.4	129.4
Female	92	3	30	60	122	639	120.3	140.5
Male	49	4	47	90	210	374	135.1	106.1
Umbralisib	76	3	39	89	150	330	101.8	73.2
Female	36	25	51	74	180	300	108.1	76.8
Male	40	3	30	90	135	330	96.2	70.3
Evinacumab-dgnb	49	1	3	7	15	592	37.5	112.4
Female	37	1	2	6	15	592	45.7	128.7
Male	12	2	6	13	16	30	12.1	7.8
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	30	1	17	27	139	606	113.9	169.8
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	30	1	17	27	139	606	113.9	169.8
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	87	1	1	2	3	140	5.7	17.7
Female	45	1	1	1	3	140	6.4	22.0
Male	42	1	1	2	3	56	5.0	11.7
Tivozanib	632	2	30	83	132	679	106.3	103.8
Female	162	5	30	82	112	560	103.0	99.0
Male	470	2	30	84	138	679	107.5	105.5
Ponesimod	106	14	74	126	270	612	175.4	144.2
Female	83	14	62	108	224	612	167.0	146.9
Male	23	30	74	175	314	449	206.1	132.6
Dasiglucagon	736	1	2	25	30	346	27.7	37.2
Female	379	1	2	20	31	210	27.5	35.3
Male	357	1	2	26	30	346	27.9	39.1
Viloxazine	7,859	1	30	60	131	625	98.9	103.5
Female	3,394	1	30	60	116	614	86.2	90.5
Male	4,465	1	30	60	150	625	108.5	111.5
Drospirenone and Estetrol	3,472	1	54	84	176	635	128.8	107.3
Female	*****	1	54	84	176	635	128.8	107.2

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	*****	13	27	28	45	379	98.4	157.3
dostarlimab-gxly	99	1	2	4	6	72	5.5	8.1
Female	69	1	2	3	6	12	4.4	3.1
Male	30	1	2	5	7	72	8.0	13.8
Loncastuximab Tesirine-lpyl	338	1	1	3	5	349	5.5	22.7
Female	135	1	1	3	5	210	5.7	19.9
Male	203	1	1	3	5	349	5.4	24.4
Serdexmethylphenidate and Dexmethylphenidate	5,031	1	30	48	92	575	74.0	72.3
Female	2,260	1	30	39	90	510	67.4	66.7
Male	2,771	1	30	58	108	575	79.3	76.1
Pegcetacoplan	65	5	140	300	479	684	301.5	190.7
Female	31	28	172	300	521	643	322.5	182.0
Male	34	5	95	295	469	684	282.4	199.1
Amivantamab-vmjw	303	1	5	8	16	224	13.5	22.4
Female	213	1	6	9	16	191	14.0	21.5
Male	90	1	4	7	14	224	12.2	24.4
Piflufolastat F 18	43,225	1	1	1	1	5	1.1	0.3
Female	73	1	1	1	1	1	1.0	0.0
Male	43,152	1	1	1	1	5	1.1	0.3
Sotorasib	1,296	1	31	90	162	647	124.3	116.8
Female	790	1	30	90	150	647	124.8	121.0
Male	506	4	37	90	170	538	123.4	109.9
Infigratinib	32	18	53	84	112	363	92.8	67.7
Female	19	18	40	75	112	168	80.1	45.6
Male	13	28	56	84	112	363	111.4	90.0
Olanzapine and Samidorphan	4,064	1	30	86	180	506	120.0	106.3
Female	2,257	1	30	76	165	469	114.0	104.0
Male	1,807	1	30	90	191	506	127.5	108.7
Ibrexafungerp	1,569	1	1	1	2	167	2.8	8.4
Female	*****	1	1	1	2	167	2.7	8.1
Male	*****	1	1	2	4	94	16.3	31.6

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Aducanumab-avwa	348	1	1	3	5	215	4.3	11.7
Female	186	1	2	3	4	215	4.7	15.7
Male	162	1	1	3	5	12	3.9	3.0
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	67	1	6	12	23	90	15.1	14.1
Female	21	1	4	10	23	90	15.2	19.5
Male	46	1	7	12	22	57	15.1	11.0
Cabotegravir	741	1	2	5	71	334	45.7	66.6
Female	55	1	2	27	60	316	45.5	70.6
Male	686	1	2	5	77	334	45.7	66.3

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Vericiguat	3,212	664	100.0%	861	100.0%	1,364	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	607	*****	*****	*****	*****	279	20.5%	55	17.1%	0	0.0%
≥ 65 years	2,566	547	82.4%	686	79.7%	1,066	78.2%	*****	*****	*****	*****
Cabotegravir and Rilpivirine (co-packaged)	1,910	306	100.0%	435	100.0%	992	100.0%	177	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	16	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	274	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	1,145	163	53.3%	259	59.5%	613	61.8%	110	62.1%	0	NaN
≥ 65 years	475	92	30.1%	119	27.4%	219	22.1%	45	25.4%	0	NaN
Voclosporin	324	77	100.0%	72	100.0%	141	100.0%	34	100.0%	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	34	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	140	*****	*****	*****	*****	62	44.0%	*****	*****	0	NaN
41-64 years	134	31	40.3%	35	48.6%	52	36.9%	16	47.1%	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Tepotinib	141	44	100.0%	*****	*****	50	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	125	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Umbrisib	76	19	100.0%	26	100.0%	31	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration												
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days			
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
41-64 years	****	****	****	****	****	****	****	****	0	NaN	0	NaN	
≥ 65 years	****	****	****	****	****	****	****	****	0	NaN	0	NaN	
Evinacumab-dgnb	49	****	****	****	****	****	0	NaN	****	****	0	NaN	
0-17 years	****	****	****	0	0.0%	0	NaN	0	0.0%	0	0	NaN	
18-24 years	****	****	****	0	0.0%	0	NaN	0	0.0%	0	0	NaN	
25-40 years	****	****	****	0	0.0%	0	NaN	0	0.0%	0	0	NaN	
41-64 years	22	****	****	****	****	0	NaN	****	****	0	0	NaN	
≥ 65 years	****	****	****	0	0.0%	0	NaN	****	****	0	0	NaN	
Trilaciclib	****	****	****	****	****	****	****	****	****	****	****	****	
0-17 years	****	****	****	****	****	****	****	****	****	****	****	****	
18-24 years	****	****	****	****	****	****	****	****	****	****	****	****	
25-40 years	****	****	****	****	****	****	****	****	****	****	****	****	
41-64 years	****	****	****	****	****	****	****	****	****	****	****	****	
≥ 65 years	****	****	****	****	****	****	****	****	****	****	****	****	
Casimersen	30	18	100.0%	****	****	****	****	****	****	****	0	NaN	
0-17 years	18	****	****	****	****	0	0.0%	****	****	0	0	NaN	
18-24 years	****	****	****	****	****	****	****	****	****	****	0	NaN	
25-40 years	****	****	****	0	0.0%	****	****	****	****	****	0	NaN	
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0	NaN	
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0	NaN	
Fosdenopterin	0	
0-17 years	0	
18-24 years	0	
25-40 years	0	
41-64 years	0	
≥ 65 years	0	
Melphalan Flufenamide	87	****	****	****	****	****	****	****	****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	0	NaN	
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	0	NaN	

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tivozanib	632	159	100.0%	235	100.0%	213	100.0%	25	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	36	22.6%	*****	*****	50	23.5%	*****	*****	0	NaN
≥ 65 years	490	*****	*****	185	78.7%	163	76.5%	*****	*****	0	NaN
Ponesimod	106	12	100.0%	26	100.0%	55	100.0%	13	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	26	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	66	*****	*****	*****	*****	30	54.5%	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Dasiglucagon	736	553	100.0%	153	100.0%	30	100.0%	0	NaN	0	NaN
0-17 years	108	82	14.8%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	75	57	10.3%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	149	113	20.4%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	288	204	36.9%	67	43.8%	17	56.7%	0	NaN	0	NaN
≥ 65 years	116	97	17.5%	*****	*****	*****	*****	0	NaN	0	NaN
Viloxazine	7,859	3,004	100.0%	2,248	100.0%	2,318	100.0%	289	100.0%	0	NaN
0-17 years	4,952	1,506	50.1%	1,382	61.5%	1,794	77.4%	270	93.4%	0	NaN
18-24 years	807	394	13.1%	244	10.9%	*****	*****	*****	*****	0	NaN
25-40 years	1,119	590	19.6%	330	14.7%	*****	*****	*****	*****	0	NaN
41-64 years	881	453	15.1%	270	12.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	100	61	2.0%	22	1.0%	17	0.7%	0	0.0%	0	NaN
Drospirenone and Estetrol	3,472	632	100.0%	1,170	100.0%	1,522	100.0%	148	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	181	11.9%	23	15.5%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	1,125	198	31.3%	358	30.6%	519	34.1%	50	33.8%	0	NaN
25-40 years	1,463	276	43.7%	524	44.8%	609	40.0%	54	36.5%	0	NaN
41-64 years	481	86	13.6%	161	13.8%	213	14.0%	21	14.2%	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
dostarlimab-gxly	99	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	24	24	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	338	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
≥ 65 years	299	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	5,031	2,142	100.0%	1,621	100.0%	1,229	100.0%	39	1	0	NaN
0-17 years	2,839	1,088	50.8%	903	55.7%	*****	*****	*****	*****	0	NaN
18-24 years	561	256	12.0%	*****	*****	121	9.8%	*****	*****	0	NaN
25-40 years	896	444	20.7%	290	17.9%	*****	*****	*****	*****	0	NaN
41-64 years	697	337	15.7%	231	14.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	38	17	0.8%	*****	*****	*****	*****	0	0.0%	0	NaN
Pegcetacoplan	65	*****	*****	*****	*****	28	100.0%	25	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	24	*****	*****	*****	*****	11	39.3%	*****	*****	0	NaN
≥ 65 years	26	*****	*****	*****	*****	*****	*****	13	52.0%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Amivantamab-vmjw	303	292	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	243	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Piflufolastat F 18	43,225	43,225	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	40,000	40,000	92.5%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	1,296	324	100.0%	428	100.0%	478	100.0%	66	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	17	25.8%	0	NaN
≥ 65 years	1,013	255	78.7%	340	79.4%	369	77.2%	49	74.2%	0	NaN
Infigratinib	32	*****	*****	15	100.0%	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olanzapine and Samidorphan	4,064	1,200	100.0%	1,069	100.0%	1,642	100.0%	153	100.0%	0	NaN
0-17 years	24	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	266	*****	*****	81	7.6%	*****	*****	*****	*****	0	NaN
25-40 years	1,291	361	30.1%	336	31.4%	543	33.1%	51	33.3%	0	NaN
41-64 years	2,072	618	51.5%	527	49.3%	841	51.2%	86	56.2%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	411	140	11.7%	*****	*****	147	9.0%	*****	*****	0	NaN
lbrefaxungerp	1,569	1,544	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	242	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	723	710	46.0%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	577	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	19	1.2%	0	0.0%	*****	*****	0	NaN	0	NaN
Aducanumab-avwa	348	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	67	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	50	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Cabotegravir	741	484	100.0%	112	100.0%	145	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	52	34	7.0%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	345	256	52.9%	42	37.5%	47	32.4%	0	NaN	0	NaN
41-64 years	271	173	35.7%	41	36.6%	57	39.3%	0	NaN	0	NaN
≥ 65 years	73	21	4.3%	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,212	1	46	104	221	768	153.0	136.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	4	30	93	150	498	116.8	101.7
41-64 years	607	1	56	113	229	660	157.1	135.1
≥ 65 years	2,566	1	44	102	220	768	152.6	137.5
Cabotegravir and Rilpivirine (co-packaged)	1,910	1	60	131	234	612	163.3	131.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	16	7	30	92	144	509	116.2	129.9
25-40 years	274	1	60	137	224	598	159.8	126.0
41-64 years	1,145	1	60	139	244	612	168.1	131.5
≥ 65 years	475	1	52	116	220	610	155.4	134.2
Voclosporin	324	2	35	119	240	628	159.1	143.5
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	34	30	90	180	270	508	198.7	125.7
25-40 years	140	2	30	109	235	567	155.3	143.0
41-64 years	134	2	44	116	214	628	157.0	148.9
≥ 65 years	*****	12	30	60	150	496	112.7	128.2
Tepotinib	141	3	30	90	180	639	125.4	129.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	3	40	90	300	628	176.3	165.7
≥ 65 years	125	4	30	87	145	639	120.1	124.0
Umbrisib	76	3	39	89	150	330	101.8	73.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	60	60	120	153	89.7	46.0
≥ 65 years	*****	3	30	90	150	330	103.4	76.2
Evinacumab-dgnb	49	1	3	7	15	592	37.5	112.4
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	3	6	11	22	30	13.8	10.5
41-64 years	22	1	3	12	18	420	46.9	114.2
≥ 65 years	*****	1	2	4	9	592	36.2	134.7
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	30	1	17	27	139	606	113.9	169.8

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	18	3	17	21	30	606	57.8	137.9
18-24 years	*****	17	24	150	389	465	199.0	195.0
25-40 years	*****	1	12	175	328	493	197.2	190.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	87	1	1	2	3	140	5.7	17.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	2	2	4	2.0	0.9
≥ 65 years	*****	1	1	2	3	140	6.2	18.7
Tivozanib	632	2	30	83	132	679	106.3	103.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	10	10	26	56	56	30.7	23.4
41-64 years	*****	2	28	84	118	679	106.0	104.9
≥ 65 years	490	4	31	83	138	560	106.9	103.7
Ponesimod	106	14	74	126	270	612	175.4	144.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	39	39	184	329	329	184.0	205.1
25-40 years	26	30	83	153	180	589	162.3	120.7
41-64 years	66	14	60	116	293	612	185.1	158.3
≥ 65 years	*****	30	84	106	233	376	149.3	108.6
Dasiglucagon	736	1	2	25	30	346	27.7	37.2
0-17 years	108	1	2	7	30	210	25.6	34.2
18-24 years	75	1	2	28	30	210	28.7	34.4
25-40 years	149	1	2	28	30	346	28.5	39.4
41-64 years	288	1	1	27	34	297	30.2	41.7
≥ 65 years	116	1	2	24	30	109	22.1	24.3
Viloxazine	7,859	1	30	60	131	625	98.9	103.5
0-17 years	4,952	1	30	74	167	625	119.7	116.0
18-24 years	807	1	30	33	90	601	71.8	79.6
25-40 years	1,119	1	30	30	76	492	60.3	55.7
41-64 years	881	1	30	30	76	535	61.1	58.1
≥ 65 years	100	4	30	30	66	214	53.5	46.0
Drospirenone and Estetrol	3,472	1	54	84	176	635	128.8	107.3
0-17 years	*****	2	56	103	204	594	142.4	116.0
18-24 years	1,125	1	54	95	180	588	130.3	106.2

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	1,463	1	50	84	168	635	122.0	103.6
41-64 years	481	3	56	87	191	534	135.3	112.3
≥ 65 years	*****	28	28	28	84	90	51.6	32.4
dostarlimab-gxly	99	1	2	4	6	72	5.5	8.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	5	6	6	4.5	2.1
41-64 years	*****	1	2	4	6	12	4.3	3.0
≥ 65 years	73	1	2	5	7	72	5.9	9.3
Loncastuximab Tesirine-lpyl	338	1	1	3	5	349	5.5	22.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	3	3	5	6	6	4.5	1.7
41-64 years	*****	1	1	2	4	349	13.1	59.4
≥ 65 years	299	1	1	3	5	210	4.7	13.6
Serdexmethylphenidate and Dexmethylphenidate	5,031	1	30	48	92	575	74.0	72.3
0-17 years	2,839	1	30	60	116	575	82.3	78.5
18-24 years	561	1	30	40	90	450	65.5	61.8
25-40 years	896	1	30	32	75	415	61.4	61.6
41-64 years	697	1	30	33	80	383	63.5	61.9
≥ 65 years	38	5	30	40	84	229	59.6	54.0
Pegcetacoplan	65	5	140	300	479	684	301.5	190.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	89	89	213	435	435	245.7	175.3
25-40 years	*****	29	103	253	409	684	273.3	198.7
41-64 years	24	25	140	240	521	643	295.5	198.1
≥ 65 years	26	5	149	372	485	573	326.5	189.0
Amivantamab-vmjw	303	1	5	8	16	224	13.5	22.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	5	7	7	7	6.3	1.2
41-64 years	*****	1	5	8	15	32	10.7	8.7
≥ 65 years	243	1	5	9	17	224	14.2	24.6
Piflufolostat F 18	43,225	1	1	1	1	5	1.1	0.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	4	1.1	0.2
≥ 65 years	40,000	1	1	1	1	5	1.1	0.3
Sotorasib	1,296	1	31	90	162	647	124.3	116.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	60	135	210	240	135.0	93.3

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	*****	3	33	90	179	647	128.2	124.1
≥ 65 years	1,013	1	30	90	150	584	123.2	114.8
Infigratinib	32	18	53	84	112	363	92.8	67.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	56	56	168	363	363	195.7	155.4
41-64 years	*****	84	84	112	140	140	108.0	25.2
≥ 65 years	*****	18	28	64	84	196	73.9	48.2
Olanzapine and Samidorphan	4,064	1	30	86	180	506	120.0	106.3
0-17 years	24	16	30	60	116	359	87.7	83.5
18-24 years	266	2	30	82	157	464	111.2	96.2
25-40 years	1,291	1	30	90	180	469	122.8	106.0
41-64 years	2,072	1	30	86	183	506	123.2	109.9
≥ 65 years	411	1	30	60	150	452	102.3	93.2
Ibrexafungerp	1,569	1	1	1	2	167	2.8	8.4
0-17 years	*****	1	1	1	2	2	1.4	0.5
18-24 years	242	1	1	1	2	41	2.5	5.3
25-40 years	723	1	1	1	2	94	2.9	7.6
41-64 years	577	1	1	1	2	123	2.5	7.9
≥ 65 years	*****	1	1	1	2	167	9.7	37.0
Aducanumab-avwa	348	1	1	3	5	215	4.3	11.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	2	4	6	10	4.1	3.1
≥ 65 years	*****	1	1	3	5	215	4.3	11.8
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	67	1	6	12	23	90	15.1	14.1
0-17 years	50	2	6	12	23	90	16.1	13.9
18-24 years	*****	1	4	10	11	21	9.1	6.4
25-40 years	*****	4	13	26	44	57	28.3	22.0
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	1	1	1	2	24	5.8	10.2

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Cabotegravir	741	1	2	5	71	334	45.7	66.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	52	1	2	5	76	334	53.8	82.3
25-40 years	345	1	2	3	33	316	33.1	57.4
41-64 years	271	1	2	6	82	323	47.0	66.5
≥ 65 years	73	1	30	67	151	264	94.6	71.8

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Vericiguat</i>	6,531	3,247	49.7%	2,010	30.8%	1,151	17.6%	*****	*****	*****	*****
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	5,025	2,716	54.0%	1,524	30.3%	737	14.7%	48	1.0%	0	0.0%
<i>Voclosporin</i>	781	433	55.4%	218	27.9%	*****	*****	*****	*****	0	0.0%
<i>Tepotinib</i>	272	159	58.5%	73	26.8%	*****	*****	*****	*****	0	0.0%
<i>Umbrisib</i>	130	75	57.7%	36	27.7%	19	14.6%	0	0.0%	0	0.0%
<i>Evinacumab-dgnb</i>	381	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	511	495	96.9%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	193	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tivozanib</i>	1,241	703	56.6%	382	30.8%	*****	*****	*****	*****	0	0.0%
<i>Ponesimod</i>	242	125	51.7%	65	26.9%	*****	*****	*****	*****	0	0.0%
<i>Dasiglucagon</i>	933	770	82.5%	145	15.5%	18	1.9%	0	0.0%	0	0.0%
<i>Viloxazine</i>	14,747	9,687	65.7%	3,533	24.0%	1,428	9.7%	99	0.7%	0	0.0%
<i>Drospirenone and Estetrol</i>	5,609	2,215	39.5%	2,128	37.9%	1,206	21.5%	60	1.1%	0	0.0%
<i>dostarlimab-gxly</i>	434	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Loncastuximab Tesirine-lpyl</i>	1,207	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	9,532	7,329	76.9%	1,707	17.9%	*****	*****	*****	*****	0	0.0%
<i>Pegcetacoplan</i>	170	69	40.6%	38	22.4%	*****	*****	*****	*****	0	0.0%
<i>Amivantamab-vmjw</i>	2,967	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Piflufolastat F 18</i>	45,605	45,605	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Sotorasib</i>	2,350	1,255	53.4%	684	29.1%	380	16.2%	31	1.3%	0	0.0%

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Infigratinib</i>	50	****	****	26	52.0%	****	****	0	0.0%	0	0.0%
<i>Olanzapine and Samidorphan</i>	7,366	4,178	56.7%	1,864	25.3%	1,248	16.9%	76	1.0%	0	0.0%
<i>Ibexafungerp</i>	2,215	2,202	99.4%	****	****	****	****	0	0.0%	0	0.0%
<i>Aducanumab-avwa</i>	1,291	****	****	****	****	****	****	0	0.0%	0	0.0%
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	1,012	1,012	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Cabotegravir</i>	1,735	1,474	85.0%	198	11.4%	63	3.6%	0	0.0%	0	0.0%

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Vericiguat</i>	6,531	1	30	32	90	768	75.3	84.5
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	5,025	1	30	30	60	564	62.1	68.2
<i>Voclosporin</i>	781	1	30	30	90	541	66.0	70.4
<i>Tepotinib</i>	272	3	30	30	60	549	65.0	74.2
<i>Umbrisib</i>	130	3	30	30	90	270	59.5	48.3
<i>Evinacumab-dgnb</i>	381	1	1	1	1	592	4.8	31.8
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	511	1	1	1	1	493	6.7	35.3
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	193	1	1	1	1	140	2.6	11.7
<i>Tivozanib</i>	1,241	1	28	28	56	483	54.1	52.0
<i>Ponesimod</i>	242	3	30	30	90	551	76.8	90.8
<i>Dasiglucagon</i>	933	1	1	6	30	346	21.9	29.7
<i>Viloxazine</i>	14,747	1	30	30	60	625	52.7	58.3
<i>Drospirenone and Estetrol</i>	5,609	1	28	56	84	588	79.7	77.0
<i>dostarlimab-gxly</i>	434	1	1	1	1	72	1.3	3.9
<i>Loncastuximab Tesirine-lpyl</i>	1,207	1	1	1	1	147	1.5	6.5
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	9,532	1	30	30	30	545	39.0	35.6
<i>Pegcetacoplan</i>	170	5	28	56	168	684	115.3	126.4
<i>Amivantamab-vmjw</i>	2,967	1	1	1	1	224	1.4	6.5
<i>Piflufolastat F 18</i>	45,605	1	1	1	1	2	1.0	0.0
<i>Sotorasib</i>	2,350	1	30	30	89	647	68.5	74.5
<i>Infigratinib</i>	50	18	28	56	84	335	59.4	48.1
<i>Olanzapine and Samidorphan</i>	7,366	1	30	30	75	476	66.2	71.5
<i>Ibrexafungerp</i>	2,215	1	1	1	1	105	2.0	5.8
<i>Aducanumab-avwa</i>	1,291	1	1	1	1	155	1.2	4.6
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	1,012	1	1	1	1	2	1.0	0.0
<i>Cabotegravir</i>	1,735	1	1	1	30	334	19.5	33.8

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vericiguat	6,531	3,247	100.0%	2,010	100.0%	1,151	100.0%	*****	*****	*****	*****
Female	2,307	1,196	36.8%	674	33.5%	394	34.2%	*****	*****	*****	*****
Male	4,224	2,051	63.2%	1,336	66.5%	757	65.8%	*****	*****	*****	*****
Cabotegravir and Rilpivirine (co-packaged)	5,025	2,716	100.0%	1,524	100.0%	737	100.0%	48	100.0%	0	NaN
Female	1,152	636	23.4%	357	23.4%	*****	*****	*****	*****	0	NaN
Male	3,873	2,080	76.6%	1,167	76.6%	*****	*****	*****	*****	0	NaN
Voclosporin	781	433	100.0%	218	100.0%	*****	*****	*****	*****	0	NaN
Female	618	347	80.1%	169	77.5%	*****	*****	*****	*****	0	NaN
Male	163	86	19.9%	49	22.5%	*****	*****	*****	*****	0	NaN
Tepotinib	272	159	100.0%	73	100.0%	*****	*****	*****	*****	0	NaN
Female	169	101	63.5%	42	57.5%	*****	*****	*****	*****	0	NaN
Male	103	58	36.5%	31	42.5%	*****	*****	*****	*****	0	NaN
Umbrisib	130	75	100.0%	36	100.0%	19	100.0%	0	NaN	0	NaN
Female	62	34	45.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	68	41	54.7%	*****	*****	*****	*****	0	NaN	0	NaN
Evinacumab-dgnb	381	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Female	265	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Male	116	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	511	495	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Male	511	495	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	193	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	95	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	98	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Tivozanib	1,241	703	100.0%	382	100.0%	*****	*****	*****	*****	0	NaN
Female	318	187	26.6%	90	23.6%	*****	*****	*****	*****	0	NaN
Male	923	516	73.4%	292	76.4%	*****	*****	*****	*****	0	NaN
Ponesimod	242	125	100.0%	65	100.0%	*****	*****	*****	*****	0	NaN
Female	185	97	77.6%	51	78.5%	*****	*****	*****	*****	0	NaN
Male	57	28	22.4%	14	21.5%	*****	*****	*****	*****	0	NaN
Dasiglucagon	933	770	100.0%	145	100.0%	18	100.0%	0	NaN	0	NaN
Female	487	404	52.5%	*****	*****	*****	*****	0	NaN	0	NaN
Male	446	366	47.5%	*****	*****	*****	*****	0	NaN	0	NaN
Viloxazine	14,747	9,687	100.0%	3,533	100.0%	1,428	100.0%	99	100.0%	0	NaN
Female	6,038	4,113	42.5%	1,411	39.9%	493	34.5%	21	21.2%	0	NaN
Male	8,709	5,574	57.5%	2,122	60.1%	935	65.5%	78	78.8%	0	NaN
Drospirenone and Estetrol	5,609	2,215	100.0%	2,128	100.0%	1,206	100.0%	60	100.0%	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	60	100.0%	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
dostarlimab-gxly	434	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	302	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	132	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	1,207	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	469	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	738	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	9,532	7,329	100.0%	1,707	100.0%	*****	*****	*****	*****	0	NaN
Female	4,015	3,122	42.6%	693	40.6%	*****	*****	*****	*****	0	NaN
Male	5,517	4,207	57.4%	1,014	59.4%	*****	*****	*****	*****	0	NaN
Pegcetacoplan	170	69	100.0%	*****	*****	53	100.0%	*****	*****	0	NaN
Female	80	30	43.5%	*****	*****	29	54.7%	*****	*****	0	NaN
Male	90	39	56.5%	*****	*****	24	45.3%	*****	*****	0	NaN
Amivantamab-vmjw	2,967	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	2,221	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	746	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Piflufolastat F 18	45,605	45,605	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	73	73	0.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	45,532	45,532	99.8%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	2,350	1,255	100.0%	684	100.0%	380	100.0%	31	100.0%	0	NaN
Female	1,438	773	61.6%	425	62.1%	*****	*****	*****	*****	0	NaN
Male	912	482	38.4%	259	37.9%	*****	*****	*****	*****	0	NaN
Infigratinib	50	*****	*****	26	100.0%	*****	*****	0	NaN	0	NaN
Female	28	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	22	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olanzapine and Samidorphan	7,366	4,178	100.0%	1,864	100.0%	1,248	100.0%	76	100.0%	0	NaN
Female	4,015	2,318	55.5%	1,010	54.2%	646	51.8%	41	53.9%	0	NaN
Male	3,351	1,860	44.5%	854	45.8%	602	48.2%	35	46.1%	0	NaN
Ibexafungerp	2,215	2,202	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	2,203	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	12	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Aducanumab-avwa	1,291	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	659	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	632	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	1,012	1,012	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	320	320	31.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	692	692	68.4%	0	NaN	0	NaN	0	NaN	0	NaN
Cabotegravir	1,735	1,474	100.0%	198	100.0%	63	100.0%	0	NaN	0	NaN
Female	106	90	6.1%	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,629	1,384	93.9%	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	6,531	1	30	32	90	768	75.3	84.5
Female	2,307	1	30	30	90	768	73.6	85.7
Male	4,224	1	30	38	90	653	76.2	83.9
Cabotegravir and Rilpivirine (co-packaged)	5,025	1	30	30	60	564	62.1	68.2
Female	1,152	1	28	30	60	528	58.8	64.4
Male	3,873	1	30	30	60	564	63.0	69.2
Voclosporin	781	1	30	30	90	541	66.0	70.4
Female	618	1	30	30	86	541	64.2	66.7
Male	163	1	30	30	90	537	72.8	82.8
Tepotinib	272	3	30	30	60	549	65.0	74.2
Female	169	3	30	30	60	549	65.5	79.6
Male	103	4	30	30	60	305	64.3	64.9
Umbrisib	130	3	30	30	90	270	59.5	48.3
Female	62	17	30	30	90	210	62.7	50.1
Male	68	3	30	30	75	270	56.6	46.8
Evinacumab-dgnb	381	1	1	1	1	592	4.8	31.8
Female	265	1	1	1	1	592	6.4	38.0
Male	116	1	1	1	1	30	1.3	2.7
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	511	1	1	1	1	493	6.7	35.3
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	511	1	1	1	1	493	6.7	35.3
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	193	1	1	1	1	140	2.6	11.7
Female	95	1	1	1	1	140	3.0	14.7
Male	98	1	1	1	1	56	2.1	7.8
Tivozanib	1,241	1	28	28	56	483	54.1	52.0
Female	318	4	28	28	56	308	52.4	46.7
Male	923	1	28	28	56	483	54.7	53.7
Ponesimod	242	3	30	30	90	551	76.8	90.8
Female	185	3	30	30	89	551	74.9	91.8
Male	57	9	30	37	120	359	83.2	87.7
Dasiglucagon	933	1	1	6	30	346	21.9	29.7
Female	487	1	1	4	30	180	21.4	28.4
Male	446	1	1	7	30	346	22.4	31.0
Viloxazine	14,747	1	30	30	60	625	52.7	58.3
Female	6,038	1	30	30	60	570	48.5	50.0
Male	8,709	1	30	30	60	625	55.6	63.3
Drospirenone and Estetrol	5,609	1	28	56	84	588	79.7	77.0
Female	*****	1	28	56	84	588	79.7	77.0

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	*****	13	27	45	127	168	70.3	58.5
dostarlimab-gxly	434	1	1	1	1	72	1.3	3.9
Female	302	1	1	1	1	1	1.0	0.0
Male	132	1	1	1	1	72	1.8	7.0
Loncastuximab Tesirine-lpyl	1,207	1	1	1	1	147	1.5	6.5
Female	469	1	1	1	1	105	1.7	6.5
Male	738	1	1	1	1	147	1.5	6.5
Serdexmethylphenidate and Dexmethylphenidate	9,532	1	30	30	30	545	39.0	35.6
Female	4,015	1	30	30	30	491	37.9	33.9
Male	5,517	1	30	30	30	545	39.8	36.7
Pegcetacoplan	170	5	28	56	168	684	115.3	126.4
Female	80	20	28	82	201	573	125.0	123.8
Male	90	5	28	56	140	684	106.7	128.8
Amivantamab-vmjw	2,967	1	1	1	1	224	1.4	6.5
Female	2,221	1	1	1	1	168	1.3	5.8
Male	746	1	1	1	1	224	1.5	8.3
Piflufolastat F 18	45,605	1	1	1	1	2	1.0	0.0
Female	73	1	1	1	1	1	1.0	0.0
Male	45,532	1	1	1	1	2	1.0	0.0
Sotorasib	2,350	1	30	30	89	647	68.5	74.5
Female	1,438	1	30	30	85	647	68.6	76.2
Male	912	1	30	30	90	538	68.5	71.7
Infigratinib	50	18	28	56	84	335	59.4	48.1
Female	28	18	28	53	80	140	54.3	30.7
Male	22	28	28	56	84	335	65.8	64.1
Olanzapine and Samidorphan	7,366	1	30	30	75	476	66.2	71.5
Female	4,015	1	30	30	65	458	64.1	69.3
Male	3,351	1	30	30	84	476	68.8	74.0
Ibrexafungerp	2,215	1	1	1	1	105	2.0	5.8
Female	2,203	1	1	1	1	105	1.9	5.4
Male	12	1	1	1	3	94	12.3	27.9

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Aducanumab-avwa	1,291	1	1	1	1	155	1.2	4.6
Female	659	1	1	1	1	155	1.3	6.4
Male	632	1	1	1	1	1	1.0	0.0
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	1,012	1	1	1	1	2	1.0	0.0
Female	320	1	1	1	1	1	1.0	0.0
Male	692	1	1	1	1	2	1.0	0.1
Cabotegravir	1,735	1	1	1	30	334	19.5	33.8
Female	106	1	1	1	30	288	23.6	47.0
Male	1,629	1	1	1	30	334	19.3	32.7

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vericiguat	6,531	3,247	100.0%	2,010	100.0%	1,151	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	59	1.8%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,320	652	20.1%	*****	*****	*****	*****	19	15.6%	0	0.0%
≥ 65 years	5,121	2,536	78.1%	1,546	76.9%	936	81.3%	*****	*****	*****	*****
Cabotegravir and Rilpivirine (co-packaged)	5,025	2,716	100.0%	1,524	100.0%	737	100.0%	48	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	43	31	1.1%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	761	449	16.5%	*****	*****	95	12.9%	*****	*****	0	NaN
41-64 years	3,043	1,597	58.8%	941	61.7%	478	64.9%	27	56.3%	0	NaN
≥ 65 years	1,178	639	23.5%	361	23.7%	*****	*****	*****	*****	0	NaN
Voclosporin	781	433	100.0%	218	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	84	32	7.4%	35	16.1%	17	*****	0	0.0%	0	NaN
25-40 years	340	196	45.3%	89	40.8%	*****	*****	*****	*****	0	NaN
41-64 years	328	189	43.6%	*****	*****	49	40.2%	*****	*****	0	NaN
≥ 65 years	*****	16	3.7%	*****	*****	*****	*****	0	0.0%	0	NaN
Tepotinib	272	159	100.0%	73	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	238	142	89.3%	*****	*****	*****	*****	*****	*****	0	NaN
Umbrisib	130	75	100.0%	36	100.0%	19	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	15	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	115	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Evinacumab-dgnb	381	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
0-17 years	20	20	*****	0	0.0%	0	NaN	0	0.0%	0	NaN
18-24 years	14	14	*****	0	0.0%	0	NaN	0	0.0%	0	NaN
25-40 years	54	54	*****	0	0.0%	0	NaN	0	0.0%	0	NaN
41-64 years	196	*****	*****	*****	*****	0	NaN	0	0.0%	0	NaN
≥ 65 years	97	*****	*****	0	0.0%	0	NaN	*****	*****	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	511	495	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	383	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	5	1.0%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	193	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tivozanib	1,241	703	100.0%	*****	*****	152	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	77	*****	38	25.0%	*****	*****	0	NaN
≥ 65 years	983	562	79.9%	*****	*****	114	75.0%	*****	*****	0	NaN
Ponesimod	242	125	100.0%	65	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	63	*****	*****	*****	*****	12	26.1%	*****	*****	0	NaN
41-64 years	158	83	66.4%	42	64.6%	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Dasiglucagon	933	770	100.0%	145	100.0%	18	100.0%	0	NaN	0	NaN
0-17 years	165	143	18.6%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	93	76	9.9%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	177	145	18.8%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	369	291	37.8%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	129	115	14.9%	14	9.7%	0	0.0%	0	NaN	0	NaN
Viloxazine	14,747	9,687	100.0%	3,533	100.0%	1,428	100.0%	99	100.0%	0	NaN
0-17 years	10,436	6,567	67.8%	2,619	74.1%	1,161	81.3%	89	89.9%	0	NaN
18-24 years	1,285	917	9.5%	279	7.9%	*****	*****	*****	*****	0	NaN
25-40 years	1,633	1,194	12.3%	341	9.7%	*****	*****	*****	*****	0	NaN
41-64 years	1,255	907	9.4%	*****	*****	80	5.6%	*****	*****	0	NaN
≥ 65 years	138	102	1.1%	*****	*****	*****	*****	0	0.0%	0	NaN
Drospirenone and Estetrol	5,609	2,215	100.0%	2,128	100.0%	1,206	100.0%	60	100.0%	0	NaN
0-17 years	688	276	12.5%	256	12.0%	*****	*****	*****	*****	0	NaN
18-24 years	1,846	740	33.4%	678	31.9%	407	33.7%	21	35.0%	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	2,286	871	39.3%	918	43.1%	479	39.7%	18	30.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
dostarlimab-gxly	434	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	104	104	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	1,207	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	18	18	1.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,082	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	9,532	7,329	100.0%	1,707	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	5,846	4,475	61.1%	1,035	60.6%	*****	*****	*****	*****	0	NaN
18-24 years	1,035	820	11.2%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	1,457	1,127	15.4%	260	15.2%	*****	*****	*****	*****	0	NaN
41-64 years	1,142	871	11.9%	217	12.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	52	36	0.5%	*****	*****	*****	*****	0	0.0%	0	NaN
Pegcetacoplan	170	69	100.0%	*****	*****	53	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	11	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	22	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	59	*****	*****	13	*****	18	34.0%	*****	*****	0	NaN
≥ 65 years	78	36	52.2%	13	*****	*****	*****	*****	*****	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Amivantamab-vmjw	2,967	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	549	549	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Piflufolostat F 18	45,605	45,605	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	42,211	42,211	92.6%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	2,350	1,255	100.0%	684	100.0%	380	100.0%	31	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	86	22.6%	*****	*****	0	NaN
≥ 65 years	1,845	985	78.5%	545	79.7%	*****	*****	*****	*****	0	NaN
Infigratinib	50	*****	*****	26	100.0%	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	31	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olanzapine and Samidorphan	7,366	4,178	100.0%	1,864	100.0%	1,248	100.0%	76	100.0%	0	NaN
0-17 years	37	22	0.5%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	485	293	7.0%	*****	*****	72	5.8%	*****	*****	0	NaN
25-40 years	2,482	1,438	34.4%	622	33.4%	404	32.4%	18	23.7%	0	NaN
41-64 years	3,667	2,015	48.2%	941	50.5%	664	53.2%	47	61.8%	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	695	410	9.8%	176	9.4%	*****	*****	*****	*****	0	NaN
lbrefaxungerp	2,215	2,202	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	314	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	1,046	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	815	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Aducumab-avwa	1,291	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	1,012	1,012	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	803	803	79.3%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	64	64	6.3%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	112	112	11.1%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Cabotegravir	1,735	1,474	100.0%	198	100.0%	63	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	123	101	6.9%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	781	701	47.6%	57	28.8%	23	36.5%	0	NaN	0	NaN
41-64 years	654	543	36.8%	86	43.4%	25	39.7%	0	NaN	0	NaN
≥ 65 years	177	129	8.8%	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	6,531	1	30	32	90	768	75.3	84.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	28	30	60	480	49.9	58.9
41-64 years	1,320	1	30	33	90	653	72.3	78.7
≥ 65 years	5,121	1	30	32	90	768	76.5	86.3
Cabotegravir and Rilpivirine (co-packaged)	5,025	1	30	30	60	564	62.1	68.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	43	3	28	30	56	282	43.2	45.0
25-40 years	761	1	30	30	60	494	57.5	62.1
41-64 years	3,043	1	30	30	60	558	63.2	68.0
≥ 65 years	1,178	1	28	30	60	564	62.7	72.8
Voclosporin	781	1	30	30	90	541	66.0	70.4
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	84	30	30	60	90	314	80.4	66.5
25-40 years	340	1	30	30	60	541	63.9	69.3
41-64 years	328	1	30	30	76	537	64.1	71.6
≥ 65 years	*****	12	30	30	67	330	60.4	63.2
Tepotinib	272	3	30	30	60	549	65.0	74.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	3	30	40	90	305	80.1	77.7
≥ 65 years	238	4	30	30	60	549	63.1	73.8
Umbrisib	130	3	30	30	90	270	59.5	48.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	15	30	30	30	60	153	53.8	36.8
≥ 65 years	115	3	30	30	90	270	60.3	49.7
Evinacumab-dgnb	381	1	1	1	1	592	4.8	31.8
0-17 years	20	1	1	1	1	1	1.0	0.0
18-24 years	14	1	1	1	1	1	1.0	0.0
25-40 years	54	1	1	1	1	30	1.5	3.9
41-64 years	196	1	1	1	1	84	5.3	13.7
≥ 65 years	97	1	1	1	1	592	7.1	60.0
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	511	1	1	1	1	493	6.7	35.3
0-17 years	383	1	1	1	1	280	2.7	17.9
18-24 years	*****	1	1	1	1	252	10.1	34.9

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	1	7	28	196	493	118.3	162.5
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	193	1	1	1	1	140	2.6	11.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	20	1	1	1	1	1	1.0	0.0
≥ 65 years	173	1	1	1	1	140	2.8	12.4
Tivozanib	1,241	1	28	28	56	483	54.1	52.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	10	10	26	56	56	30.7	23.4
41-64 years	*****	2	28	28	84	367	57.8	52.1
≥ 65 years	983	1	28	28	56	483	53.3	52.0
Ponesimod	242	3	30	30	90	551	76.8	90.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	39	39	90	239	239	122.7	103.9
25-40 years	63	3	30	30	90	499	67.0	79.8
41-64 years	158	3	30	30	89	551	77.3	94.4
≥ 65 years	*****	14	30	84	108	376	99.5	93.1
Dasiglucagon	933	1	1	6	30	346	21.9	29.7
0-17 years	165	1	1	2	30	144	16.7	25.3
18-24 years	93	1	1	18	30	150	23.1	28.0
25-40 years	177	1	1	14	30	346	24.0	36.2
41-64 years	369	1	1	6	30	180	23.6	30.7
≥ 65 years	129	1	2	18	30	90	19.9	21.4
Viloxazine	14,747	1	30	30	60	625	52.7	58.3
0-17 years	10,436	1	30	30	60	625	56.8	63.5
18-24 years	1,285	1	30	30	48	494	45.1	45.9
25-40 years	1,633	1	30	30	35	492	41.3	37.5
41-64 years	1,255	1	30	30	44	535	42.9	42.8
≥ 65 years	138	4	30	30	33	194	38.8	29.7
Drospirenone and Estetrol	5,609	1	28	56	84	588	79.7	77.0
0-17 years	*****	1	28	56	84	533	82.4	81.6
18-24 years	1,846	1	28	56	84	588	79.4	77.0
25-40 years	2,286	1	28	56	84	516	78.1	73.1
41-64 years	784	2	28	56	84	534	83.0	83.9
≥ 65 years	*****	28	28	28	84	90	51.6	32.4

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dostarlimab-gxly	434	1	1	1	1	72	1.3	3.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	321	1	1	1	1	72	1.3	4.5
Loncastuximab Tesirine-lpyl	1,207	1	1	1	1	147	1.5	6.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	104	1	1	1	1	147	4.3	17.1
≥ 65 years	1,082	1	1	1	1	105	1.3	4.3
Serdexmethylphenidate and Dexmethylphenidate	9,532	1	30	30	30	545	39.0	35.6
0-17 years	5,846	1	30	30	30	545	40.0	37.2
18-24 years	1,035	1	30	30	30	244	35.5	26.1
25-40 years	1,457	1	30	30	30	391	37.8	35.1
41-64 years	1,142	1	30	30	30	383	38.8	34.2
≥ 65 years	52	5	25	30	53	229	43.5	43.2
Pegcetacoplan	170	5	28	56	168	684	115.3	126.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	28	28	45	84	252	67.0	65.1
25-40 years	22	28	56	95	205	684	149.1	152.6
41-64 years	59	20	28	60	191	506	120.2	126.9
≥ 65 years	78	5	28	56	146	573	108.8	123.8
Amivantamab-vmjw	2,967	1	1	1	1	224	1.4	6.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	1	1	1	1	2	1.2	0.4
41-64 years	549	1	1	1	1	28	1.1	1.2
≥ 65 years	2,402	1	1	1	1	224	1.4	7.2
Piflufolostat F 18	45,605	1	1	1	1	2	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	42,211	1	1	1	1	2	1.0	0.0
Sotorasib	2,350	1	30	30	89	647	68.5	74.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	90	120	180	90.0	60.0
41-64 years	*****	3	30	30	90	647	71.7	83.5
≥ 65 years	1,845	1	30	30	85	563	67.6	71.9
Infigratinib	50	18	28	56	84	335	59.4	48.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	56	140	335	117.4	130.0
41-64 years	*****	28	28	56	84	84	54.0	25.7
≥ 65 years	31	18	28	56	75	112	52.5	24.9
Olanzapine and Samidorphan	7,366	1	30	30	75	476	66.2	71.5
0-17 years	37	6	30	30	60	359	56.9	63.9
18-24 years	485	1	30	30	60	464	61.0	66.1
25-40 years	2,482	1	30	30	62	448	63.9	68.5
41-64 years	3,667	1	30	30	90	476	69.6	75.2
≥ 65 years	695	1	30	30	60	425	60.5	65.1
lbrexafungerp	2,215	1	1	1	1	105	2.0	5.8
0-17 years	*****	1	1	1	1	2	1.1	0.3
18-24 years	314	1	1	1	1	31	1.9	4.3
25-40 years	1,046	1	1	1	1	94	2.0	5.6
41-64 years	815	1	1	1	1	105	1.8	5.7
≥ 65 years	*****	1	1	1	1	84	6.2	16.4
Aducanumab-avwa	1,291	1	1	1	1	155	1.2	4.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	37	1	1	1	1	1	1.0	0.0
≥ 65 years	1,254	1	1	1	1	155	1.2	4.7
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	1,012	1	1	1	1	2	1.0	0.0
0-17 years	803	1	1	1	1	2	1.0	0.0
18-24 years	64	1	1	1	1	1	1.0	0.0
25-40 years	112	1	1	1	1	2	1.0	0.1
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Cabotegravir	1,735	1	1	1	30	334	19.5	33.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	123	1	1	1	30	334	22.8	43.2
25-40 years	781	1	1	1	28	288	14.6	30.2
41-64 years	654	1	1	1	30	273	19.5	33.7
≥ 65 years	177	1	30	30	36	264	39.0	34.7

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Vericiguat</i>	3,212	1,528	47.6%	966	30.1%	630	19.6%	*****	*****	*****	*****
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	1,910	1,080	56.5%	559	29.3%	248	13.0%	23	1.2%	0	0.0%
<i>Voclosporin</i>	324	169	52.2%	86	26.5%	*****	*****	*****	*****	0	0.0%
<i>Tepotinib</i>	141	78	55.3%	39	27.7%	*****	*****	*****	*****	0	0.0%
<i>Umbrisib</i>	76	40	52.6%	22	28.9%	14	18.4%	0	0.0%	0	0.0%
<i>Evinacumab-dgnb</i>	49	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	30	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	87	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tivozanib</i>	632	355	56.2%	199	31.5%	*****	*****	*****	*****	0	0.0%
<i>Ponesimod</i>	106	46	43.4%	32	30.2%	*****	*****	*****	*****	0	0.0%
<i>Dasiglucagon</i>	736	594	80.7%	126	17.1%	16	2.2%	0	0.0%	0	0.0%
<i>Viloxazine</i>	7,859	5,276	67.1%	1,765	22.5%	746	9.5%	72	0.9%	0	0.0%
<i>Drospirenone and Estetrol</i>	3,472	1,241	35.7%	1,395	40.2%	784	22.6%	52	1.5%	0	0.0%
<i>dostarlimab-gxly</i>	99	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Loncastuximab Tesirine-lpyl</i>	338	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	5,031	3,773	75.0%	962	19.1%	*****	*****	*****	*****	0	0.0%
<i>Pegcetacoplan</i>	65	31	47.7%	*****	*****	19	29.2%	*****	*****	0	0.0%
<i>Amivantamab-vmjw</i>	303	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Piflufolastat F 18</i>	43,225	43,225	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Sotorasib</i>	1,296	646	49.8%	396	30.6%	232	17.9%	22	1.7%	0	0.0%

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Infigratinib</i>	32	*****	*****	20	62.5%	*****	*****	0	0.0%	0	0.0%
<i>Olanzapine and Samidorphan</i>	4,064	2,251	55.4%	997	24.5%	750	18.5%	66	1.6%	0	0.0%
<i>Ibrexafungerp</i>	1,569	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Aducanumab-avwa</i>	348	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	67	67	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Cabotegravir</i>	741	596	80.4%	106	14.3%	39	5.3%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Vericiguat</i>	3,212	1	30	43	90	768	83.4	94.9
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	1,910	1	30	30	60	558	62.8	71.6
<i>Voclosporin</i>	324	2	30	30	90	541	77.4	87.9
<i>Tepotinib</i>	141	3	30	30	90	390	65.7	67.0
<i>Umbrisib</i>	76	3	30	30	90	210	64.8	50.1
<i>Evinacumab-dgnb</i>	49	1	1	1	1	592	16.0	84.7
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	30	1	1	1	28	493	56.7	117.9
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	87	1	1	1	1	140	4.2	17.1
<i>Tivozanib</i>	632	2	28	28	56	483	53.6	52.5
<i>Ponesimod</i>	106	14	30	44	104	455	83.8	88.5
<i>Dasiglucagon</i>	736	1	1	15	30	346	23.6	30.9
<i>Viloxazine</i>	7,859	1	30	30	60	625	53.2	62.8
<i>Drospirenone and Estetrol</i>	3,472	1	28	60	84	588	85.6	81.9
<i>dostarlimab-gxly</i>	99	1	1	1	1	72	2.1	8.1
<i>Loncastuximab Tesirine-lpyl</i>	338	1	1	1	1	147	1.8	9.8
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	5,031	1	30	30	31	491	40.6	38.0
<i>Pegcetacoplan</i>	65	5	28	56	196	684	117.9	142.2
<i>Amivantamab-vmjw</i>	303	1	1	2	2	224	3.9	18.9
<i>Piflufolastat F 18</i>	43,225	1	1	1	1	2	1.0	0.0
<i>Sotorasib</i>	1,296	1	30	32	90	647	73.2	80.4
<i>Infigratinib</i>	32	18	28	56	81	112	54.9	24.9
<i>Olanzapine and Samidorphan</i>	4,064	1	30	30	90	464	71.8	79.1
<i>Ibexafungerp</i>	1,569	1	1	1	1	105	1.8	5.3
<i>Aducanumab-avwa</i>	348	1	1	1	1	60	1.2	3.2
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	67	1	1	1	1	1	1.0	0.0
<i>Cabotegravir</i>	741	1	1	1	30	334	24.2	39.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Vericiguat	3,212	1,528	100.0%	966	100.0%	630	100.0%	*****	*****	*****	*****
Female	1,108	542	35.5%	321	33.2%	216	34.3%	*****	*****	*****	*****
Male	2,104	986	64.5%	645	66.8%	414	65.7%	59	67.8%	0	0.0%
Cabotegravir and Rilpivirine (co-packaged)	1,910	1,080	100.0%	559	100.0%	248	100.0%	23	100.0%	0	NaN
Female	454	271	25.1%	125	22.4%	*****	*****	*****	*****	0	NaN
Male	1,456	809	74.9%	434	77.6%	*****	*****	*****	*****	0	NaN
Voclosporin	324	169	100.0%	86	100.0%	*****	*****	*****	*****	0	NaN
Female	261	141	83.4%	69	80.2%	*****	*****	*****	*****	0	NaN
Male	63	28	16.6%	17	19.8%	*****	*****	*****	*****	0	NaN
Tepotinib	141	78	100.0%	39	100.0%	*****	*****	*****	*****	0	NaN
Female	92	54	69.2%	*****	*****	*****	*****	*****	*****	0	NaN
Male	49	24	30.8%	*****	*****	*****	*****	0	0.0%	0	NaN
Umbrisib	76	40	100.0%	22	100.0%	14	100.0%	0	NaN	0	NaN
Female	36	17	42.5%	*****	*****	*****	*****	0	NaN	0	NaN
Male	40	23	57.5%	*****	*****	*****	*****	0	NaN	0	NaN
Evinacumab-dgnb	49	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Female	37	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
Male	12	*****	*****	0	0.0%	0	NaN	0	0.0%	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	30	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Male	30	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	87	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	45	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Male	42	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Tivozanib	632	355	100.0%	199	100.0%	*****	*****	*****	*****	0	NaN
Female	162	95	26.8%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	470	260	73.2%	*****	*****	*****	*****	*****	*****	0	NaN
Ponesimod	106	46	100.0%	32	100.0%	*****	*****	*****	*****	0	NaN
Female	83	35	76.1%	*****	*****	*****	*****	*****	*****	0	NaN
Male	23	11	23.9%	*****	*****	*****	*****	0	0.0%	0	NaN
Dasiglucagon	736	594	100.0%	126	100.0%	16	100.0%	0	NaN	0	NaN
Female	379	308	51.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	357	286	48.1%	*****	*****	*****	*****	0	NaN	0	NaN
Viloxazine	7,859	5,276	100.0%	1,765	100.0%	746	100.0%	72	100.0%	0	NaN
Female	3,394	2,376	45.0%	731	41.4%	272	36.5%	15	20.8%	0	NaN
Male	4,465	2,900	55.0%	1,034	58.6%	474	63.5%	57	79.2%	0	NaN
Drospirenone and Estetrol	3,472	1,241	100.0%	1,395	100.0%	784	100.0%	52	100.0%	0	NaN
Female	*****	*****	*****	*****	*****	784	100.0%	52	100.0%	0	NaN
Male	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
dostarlimab-gxly	99	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	69	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	30	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	338	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	135	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Male	203	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Serdexmethylphenidate and	5,031	3,773	100.0%	962	100.0%	*****	*****	*****	*****	0	NaN
Female	2,260	1,712	45.4%	421	43.8%	*****	*****	*****	*****	0	NaN
Male	2,771	2,061	54.6%	541	56.2%	*****	*****	*****	*****	0	NaN
Pegcetacoplan	65	31	100.0%	*****	*****	19	100.0%	*****	*****	0	NaN
Female	31	15	48.4%	*****	*****	*****	*****	*****	*****	0	NaN
Male	34	16	51.6%	*****	*****	*****	*****	*****	*****	0	NaN
Amivantamab-vmjw	303	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	213	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	90	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Piflufolastat F 18	43,225	43,225	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	73	73	0.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	43,152	43,152	99.8%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	1,296	646	100.0%	396	100.0%	232	100.0%	22	100.0%	0	NaN
Female	790	408	63.2%	243	61.4%	*****	*****	*****	*****	0	NaN
Male	506	238	36.8%	153	38.6%	*****	*****	*****	*****	0	NaN
Infigratinib	32	*****	*****	20	100.0%	*****	*****	0	NaN	0	NaN
Female	19	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	13	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Olanzapine and Samidorphan	4,064	2,251	100.0%	997	100.0%	750	100.0%	66	100.0%	0	NaN
Female	2,257	1,275	56.6%	565	56.7%	382	50.9%	35	53.0%	0	NaN
Male	1,807	976	43.4%	432	43.3%	368	49.1%	31	47.0%	0	NaN
Ibrexafungerp	1,569	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,560	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Aducanumab-avwa	348	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	186	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	162	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	67	67	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	21	21	31.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	46	46	68.7%	0	NaN	0	NaN	0	NaN	0	NaN
Cabotegravir	741	596	100.0%	106	100.0%	39	100.0%	0	NaN	0	NaN
Female	55	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	686	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database - from January 1, 2021 to May 31, 2023, by Sex

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,212	1	30	43	90	768	83.4	94.9
Female	1,108	1	30	34	90	768	82.6	95.9
Male	2,104	1	30	45	90	653	83.8	94.3
Cabotegravir and Rilpivirine (co-packaged)	1,910	1	30	30	60	558	62.8	71.6
Female	454	1	28	30	60	528	60.4	72.5
Male	1,456	1	30	30	60	558	63.6	71.3
Voclosporin	324	2	30	30	90	541	77.4	87.9
Female	261	2	30	30	90	541	71.8	79.9
Male	63	3	30	60	120	537	100.8	113.4
Tepotinib	141	3	30	30	90	390	65.7	67.0
Female	92	3	30	30	60	390	60.1	60.7
Male	49	4	30	47	90	305	76.3	77.0
Umbralisib	76	3	30	30	90	210	64.8	50.1
Female	36	25	30	51	105	210	74.3	58.8
Male	40	3	30	30	90	180	56.3	39.6
Evinacumab-dgnb	49	1	1	1	1	592	16.0	84.7
Female	37	1	1	1	1	592	20.1	97.3
Male	12	1	1	1	1	30	3.4	8.4
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	30	1	1	1	28	493	56.7	117.9
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	30	1	1	1	28	493	56.7	117.9
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	87	1	1	1	1	140	4.2	17.1
Female	45	1	1	1	1	140	4.7	21.0
Male	42	1	1	1	1	56	3.6	11.9
Tivozanib	632	2	28	28	56	483	53.6	52.5
Female	162	5	28	28	56	286	51.5	45.6
Male	470	2	28	28	56	483	54.4	54.7
Ponesimod	106	14	30	44	104	455	83.8	88.5
Female	83	14	30	47	106	455	87.0	92.1
Male	23	14	30	37	90	284	72.2	75.1
Dasiglucagon	736	1	1	15	30	346	23.6	30.9
Female	379	1	1	15	30	180	23.4	30.0
Male	357	1	1	15	30	346	23.8	31.9
Viloxazine	7,859	1	30	30	60	625	53.2	62.8
Female	3,394	1	30	30	60	570	48.5	53.1

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database - from January 1, 2021 to May 31, 2023, by Sex

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	4,465	1	30	30	60	625	56.8	69.1
Drospirenone and Estetrol	3,472	1	28	60	84	588	85.6	81.9
Female	*****	1	28	60	84	588	85.7	82.0
Male	*****	13	27	28	45	84	39.4	27.4
dostarlimab-gxly	99	1	1	1	1	72	2.1	8.1
Female	69	1	1	1	1	1	1.0	0.0
Male	30	1	1	1	1	72	4.6	14.5
Loncastuximab Tesirine-lpyl	338	1	1	1	1	147	1.8	9.8
Female	135	1	1	1	1	105	1.9	9.1
Male	203	1	1	1	1	147	1.7	10.3
Serdexmethylphenidate and Dexmethylphenidate	5,031	1	30	30	31	491	40.6	38.0
Female	2,260	1	30	30	30	491	39.4	36.9
Male	2,771	1	30	30	34	488	41.5	38.8
Pegcetacoplan	65	5	28	56	196	684	117.9	142.2
Female	31	28	28	56	224	573	126.5	133.1
Male	34	5	28	45	112	684	110.1	151.6
Amivantamab-vmjw	303	1	1	2	2	224	3.9	18.9
Female	213	1	1	2	2	168	3.7	16.7
Male	90	1	1	2	2	224	4.4	23.6
Piflufolastat F 18	43,225	1	1	1	1	2	1.0	0.0
Female	73	1	1	1	1	1	1.0	0.0
Male	43,152	1	1	1	1	2	1.0	0.0
Sotorasib	1,296	1	30	32	90	647	73.2	80.4
Female	790	1	30	30	90	647	71.1	80.2
Male	506	4	30	49	90	538	76.5	80.7
Infigratinib	32	18	28	56	81	112	54.9	24.9
Female	19	18	28	56	84	112	56.1	26.4
Male	13	28	28	56	77	84	53.3	23.5
Olanzapine and Samidorphan	4,064	1	30	30	90	464	71.8	79.1
Female	2,257	1	30	30	78	458	68.4	75.5
Male	1,807	1	30	30	90	464	76.1	83.3
Ibrexafungerp	1,569	1	1	1	1	105	1.8	5.3
Female	*****	1	1	1	1	105	1.7	4.6
Male	*****	1	1	1	4	94	16.0	31.8
Aducanumab-avwa	348	1	1	1	1	60	1.2	3.2
Female	186	1	1	1	1	60	1.3	4.3
Male	162	1	1	1	1	1	1.0	0.0
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	67	1	1	1	1	1	1.0	0.0

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database - from January 1, 2021 to May 31, 2023, by Sex

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	21	1	1	1	1	1	1.0	0.0
Male	46	1	1	1	1	1	1.0	0.0
Cabotegravir	741	1	1	1	30	334	24.2	39.2
Female	55	1	1	27	30	273	30.4	48.3
Male	686	1	1	1	30	334	23.7	38.4

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Vericiguat	3,212	1,528	100.0%	966	100.0%	630	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	24	1.6%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	607	273	17.9%	*****	*****	*****	*****	13	14.9%	0	0.0%
≥ 65 years	2,566	1,231	80.6%	757	78.4%	504	80.0%	*****	*****	*****	*****
Cabotegravir and Rilpivirine (co-packaged)	1,910	1,080	100.0%	559	100.0%	248	100.0%	23	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	16	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	274	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	1,145	640	59.3%	338	60.5%	152	61.3%	*****	*****	0	NaN
≥ 65 years	475	276	25.6%	136	24.3%	56	22.6%	*****	*****	0	NaN
Voclosporin	324	169	100.0%	86	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	34	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	140	78	46.2%	32	37.2%	*****	*****	*****	*****	0	NaN
41-64 years	134	71	42.0%	37	43.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Tepotinib	141	78	100.0%	39	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	125	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Umbrisib	76	40	100.0%	22	100.0%	14	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Evinacumab-dgnb	49	*****	*****	*****	*****	0	NaN	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	0.0%	0	NaN
41-64 years	22	*****	*****	*****	*****	0	NaN	0	0.0%	0	NaN
≥ 65 years	*****	18	38.3%	0	0.0%	0	NaN	*****	*****	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	30	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	18	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	87	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tivozanib	632	355	100.0%	199	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	21	28.4%	*****	*****	0	NaN
≥ 65 years	490	282	79.4%	152	76.4%	*****	*****	*****	*****	0	NaN
Ponesimod	106	46	100.0%	32	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	26	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	66	29	63.0%	18	56.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Dasiglucagon	736	594	100.0%	126	100.0%	16	100.0%	0	NaN	0	NaN
0-17 years	108	87	14.6%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	75	61	10.3%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	149	119	20.0%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	288	224	37.7%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	116	103	17.3%	13	10.3%	0	0.0%	0	NaN	0	NaN
Viloxazine	7,859	5,276	100.0%	1,765	100.0%	746	100.0%	72	100.0%	0	NaN
0-17 years	4,952	3,134	59.4%	1,193	67.6%	*****	*****	*****	*****	0	NaN
18-24 years	807	594	11.3%	161	9.1%	*****	*****	*****	*****	0	NaN
25-40 years	1,119	827	15.7%	223	12.6%	*****	*****	*****	*****	0	NaN
41-64 years	881	643	12.2%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	100	78	1.5%	*****	*****	*****	*****	0	0.0%	0	NaN
Drospirenone and Estetrol	3,472	1,241	100.0%	1,395	100.0%	784	100.0%	52	100.0%	0	NaN
0-17 years	*****	*****	*****	158	11.3%	85	10.8%	*****	*****	0	NaN
18-24 years	1,125	439	35.4%	410	29.4%	257	32.8%	19	36.5%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	1,463	480	38.7%	635	45.5%	332	42.3%	16	30.8%	0	NaN
41-64 years	481	170	13.7%	*****	*****	110	14.0%	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
dostarlimab-gxly	99	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	73	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	338	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
≥ 65 years	299	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	5,031	3,773	100.0%	962	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	2,839	2,121	56.2%	533	55.4%	*****	*****	*****	*****	0	NaN
18-24 years	561	*****	*****	*****	*****	22	7.6%	0	0.0%	0	NaN
25-40 years	896	672	17.8%	177	18.4%	*****	*****	*****	*****	0	NaN
41-64 years	697	516	13.7%	142	14.8%	*****	*****	*****	*****	0	NaN
≥ 65 years	38	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Pegcetacoplan	65	31	100.0%	*****	*****	19	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	24	13	41.9%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	26	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Amivantamab-vmjw	303	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	243	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Piflufolastat F 18	43,225	43,225	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	40,000	40,000	92.5%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	1,296	646	100.0%	396	100.0%	232	100.0%	22	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	*****	144	22.3%	74	18.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,013	*****	*****	322	81.3%	176	75.9%	*****	*****	0	NaN
Infigratinib	32	*****	*****	20	100.0%	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olanzapine and Samidorphan	4,064	2,251	100.0%	997	100.0%	750	100.0%	66	100.0%	0	NaN
0-17 years	24	12	0.5%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	266	142	6.3%	74	7.4%	*****	*****	*****	*****	0	NaN
25-40 years	1,291	738	32.8%	299	30.0%	*****	*****	*****	*****	0	NaN
41-64 years	2,072	1,116	49.6%	518	52.0%	396	52.8%	42	63.6%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	411	243	10.8%	*****	*****	65	8.7%	*****	*****	0	NaN
lbrefaxungerp	1,569	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	242	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	723	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	577	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
Aducanumab-avwa	348	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	67	67	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	50	50	74.6%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Cabotegravir	741	596	100.0%	106	100.0%	39	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	52	39	6.5%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	345	296	49.7%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	271	213	35.7%	41	38.7%	17	43.6%	0	NaN	0	NaN
≥ 65 years	73	48	8.1%	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,212	1	30	43	90	768	83.4	94.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	4	30	30	73	480	61.0	80.1
41-64 years	607	1	30	52	90	653	83.4	90.8
≥ 65 years	2,566	1	30	42	90	768	83.7	96.0
Cabotegravir and Rilpivirine (co-packaged)	1,910	1	30	30	60	558	62.8	71.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	16	7	29	30	45	282	54.3	68.8
25-40 years	274	1	30	30	60	494	61.4	64.0
41-64 years	1,145	1	29	30	60	558	63.7	72.7
≥ 65 years	475	1	28	30	60	528	61.7	73.1
Voclosporin	324	2	30	30	90	541	77.4	87.9
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	34	30	30	90	120	314	98.9	78.5
25-40 years	140	2	30	30	90	541	73.8	86.3
41-64 years	134	2	30	30	90	537	76.8	93.2
≥ 65 years	*****	12	30	30	60	150	52.4	38.5
Tepotinib	141	3	30	30	90	390	65.7	67.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	3	30	40	90	305	84.8	89.0
≥ 65 years	125	4	30	30	60	390	63.7	64.2
Umbrisib	76	3	30	30	90	210	64.8	50.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	60	153	59.7	45.8
≥ 65 years	*****	3	30	30	90	210	65.5	50.9
Evinacumab-dgnb	49	1	1	1	1	592	16.0	84.7
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	30	5.8	11.8
41-64 years	22	1	1	1	1	64	6.3	15.1
≥ 65 years	*****	1	1	1	1	592	32.1	135.6
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	30	1	1	1	28	493	56.7	117.9
0-17 years	18	1	1	1	1	280	18.0	65.7

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	43	112	252	75.2	99.2
25-40 years	*****	1	7	76	273	493	154.2	197.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	87	1	1	1	1	140	4.2	17.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	140	4.6	18.2
Tivozanib	632	2	28	28	56	483	53.6	52.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	10	10	26	56	56	30.7	23.4
41-64 years	*****	2	28	28	84	367	56.5	46.2
≥ 65 years	490	4	28	28	56	483	53.0	54.2
Ponesimod	106	14	30	44	104	455	83.8	88.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	39	39	65	90	90	64.5	36.1
25-40 years	26	14	30	40	90	270	70.3	63.0
41-64 years	66	14	30	44	106	455	87.6	95.3
≥ 65 years	*****	14	30	71	99	376	95.4	106.0
Dasiglucagon	736	1	1	15	30	346	23.6	30.9
0-17 years	108	1	2	4	30	144	21.6	28.8
18-24 years	75	1	2	26	30	150	24.9	29.2
25-40 years	149	1	2	28	30	346	26.4	38.4
41-64 years	288	1	1	13	30	180	24.0	30.9
≥ 65 years	116	1	1	17	30	90	19.9	21.9
Viloxazine	7,859	1	30	30	60	625	53.2	62.8
0-17 years	4,952	1	30	30	60	625	59.2	71.2
18-24 years	807	1	30	30	40	423	43.9	44.6
25-40 years	1,119	1	30	30	34	492	41.9	40.2
41-64 years	881	1	30	30	40	535	44.3	47.0
≥ 65 years	100	4	30	30	30	194	40.0	32.4
Drospirenone and Estetrol	3,472	1	28	60	84	588	85.6	81.9
0-17 years	*****	2	28	60	84	533	85.9	82.5
18-24 years	1,125	1	28	56	84	588	84.5	83.4
25-40 years	1,463	1	28	64	84	516	84.4	76.9
41-64 years	481	3	28	63	95	534	92.1	92.5

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	*****	28	28	28	84	90	51.6	32.4
dostarlimab-gxly	99	1	1	1	1	72	2.1	8.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	73	1	1	1	1	72	2.5	9.4
Loncastuximab Tesirine-lpyl	338	1	1	1	1	147	1.8	9.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	147	5.3	25.0
≥ 65 years	299	1	1	1	1	105	1.4	6.1
Serdexmethylphenidate and Dexmethylphenidate	5,031	1	30	30	31	491	40.6	38.0
0-17 years	2,839	1	30	30	33	491	41.6	39.5
18-24 years	561	1	30	30	30	244	36.4	27.9
25-40 years	896	1	30	30	31	391	39.7	38.5
41-64 years	697	1	30	30	34	383	40.4	37.0
≥ 65 years	38	5	20	30	60	229	46.5	48.7
Pegcetacoplan	65	5	28	56	196	684	117.9	142.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	28	89	89	48.3	35.2
25-40 years	*****	28	29	98	254	684	170.4	195.4
41-64 years	24	25	28	30	154	362	93.5	98.6
≥ 65 years	26	5	28	45	224	573	124.2	153.1
Amivantamab-vmjw	303	1	1	2	2	224	3.9	18.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	2	2	2	2	2	2.0	0.0
41-64 years	*****	1	1	2	2	28	2.0	3.5
≥ 65 years	243	1	1	2	2	224	4.4	21.1
Piflufolostat F 18	43,225	1	1	1	1	2	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	40,000	1	1	1	1	2	1.0	0.0
Sotorasib	1,296	1	30	32	90	647	73.2	80.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	75	150	180	90.0	73.5
41-64 years	*****	3	30	30	90	647	79.2	97.1
≥ 65 years	1,013	1	30	37	90	563	71.5	75.2

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Infigratinib	32	18	28	56	81	112	54.9	24.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	28	56	56	37.3	16.2
41-64 years	*****	28	56	84	84	84	68.0	22.0
≥ 65 years	*****	18	28	56	75	112	53.2	25.4
Olanzapine and Samidorphan	4,064	1	30	30	90	464	71.8	79.1
0-17 years	24	16	30	37	60	359	65.5	73.5
18-24 years	266	2	30	30	77	464	67.7	72.4
25-40 years	1,291	1	30	30	87	448	70.1	77.2
41-64 years	2,072	1	30	30	90	458	74.8	82.3
≥ 65 years	411	1	30	30	60	425	65.2	72.4
Ibexafungerp	1,569	1	1	1	1	105	1.8	5.3
0-17 years	*****	1	1	1	1	2	1.1	0.4
18-24 years	242	1	1	1	1	31	2.0	4.6
25-40 years	723	1	1	1	1	94	1.8	5.3
41-64 years	577	1	1	1	1	105	1.7	5.6
≥ 65 years	*****	1	1	1	1	2	1.1	0.2
Aducanumab-avwa	348	1	1	1	1	60	1.2	3.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	60	1.2	3.2
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	67	1	1	1	1	1	1.0	0.0
0-17 years	50	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Cabotegravir	741	1	1	1	30	334	24.2	39.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	52	1	1	1	32	334	28.9	52.7
25-40 years	345	1	1	1	28	223	18.0	32.9
41-64 years	271	1	1	1	30	273	25.3	39.4
≥ 65 years	73	1	30	30	60	264	46.7	46.5

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Vericiguat</i>	3,319	1,719	51.8%	1,044	31.5%	521	15.7%	35	1.1%	0	0.0%
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	3,115	1,636	52.5%	965	31.0%	489	15.7%	25	0.8%	0	0.0%
<i>Voclosporin</i>	457	264	57.8%	132	28.9%	*****	*****	*****	*****	0	0.0%
<i>Tepotinib</i>	131	81	61.8%	34	26.0%	*****	*****	*****	*****	0	0.0%
<i>Umbrisib</i>	54	35	64.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Evinacumab-dgnb</i>	332	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	481	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	106	106	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tivozanib</i>	609	348	57.1%	183	30.0%	78	12.8%	0	0.0%	0	0.0%
<i>Ponesimod</i>	136	79	58.1%	33	24.3%	*****	*****	*****	*****	0	0.0%
<i>Dasiglucagon</i>	197	176	89.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Viloxazine</i>	6,888	4,411	64.0%	1,768	25.7%	682	9.9%	27	0.4%	0	0.0%
<i>Drospirenone and Estetrol</i>	2,137	974	45.6%	733	34.3%	*****	*****	*****	*****	0	0.0%
<i>dostarlimab-gxly</i>	335	335	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Loncastuximab Tesirine-lpyl</i>	869	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Serdexmethylphenidate and</i>	4,501	3,556	79.0%	745	16.6%	*****	*****	*****	*****	0	0.0%
<i>Pegcetacoplan</i>	105	38	36.2%	*****	*****	34	32.4%	*****	*****	0	0.0%
<i>Amivantamab-vmjw</i>	2,664	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Piflufolstat F 18</i>	2,380	2,380	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Sotorasib</i>	1,054	609	57.8%	288	27.3%	*****	*****	*****	*****	0	0.0%
<i>Infigratinib</i>	18	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Olanzapine and Samidorphan</i>	3,302	1,927	58.4%	867	26.3%	*****	*****	*****	*****	0	0.0%
<i>Ibrexafungerp</i>	646	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Aducanumab-avwa</i>	943	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	945	945	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Cabotegravir</i>	994	878	88.3%	92	9.3%	24	2.4%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Vericiguat</i>	3,319	1	30	30	90	583	67.4	72.3
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	3,115	1	30	30	60	564	61.6	66.0
<i>Voclosporin</i>	457	1	30	30	60	375	57.9	53.2
<i>Tepotinib</i>	131	5	30	30	60	549	64.3	81.6
<i>Umbrisib</i>	54	17	30	30	60	270	52.1	45.0
<i>Evinacumab-dgnb</i>	332	1	1	1	1	84	3.2	10.0
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	481	1	1	1	1	196	3.6	17.8
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	106	1	1	1	1	28	1.3	2.6
<i>Tivozanib</i>	609	1	28	28	56	355	54.7	51.5
<i>Ponesimod</i>	136	3	30	30	75	551	71.4	92.4
<i>Dasiglucagon</i>	197	1	1	2	30	154	15.4	23.3
<i>Viloxazine</i>	6,888	1	30	30	60	560	52.1	52.7
<i>Drospirenone and Estetrol</i>	2,137	1	28	49	84	521	70.1	67.2
<i>dostarlimab-gxly</i>	335	1	1	1	1	1	1.0	0.0
<i>Loncastuximab Tesirine-lpyl</i>	869	1	1	1	1	84	1.4	4.6
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	4,501	1	30	30	30	545	37.3	32.6
<i>Pegcetacoplan</i>	105	6	28	60	146	506	113.7	116.2
<i>Amivantamab-vmjw</i>	2,664	1	1	1	1	112	1.1	2.5
<i>Piflufolastat F 18</i>	2,380	1	1	1	1	1	1.0	0.0
<i>Sotorasib</i>	1,054	1	30	30	60	464	62.8	66.0
<i>Infigratinib</i>	18	28	28	42	84	335	67.3	73.8
<i>Olanzapine and Samidorphan</i>	3,302	1	30	30	60	476	59.3	60.1
<i>Ibrexafungerp</i>	646	1	1	1	1	84	2.4	6.8
<i>Aducanumab-avwa</i>	943	1	1	1	1	155	1.2	5.0
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	945	1	1	1	1	2	1.0	0.0
<i>Cabotegravir</i>	994	1	1	1	30	288	16.0	28.6

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vericiguat	3,319	1,719	100.0%	1,044	100.0%	521	100.0%	35	100.0%	0	NaN
Female	1,199	654	38.0%	353	33.8%	178	34.2%	14	40.0%	0	NaN
Male	2,120	1,065	62.0%	691	66.2%	343	65.8%	21	60.0%	0	NaN
Cabotegravir and Rilpivirine (co-packaged)	3,115	1,636	100.0%	965	100.0%	489	100.0%	25	100.0%	0	NaN
Female	698	365	22.3%	232	24.0%	*****	*****	*****	*****	0	NaN
Male	2,417	1,271	77.7%	733	76.0%	*****	*****	*****	*****	0	NaN
Voclosporin	457	264	100.0%	132	100.0%	*****	*****	*****	*****	0	NaN
Female	357	206	78.0%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	100	58	22.0%	*****	*****	*****	*****	*****	*****	0	NaN
Tepotinib	131	81	100.0%	34	100.0%	*****	*****	*****	*****	0	NaN
Female	77	47	58.0%	*****	*****	*****	*****	*****	*****	0	NaN
Male	54	34	42.0%	*****	*****	*****	*****	0	0.0%	0	NaN
Umbrisib	54	35	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	26	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	28	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Evinacumab-dgnb	332	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	481	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Male	481	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	106	106	100.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	50	50	47.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	56	56	52.8%	0	NaN	0	NaN	0	NaN	0	NaN
Tivozanib	609	348	100.0%	183	100.0%	78	100.0%	0	NaN	0	NaN
Female	156	92	26.4%	43	23.5%	21	26.9%	0	NaN	0	NaN
Male	453	256	73.6%	140	76.5%	57	73.1%	0	NaN	0	NaN
Ponesimod	136	79	100.0%	33	100.0%	*****	*****	*****	*****	0	NaN
Female	102	62	78.5%	*****	*****	*****	*****	*****	*****	0	NaN
Male	34	17	21.5%	*****	*****	*****	*****	0	0.0%	0	NaN
Dasiglucagon	197	176	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	108	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	89	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Viloxazine	6,888	4,411	100.0%	1,768	100.0%	682	100.0%	27	100.0%	0	NaN
Female	2,644	1,737	39.4%	680	38.5%	*****	*****	*****	*****	0	NaN
Male	4,244	2,674	60.6%	1,088	61.5%	*****	*****	*****	*****	0	NaN
Drospirenone and Estetrol	2,137	974	100.0%	733	100.0%	*****	*****	*****	*****	0	NaN
Female	*****	974	100.0%	733	100.0%	*****	*****	*****	*****	0	NaN
Male	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
dostarlimab-gxly	335	335	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	233	233	69.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	102	102	30.4%	0	NaN	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	869	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	334	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	535	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	4,501	3,556	100.0%	745	100.0%	*****	*****	*****	*****	0	NaN
Female	1,755	1,410	39.7%	272	36.5%	*****	*****	*****	*****	0	NaN
Male	2,746	2,146	60.3%	473	63.5%	*****	*****	*****	*****	0	NaN
Pegcetacoplan	105	38	100.0%	*****	*****	34	100.0%	*****	*****	0	NaN
Female	49	15	39.5%	*****	*****	18	52.9%	*****	*****	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	56	23	60.5%	****	****	16	47.1%	****	****	0	NaN
Amivantamab-vmjw	2,664	****	****	****	****	****	****	0	NaN	0	NaN
Female	2,008	****	****	****	****	****	****	0	NaN	0	NaN
Male	656	656	24.6%	0	0.0%	0	0.0%	0	NaN	0	NaN
Piflufolastat F 18	2,380	2,380	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,380	2,380	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	1,054	609	100.0%	288	100.0%	****	****	****	****	0	NaN
Female	648	365	59.9%	182	63.2%	****	****	****	****	0	NaN
Male	406	244	40.1%	106	36.8%	****	****	****	****	0	NaN
Infigratinib	18	****	****	****	****	****	****	0	NaN	0	NaN
Female	****	****	****	****	****	****	****	0	NaN	0	NaN
Male	****	****	****	****	****	****	****	0	NaN	0	NaN
Olanzapine and Samidorphan	3,302	1,927	100.0%	867	100.0%	****	****	****	****	0	NaN
Female	1,758	1,043	54.1%	445	51.3%	****	****	****	****	0	NaN
Male	1,544	884	45.9%	422	48.7%	****	****	****	****	0	NaN
Ibrexafungerp	646	****	****	****	****	0	NaN	0	NaN	0	NaN
Female	****	****	****	****	****	0	NaN	0	NaN	0	NaN
Male	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Aducanumab-avwa	943	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	473	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Male	470	470	49.9%	0	NaN	0	0.0%	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	945	945	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	299	299	31.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	646	646	68.4%	0	NaN	0	NaN	0	NaN	0	NaN
Cabotegravir	994	878	100.0%	92	100.0%	24	100.0%	0	NaN	0	NaN
Female	51	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	943	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,319	1	30	30	90	583	67.4	72.3
Female	1,199	1	30	30	84	553	65.3	74.1
Male	2,120	1	30	30	90	583	68.6	71.3
Cabotegravir and Rilpivirine (co-packaged)	3,115	1	30	30	60	564	61.6	66.0
Female	698	1	28	30	60	461	57.8	58.5
Male	2,417	1	30	30	60	564	62.7	68.0
Voclosporin	457	1	30	30	60	375	57.9	53.2
Female	357	1	30	30	60	330	58.7	54.5
Male	100	1	30	30	66	375	55.1	48.6
Tepotinib	131	5	30	30	60	549	64.3	81.6
Female	77	5	30	30	60	549	71.9	97.5
Male	54	12	30	30	60	284	53.4	49.8
Umbralisib	54	17	30	30	60	270	52.1	45.0
Female	26	17	30	30	60	120	46.8	28.8
Male	28	22	30	30	60	270	57.0	56.2
Evinacumab-dgnb	332	1	1	1	1	84	3.2	10.0
Female	228	1	1	1	1	84	4.1	12.0
Male	104	1	1	1	1	1	1.0	0.0
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	481	1	1	1	1	196	3.6	17.8
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	481	1	1	1	1	196	3.6	17.8
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	106	1	1	1	1	28	1.3	2.6
Female	50	1	1	1	1	28	1.5	3.8
Male	56	1	1	1	1	1	1.0	0.0
Tivozanib	609	1	28	28	56	355	54.7	51.5
Female	156	4	28	28	56	308	53.4	47.8
Male	453	1	28	28	56	355	55.1	52.8
Ponesimod	136	3	30	30	75	551	71.4	92.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	102	3	30	30	60	551	65.1	90.9
Male	34	9	30	37	120	359	90.6	95.6
Dasiglucagon	197	1	1	2	30	154	15.4	23.3
Female	108	1	1	2	30	90	14.4	20.6
Male	89	1	1	2	30	154	16.7	26.3
Viloxazine	6,888	1	30	30	60	560	52.1	52.7
Female	2,644	1	30	30	60	514	48.4	45.7
Male	4,244	1	30	30	60	560	54.4	56.6
Drospirenone and Estetrol	2,137	1	28	49	84	521	70.1	67.2
Female	*****	1	28	49	84	521	70.0	67.1
Male	*****	127	127	148	168	168	147.5	29.0
dostarlimab-gxly	335	1	1	1	1	1	1.0	0.0
Female	233	1	1	1	1	1	1.0	0.0
Male	102	1	1	1	1	1	1.0	0.0
Loncastuximab Tesirine-lpyl	869	1	1	1	1	84	1.4	4.6
Female	334	1	1	1	1	84	1.5	5.1
Male	535	1	1	1	1	84	1.4	4.3
Serdexmethylphenidate and Dexmethylphenidate	4,501	1	30	30	30	545	37.3	32.6
Female	1,755	1	30	30	30	388	36.0	29.4
Male	2,746	1	30	30	30	545	38.2	34.5
Pegcetacoplan	105	6	28	60	146	506	113.7	116.2
Female	49	20	28	84	176	506	124.0	118.9
Male	56	6	29	56	140	492	104.6	114.2
Amivantamab-vmjw	2,664	1	1	1	1	112	1.1	2.5
Female	2,008	1	1	1	1	112	1.1	2.8
Male	656	1	1	1	1	28	1.1	1.1
Piflufolastat F 18	2,380	1	1	1	1	1	1.0	0.0
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	2,380	1	1	1	1	1	1.0	0.0
Sotorasib	1,054	1	30	30	60	464	62.8	66.0
Female	648	1	30	30	60	464	65.5	70.9
Male	406	1	30	30	65	405	58.5	57.2
Infigratinib	18	28	28	42	84	335	67.3	73.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	*****	28	28	28	56	140	50.7	40.0
Male	*****	28	28	56	84	335	83.9	96.7
Olanzapine and Samidorphan	3,302	1	30	30	60	476	59.3	60.1
Female	1,758	1	30	30	60	398	58.5	60.0
Male	1,544	1	30	30	66	476	60.2	60.3
Ibexafungerp	646	1	1	1	1	84	2.4	6.8
Female	*****	1	1	1	1	84	2.4	6.9
Male	*****	1	1	1	1	1	1.0	0.0
Aducanumab-avwa	943	1	1	1	1	155	1.2	5.0
Female	473	1	1	1	1	155	1.3	7.1
Male	470	1	1	1	1	1	1.0	0.0
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	945	1	1	1	1	2	1.0	0.0
Female	299	1	1	1	1	1	1.0	0.0
Male	646	1	1	1	1	2	1.0	0.1
Cabotegravir	994	1	1	1	30	288	16.0	28.6
Female	51	1	1	1	5	288	16.3	44.9
Male	943	1	1	1	30	234	16.0	27.4

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vericiguat	3,319	1,719	100.0%	1,044	100.0%	521	100.0%	35	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	51	35	2.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	713	379	22.0%	*****	*****	87	16.7%	*****	*****	0	NaN
≥ 65 years	2,555	1,305	75.9%	789	75.6%	*****	*****	*****	*****	0	NaN
Cabotegravir and Rilpivirine (co-packaged)	3,115	1,636	100.0%	965	100.0%	489	100.0%	25	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	27	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	487	*****	*****	129	13.4%	57	11.7%	*****	*****	0	NaN
41-64 years	1,898	957	58.5%	603	62.5%	326	66.7%	12	48.0%	0	NaN
≥ 65 years	703	363	22.2%	*****	*****	106	21.7%	*****	*****	0	NaN
Voclosporin	457	264	100.0%	132	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	50	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	200	118	44.7%	57	43.2%	*****	*****	*****	*****	0	NaN
41-64 years	194	118	44.7%	49	37.1%	27	45.0%	0	0.0%	0	NaN
≥ 65 years	13	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Tepotinib	131	81	100.0%	34	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	18	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	113	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Umbrisib	54	35	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Evinacumab-dgnb	332	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN	
0-17 years	19	19	5.8%	0	0.0%	0	NaN	0	NaN	0	NaN	
18-24 years	13	13	4.0%	0	0.0%	0	NaN	0	NaN	0	NaN	
25-40 years	48	48	14.7%	0	0.0%	0	NaN	0	NaN	0	NaN	
41-64 years	174	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN	
≥ 65 years	78	78	23.9%	0	0.0%	0	NaN	0	NaN	0	NaN	
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
Casimersen	481	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN	
0-17 years	365	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN	
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN	
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN	
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN	
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN	
Fosdenopterin	0	
0-17 years	0	
18-24 years	0	
25-40 years	0	
41-64 years	0	
≥ 65 years	0	
Melphalan Flufenamide	106	106	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
Tivozanib	609	348	100.0%	183	100.0%	78	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	116	68	19.5%	31	16.9%	17	21.8%	0	NaN	0	NaN
≥ 65 years	493	280	80.5%	152	83.1%	61	78.2%	0	NaN	0	NaN
Ponesimod	136	79	100.0%	33	100.0%	****	****	****	****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	****	0	0.0%	0	0.0%	****	****	0	0.0%	0	NaN
25-40 years	****	****	****	****	****	****	****	****	****	0	NaN
41-64 years	92	54	68.4%	****	****	****	****	****	****	0	NaN
≥ 65 years	****	****	****	****	****	****	****	0	0.0%	0	NaN
Dasiglucagon	197	176	100.0%	****	****	****	****	0	NaN	0	NaN
0-17 years	57	****	****	****	****	0	0.0%	0	NaN	0	NaN
18-24 years	18	****	****	****	****	0	0.0%	0	NaN	0	NaN
25-40 years	28	****	****	****	****	0	0.0%	0	NaN	0	NaN
41-64 years	81	****	****	****	****	****	****	0	NaN	0	NaN
≥ 65 years	13	****	****	****	****	0	0.0%	0	NaN	0	NaN
Viloxazine	6,888	4,411	100.0%	1,768	100.0%	682	100.0%	27	100.0%	0	NaN
0-17 years	5,484	3,433	77.8%	1,426	80.7%	****	****	****	****	0	NaN
18-24 years	478	323	7.3%	118	6.7%	****	****	****	****	0	NaN
25-40 years	514	367	8.3%	118	6.7%	29	4.3%	0	0.0%	0	NaN
41-64 years	374	264	6.0%	****	****	****	****	0	0.0%	0	NaN
≥ 65 years	38	24	0.5%	****	****	****	****	0	0.0%	0	NaN
Drospirenone and Estetrol	2,137	974	100.0%	733	100.0%	****	****	****	****	0	NaN
0-17 years	290	127	13.0%	98	13.4%	****	****	****	****	0	NaN
18-24 years	721	301	30.9%	268	36.6%	****	****	****	****	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	823	391	40.1%	283	38.6%	*****	*****	*****	*****	0	NaN
41-64 years	303	155	15.9%	84	11.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
dostarlimab-gxly	335	335	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	248	248	74.0%	0	NaN	0	NaN	0	NaN	0	NaN
Loncastuximab Tesirine-lpyl	869	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	70	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	783	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Serdexmethylphenidate and Dexmethylphenidate	4,501	3,556	100.0%	745	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	3,007	2,354	66.2%	502	67.4%	*****	*****	*****	*****	0	NaN
18-24 years	474	381	10.7%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	561	455	12.8%	83	11.1%	23	11.7%	0	0.0%	0	NaN
41-64 years	445	*****	*****	*****	*****	15	7.6%	0	0.0%	0	NaN
≥ 65 years	14	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
Pegcetacoplan	105	38	100.0%	*****	*****	34	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	35	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	52	24	63.2%	*****	*****	17	50.0%	*****	*****	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Amivantamab-vmjw	2,664	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	13	13	0.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	492	492	18.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	2,159	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Piflufolostat F 18	2,380	2,380	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	169	169	7.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	2,211	2,211	92.9%	0	NaN	0	NaN	0	NaN	0	NaN
Sotorasib	1,054	609	100.0%	288	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	124	20.4%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	832	485	79.6%	223	77.4%	*****	*****	*****	*****	0	NaN
Infigratinib	18	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Olanzapine and Samidorphan	3,302	1,927	100.0%	867	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	13	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	219	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	1,191	700	36.3%	323	37.3%	*****	*****	*****	*****	0	NaN
41-64 years	1,595	899	46.7%	423	48.8%	*****	*****	*****	*****	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	284	167	8.7%	78	9.0%	*****	*****	*****	*****	0	NaN
lbrefaxungerp	646	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	72	72	11.2%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	323	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	238	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Aducanumab-avwa	943	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	28	28	3.0%	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	915	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	945	945	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	753	753	79.7%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	57	57	6.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	108	108	11.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Cabotegravir	994	878	100.0%	92	100.0%	24	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	71	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	436	405	46.1%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	383	330	37.6%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	104	*****	*****	20	21.7%	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,319	1	30	30	90	583	67.4	72.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	51	1	28	30	60	210	41.6	34.6
41-64 years	713	1	30	30	84	553	62.7	65.3
≥ 65 years	2,555	1	30	30	90	583	69.2	74.6
Cabotegravir and Rilpivirine (co-packaged)	3,115	1	30	30	60	564	61.6	66.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	27	3	28	30	56	90	36.7	20.4
25-40 years	487	1	30	30	60	453	55.4	61.0
41-64 years	1,898	1	30	30	60	479	62.9	64.9
≥ 65 years	703	1	28	30	60	564	63.3	72.6
Voclosporin	457	1	30	30	60	375	57.9	53.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	50	30	30	60	90	300	67.9	54.3
25-40 years	200	1	30	30	60	375	57.1	53.5
41-64 years	194	1	30	30	60	330	55.4	50.1
≥ 65 years	13	16	30	30	75	330	69.5	84.2
Tepotinib	131	5	30	30	60	549	64.3	81.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	18	28	30	42	90	240	76.2	69.4
≥ 65 years	113	5	30	30	60	549	62.4	83.5
Umbrisib	54	17	30	30	60	270	52.1	45.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	45	60	60	45.0	16.4
≥ 65 years	*****	17	30	30	60	270	53.0	47.4
Evinacumab-dgnb	332	1	1	1	1	84	3.2	10.0
0-17 years	19	1	1	1	1	1	1.0	0.0
18-24 years	13	1	1	1	1	1	1.0	0.0
25-40 years	48	1	1	1	1	1	1.0	0.0
41-64 years	174	1	1	1	1	84	5.1	13.5
≥ 65 years	78	1	1	1	1	1	1.0	0.0
Trilaciclib	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
Casimersen	481	1	1	1	1	196	3.6	17.8
0-17 years	365	1	1	1	1	154	2.0	11.1

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	1	1	193	6.6	24.4
25-40 years	*****	7	10	28	119	196	64.5	89.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	106	1	1	1	1	28	1.3	2.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	28	1.3	2.8
Tivozanib	609	1	28	28	56	355	54.7	51.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	116	5	28	28	84	355	59.3	58.5
≥ 65 years	493	1	28	28	56	336	53.6	49.8
Ponesimod	136	3	30	30	75	551	71.4	92.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	3	30	30	60	499	64.6	90.5
41-64 years	92	3	30	30	60	551	70.0	93.6
≥ 65 years	*****	30	71	90	139	226	107.7	67.8
Dasiglucagon	197	1	1	2	30	154	15.4	23.3
0-17 years	57	1	1	2	4	60	7.5	12.3
18-24 years	18	1	1	2	30	60	15.8	21.6
25-40 years	28	1	1	2	28	48	10.9	15.2
41-64 years	81	1	1	2	30	154	21.9	30.1
≥ 65 years	13	1	2	19	30	60	19.5	17.6
Viloxazine	6,888	1	30	30	60	560	52.1	52.7
0-17 years	5,484	1	30	30	60	560	54.6	55.7
18-24 years	478	1	30	30	60	494	47.2	48.0
25-40 years	514	1	30	30	43	222	39.9	31.1
41-64 years	374	1	30	30	47	322	39.5	30.7
≥ 65 years	38	5	30	30	41	120	35.5	21.2
Drospirenone and Estetrol	2,137	1	28	49	84	521	70.1	67.2
0-17 years	290	1	28	56	84	521	77.4	80.2
18-24 years	721	1	28	56	84	413	71.5	65.1
25-40 years	823	1	28	42	84	495	66.8	64.3
41-64 years	303	2	28	28	84	371	68.6	65.7

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
dostarlimab-gxly	335	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	248	1	1	1	1	1	1.0	0.0
Loncastuximab Tesirine-lpyl	869	1	1	1	1	84	1.4	4.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	70	1	1	1	1	84	3.8	11.6
≥ 65 years	783	1	1	1	1	84	1.2	3.4
Serdexmethylphenidate and Dexmethylphenidate	4,501	1	30	30	30	545	37.3	32.6
0-17 years	3,007	1	30	30	30	545	38.4	34.9
18-24 years	474	1	30	30	30	203	34.4	23.9
25-40 years	561	1	27	30	30	251	34.7	28.6
41-64 years	445	1	30	30	30	271	36.3	29.1
≥ 65 years	14	7	30	30	30	90	35.4	21.2
Pegcetacoplan	105	6	28	60	146	506	113.7	116.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	36	51	70	252	74.0	74.1
25-40 years	*****	28	57	95	188	252	123.5	79.5
41-64 years	35	20	28	84	191	506	138.5	141.6
≥ 65 years	52	6	28	56	143	455	101.2	107.1
Amivantamab-vmjw	2,664	1	1	1	1	112	1.1	2.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	1	1	1	1	1	1.0	0.0
41-64 years	492	1	1	1	1	4	1.0	0.1
≥ 65 years	2,159	1	1	1	1	112	1.1	2.8
Piflufolastat F 18	2,380	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	169	1	1	1	1	1	1.0	0.0
≥ 65 years	2,211	1	1	1	1	1	1.0	0.0
Sotorasib	1,054	1	30	30	60	464	62.8	66.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	60	60	90	120	120	90.0	42.4
41-64 years	*****	6	30	30	78	349	62.1	61.0
≥ 65 years	832	1	30	30	60	464	62.9	67.3

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Infigratinib	18	28	28	42	84	335	67.3	73.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	140	140	238	335	335	237.5	137.9
41-64 years	*****	28	28	28	56	84	40.0	22.0
≥ 65 years	*****	28	28	56	56	92	50.7	24.9
Olanzapine and Samidorphan	3,302	1	30	30	60	476	59.3	60.1
0-17 years	13	6	30	30	30	150	41.1	38.4
18-24 years	219	1	30	30	60	369	52.9	56.6
25-40 years	1,191	1	30	30	60	389	57.1	56.9
41-64 years	1,595	1	30	30	75	476	62.9	64.1
≥ 65 years	284	1	30	30	60	375	53.7	52.3
Ibexafungerp	646	1	1	1	1	84	2.4	6.8
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	72	1	1	1	1	30	1.6	3.5
25-40 years	323	1	1	1	1	60	2.3	6.1
41-64 years	238	1	1	1	1	61	2.2	6.1
≥ 65 years	*****	1	1	1	28	84	15.6	25.6
Aducanumab-avwa	943	1	1	1	1	155	1.2	5.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	28	1	1	1	1	1	1.0	0.0
≥ 65 years	915	1	1	1	1	155	1.2	5.1
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	945	1	1	1	1	2	1.0	0.0
0-17 years	753	1	1	1	1	2	1.0	0.0
18-24 years	57	1	1	1	1	1	1.0	0.0
25-40 years	108	1	1	1	1	2	1.0	0.1
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Cabotegravir	994	1	1	1	30	288	16.0	28.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	71	1	1	1	28	174	18.2	34.3
25-40 years	436	1	1	1	7	288	12.0	27.6
41-64 years	383	1	1	1	30	234	15.4	28.4
≥ 65 years	104	1	28	30	30	111	33.6	21.7

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Vericiguat</i>	3,319	1	3	7	20	421	19.3	34.4
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	3,115	1	4	11	27	487	18.2	23.5
<i>Voclosporin</i>	457	1	3	9	19	375	19.3	37.0
<i>Tepotinib</i>	131	1	3	5	17	202	15.6	25.7
<i>Umbralisib</i>	54	1	2	5	11	116	12.1	19.5
<i>Evinacumab-dgnb</i>	332	1	27	27	28	485	30.9	29.5
<i>Trilaciclib</i>	0
<i>Casimersen</i>	481	1	6	10	18	188	14.2	15.1
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	106	10	27	27	41	91	34.2	12.2
<i>Tivozanib</i>	609	1	3	6	14	146	12.7	19.3
<i>Ponesimod</i>	136	1	3	8	12	170	11.2	17.1
<i>Dasiglucagon</i>	197	1	3	21	55	421	49.8	77.4
<i>Viloxazine</i>	6,888	1	3	7	18	469	16.8	29.8
<i>Drospirenone and Estetrol</i>	2,137	1	3	7	21	385	19.2	36.1
<i>dostarlimab-gxly</i>	335	4	20	20	41	135	28.2	13.2
<i>Loncastuximab Tesirine-lpyl</i>	869	2	20	20	22	235	24.4	14.3
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	4,501	1	3	8	19	461	16.2	25.9
<i>Pegcetacoplan</i>	105	1	1	3	6	108	6.6	12.8
<i>Amivantamab-vmjw</i>	2,664	1	11	13	13	167	12.9	7.8
<i>Piflufolastat F 18</i>	2,380	1	108	153	204	459	161.7	71.0
<i>Sotorasib</i>	1,054	1	3	6	19	394	17.6	32.3
<i>Infigratinib</i>	18	1	2	6	21	62	12.6	15.4
<i>Olanzapine and Samidorphan</i>	3,302	1	3	6	15	367	15.1	28.1
<i>Ibrexafungerp</i>	646	1	10	27	62	512	50.3	65.9
<i>Aducanumab-avwa</i>	943	1	27	27	32	300	37.6	35.3
<i>Asparaginase Erwinia Chrysanthemi (recombinant)- rywn</i>	945	1	1	1	2	320	4.6	15.0
<i>Cabotegravir</i>	994	1	20	32	55	174	36.1	22.9

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,319	1	3	7	20	421	19.3	34.4
Female	1,199	1	3	7	18	357	17.9	33.2
Male	2,120	1	3	8	22	421	20.0	35.0
Cabotegravir and Rilpivirine (co-	3,115	1	4	11	27	487	18.2	23.5
Female	698	1	4	10	26	242	16.8	19.6
Male	2,417	1	4	12	28	487	18.5	24.5
Voclosporin	457	1	3	9	19	375	19.3	37.0
Female	357	1	4	10	20	375	21.0	40.7
Male	100	1	3	6	17	91	13.4	17.8
Tepotinib	131	1	3	5	17	202	15.6	25.7
Female	77	1	3	5	17	202	17.6	30.6
Male	54	1	3	7	16	80	12.9	16.1
Umbralisib	54	1	2	5	11	116	12.1	19.5
Female	26	1	2	4	21	116	16.8	26.4
Male	28	1	2	6	10	27	7.7	7.4
Evinacumab-dgnb	332	1	27	27	28	485	30.9	29.5
Female	228	1	27	27	29	485	30.8	32.5
Male	104	23	27	27	28	240	31.1	21.5
Trilaciclib	0
Female	0
Male	0
Casimersen	481	1	6	10	18	188	14.2	15.1
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	481	1	6	10	18	188	14.2	15.1
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	106	10	27	27	41	91	34.2	12.2
Female	50	21	27	27	41	75	33.8	11.5
Male	56	10	27	29	41	91	34.5	12.9
Tivozanib	609	1	3	6	14	146	12.7	19.3
Female	156	1	3	7	15	139	14.3	22.2
Male	453	1	3	6	13	146	12.1	18.2
Ponesimod	136	1	3	8	12	170	11.2	17.1
Female	102	1	3	7	12	170	11.4	19.0
Male	34	1	5	8	14	48	10.7	9.4
Dasiglucagon	197	1	3	21	55	421	49.8	77.4
Female	108	1	3	17	53	361	43.2	68.8
Male	89	1	7	27	69	421	57.8	86.3
Viloxazine	6,888	1	3	7	18	469	16.8	29.8
Female	2,644	1	3	7	18	413	17.2	30.1
Male	4,244	1	3	7	18	469	16.6	29.6
Drospirenone and Estetrol	2,137	1	3	7	21	385	19.2	36.1
Female	2,135	1	3	7	21	385	19.2	36.1
Male	2	5	5	11	17	17	11.0	8.5

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dostarlimab-gxly	335	4	20	20	41	135	28.2	13.2
Female	233	4	20	21	41	82	30.0	12.6
Male	102	13	20	20	20	135	24.2	13.6
Loncastuximab Tesirine-lpyl	869	2	20	20	22	235	24.4	14.3
Female	334	3	20	20	27	235	26.1	19.5
Male	535	2	20	20	21	89	23.3	9.6
Serdexmethylphenidate and Dexmethylphenidate	4,501	1	3	8	19	461	16.2	25.9
Female	1,755	1	3	8	19	372	16.2	25.6
Male	2,746	1	3	8	19	461	16.3	26.1
Pegcetacoplan	105	1	1	3	6	108	6.6	12.8
Female	49	1	1	3	6	28	4.7	5.3
Male	56	1	1	3	7	108	8.4	16.8
Amivantamab-vmjw	2,664	1	11	13	13	167	12.9	7.8
Female	2,008	1	12	13	13	167	12.8	7.4
Male	656	4	11	13	13	121	13.1	8.9
Piflufolostat F 18	2,380	1	108	153	204	459	161.7	71.0
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	2,380	1	108	153	204	459	161.7	71.0
Sotorasib	1,054	1	3	6	19	394	17.6	32.3
Female	648	1	3	6	19	394	17.3	32.7
Male	406	1	3	6	18	234	18.2	31.8
Infigratinib	18	1	2	6	21	62	12.6	15.4
Female	9	1	2	5	8	27	8.3	9.3
Male	9	1	5	6	22	62	16.9	19.5
Olanzapine and Samidorphan	3,302	1	3	6	15	367	15.1	28.1
Female	1,758	1	3	6	16	367	16.7	31.6
Male	1,544	1	2	6	14	362	13.3	23.3
Ibexafungerp	646	1	10	27	62	512	50.3	65.9
Female	643	1	10	27	63	512	50.4	66.0
Male	3	3	3	16	37	37	18.7	17.2
Aducanumab-avwa	943	1	27	27	32	300	37.6	35.3
Female	473	1	27	27	32	291	35.5	29.6
Male	470	7	27	27	31	300	39.6	40.0
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	945	1	1	1	2	320	4.6	15.0
Female	299	1	1	1	2	146	3.8	12.4
Male	646	1	1	1	2	320	5.0	16.0
Cabotegravir	994	1	20	32	55	174	36.1	22.9
Female	51	2	18	42	58	82	39.3	23.2
Male	943	1	20	31	55	174	35.9	22.9

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	3,319	1	3	7	20	421	19.3	34.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	51	1	3	10	38	270	32.1	52.4
41-64 years	713	1	3	7	20	334	20.1	34.4
≥ 65 years	2,555	1	3	8	20	421	18.8	33.9
Cabotegravir and Rilpivirine (co-packaged)	3,115	1	4	11	27	487	18.2	23.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	27	1	7	20	28	38	18.7	12.2
25-40 years	487	1	5	16	28	191	19.5	20.0
41-64 years	1,898	1	4	11	27	487	18.1	24.3
≥ 65 years	703	1	4	10	27	316	17.3	23.8
Voclosporin	457	1	3	9	19	375	19.3	37.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	50	1	3	5	15	77	12.8	16.7
25-40 years	200	1	4	9	18	318	18.8	33.2
41-64 years	194	1	4	10	22	375	21.9	44.6
≥ 65 years	13	1	2	3	21	71	14.0	20.4
Tepotinib	131	1	3	5	17	202	15.6	25.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	18	1	2	4	9	35	7.2	8.5
≥ 65 years	113	1	3	6	19	202	17.0	27.2
Umbrisib	54	1	2	5	11	116	12.1	19.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	6	3	7	10	11	116	26.0	44.2
≥ 65 years	48	1	2	5	13	60	10.4	13.9
Evinacumab-dgnb	332	1	27	27	28	485	30.9	29.5
0-17 years	19	22	27	27	27	55	29.9	9.0
18-24 years	13	27	27	27	28	240	46.6	59.1
25-40 years	48	5	27	27	28	40	27.8	5.0
41-64 years	174	1	27	27	27	64	27.6	8.3

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	78	23	27	27	31	485	37.7	53.7
Trilaciclib	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Casimersen	481	1	6	10	18	188	14.2	15.1
0-17 years	365	2	6	13	27	188	16.0	14.7
18-24 years	112	1	6	6	7	160	9.0	15.2
25-40 years	4	1	1	2	3	3	2.0	1.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	106	10	27	27	41	91	34.2	12.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	10	19	27	27	27	45	28.6	6.8
≥ 65 years	96	10	27	28	41	91	34.8	12.5
Tivozanib	609	1	3	6	14	146	12.7	19.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	116	1	2	5	13	110	9.3	12.8
≥ 65 years	493	1	3	6	14	146	13.5	20.5
Ponesimod	136	1	3	8	12	170	11.2	17.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	1	1	1	1	1	1.0	NaN
25-40 years	37	1	3	9	13	33	10.5	8.5

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	92	1	4	7	12	170	12.0	19.9
≥ 65 years	6	1	2	5	8	18	6.3	6.3
Dasiglucagon	197	1	3	21	55	421	49.8	77.4
0-17 years	57	1	3	21	56	279	43.9	61.3
18-24 years	18	1	2	18	86	152	43.0	51.6
25-40 years	28	1	4	19	65	365	70.8	112.6
41-64 years	81	1	3	16	53	421	45.2	76.3
≥ 65 years	13	16	29	41	48	334	68.3	85.4
Viloxazine	6,888	1	3	7	18	469	16.8	29.8
0-17 years	5,484	1	3	7	18	469	17.0	31.0
18-24 years	478	1	4	9	19	160	16.5	23.6
25-40 years	514	1	4	8	17	291	14.7	22.8
41-64 years	374	1	3	8	19	200	18.2	28.7
≥ 65 years	38	1	3	8	23	74	15.4	17.4
Drospirenone and Estetrol	2,137	1	3	7	21	385	19.2	36.1
0-17 years	290	1	2	7	20	333	19.1	34.0
18-24 years	721	1	2	6	21	354	18.8	34.7
25-40 years	823	1	3	7	23	385	20.1	38.2
41-64 years	303	1	3	6	17	373	17.5	35.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
dostarlimab-gxly	335	4	20	20	41	135	28.2	13.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	7	19	20	20	20	21	20.0	0.6
41-64 years	80	4	20	20	41	135	31.0	18.4
≥ 65 years	248	13	20	20	41	69	27.6	11.0
Loncastuximab Tesirine-lpyl	869	2	20	20	22	235	24.4	14.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	25	25	34	42	42	33.5	12.0
25-40 years	14	17	20	22	27	69	29.1	16.5
41-64 years	70	2	20	20	20	235	26.5	34.3
≥ 65 years	783	3	20	20	22	145	24.1	10.8
Serdexmethylphenidate and Dexmethylphenidate	4,501	1	3	8	19	461	16.2	25.9
0-17 years	3,007	1	3	8	20	461	16.5	26.0

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	474	1	3	8	20	200	16.7	22.7
25-40 years	561	1	3	7	17	249	15.3	25.2
41-64 years	445	1	3	7	16	372	14.9	29.0
≥ 65 years	14	1	3	5	32	95	18.3	27.1
Pegcetacoplan	105	1	1	3	6	108	6.6	12.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	8	1	3	5	13	42	10.4	13.5
25-40 years	10	1	1	4	6	45	7.7	13.3
41-64 years	35	1	1	3	6	108	8.2	18.6
≥ 65 years	52	1	2	3	6	36	4.8	6.5
Amivantamab-vmjw	2,664	1	11	13	13	167	12.9	7.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	5	5	6	6	14	7.4	3.4
41-64 years	492	4	12	13	13	69	13.3	7.2
≥ 65 years	2,159	1	11	13	13	167	12.8	7.9
Piflufolastat F 18	2,380	1	108	153	204	459	161.7	71.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	169	10	108	151	205	387	158.5	71.3
≥ 65 years	2,211	1	108	153	203	459	161.9	70.9
Sotorasib	1,054	1	3	6	19	394	17.6	32.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	4	4	67	130	130	67.0	89.1
41-64 years	220	1	2	6	16	265	15.4	29.9
≥ 65 years	832	1	3	6	20	394	18.1	32.7
Infigratinib	18	1	2	6	21	62	12.6	15.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	5	5	6	6	6	5.5	0.7
41-64 years	7	1	1	4	22	27	8.9	10.9
≥ 65 years	9	1	6	8	21	62	17.1	19.2
Olanzapine and Samidorphan	3,302	1	3	6	15	367	15.1	28.1

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	13	3	4	5	6	27	7.5	6.8
18-24 years	219	1	3	6	16	172	14.6	23.2
25-40 years	1,191	1	3	6	16	367	15.8	32.4
41-64 years	1,595	1	2	6	15	211	14.3	24.5
≥ 65 years	284	1	3	7	20	277	17.6	31.4
lbrefaxungerp	646	1	10	27	62	512	50.3	65.9
0-17 years	2	1	1	13	25	25	13.0	17.0
18-24 years	72	1	15	34	68	341	59.0	67.4
25-40 years	323	1	10	26	52	512	47.5	65.9
41-64 years	238	1	9	29	69	464	52.2	65.4
≥ 65 years	11	1	2	20	33	260	40.7	74.6
Aducanumab-avwa	943	1	27	27	32	300	37.6	35.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	28	22	27	28	33	83	32.0	11.5
≥ 65 years	915	1	27	27	32	300	37.7	35.7
Asparaginase Erwinia Chrysanthemii (recombinant)-rywn	945	1	1	1	2	320	4.6	15.0
0-17 years	753	1	1	1	2	97	4.3	10.6
18-24 years	57	1	1	1	2	320	11.2	46.2
25-40 years	108	1	1	1	1	37	3.1	6.5
41-64 years	3	1	1	1	3	3	1.7	1.2
≥ 65 years	24	1	1	1	2	29	3.8	7.1
Cabotegravir	994	1	20	32	55	174	36.1	22.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	71	1	19	28	55	174	34.0	26.7
25-40 years	436	1	22	33	57	131	38.2	23.1
41-64 years	383	1	20	34	55	138	36.9	22.7
≥ 65 years	104	1	15	26	33	92	25.6	16.9

NaN: Not a Number

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Vericiguat</i>	1,533	1	3	10	26	421	23.5	39.8
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	1,277	1	4	10	25	487	18.1	27.8
<i>Voclosporin</i>	174	1	3	10	21	318	23.2	44.8
<i>Tepotinib</i>	57	1	3	5	12	64	11.9	15.5
<i>Umbralisib</i>	31	1	2	5	15	116	12.5	22.6
<i>Evinacumab-dgnb</i>	42	4	27	27	34	240	34.4	33.9
<i>Trilaciclib</i>	0
<i>Casimersen</i>	26	1	6	13	15	103	16.5	20.8
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	44	10	27	27	41	91	33.8	14.4
<i>Tivozanib</i>	293	1	3	6	15	130	13.5	20.3
<i>Ponesimod</i>	54	1	3	8	12	43	9.6	8.7
<i>Dasiglucagon</i>	126	1	3	21	78	421	61.0	91.7
<i>Viloxazine</i>	3,193	1	3	8	19	469	18.3	31.6
<i>Drospirenone and Estetrol</i>	1,247	1	4	10	29	385	25.3	42.9
<i>dostarlimab-gxly</i>	79	19	20	20	21	135	25.5	16.5
<i>Loncastuximab Tesirine-lpyl</i>	242	3	20	20	22	145	23.5	11.2
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	2,093	1	3	8	19	461	17.3	29.2
<i>Pegcetacoplan</i>	40	1	2	4	9	108	9.6	18.3
<i>Amivantamab-vmjw</i>	267	1	5	6	13	167	9.9	13.9
<i>Piflufolastat F 18</i>	2,161	1	113	159	210	459	166.8	71.3
<i>Sotorasib</i>	531	1	3	7	22	394	21.4	39.9
<i>Infigratinib</i>	14	1	2	6	8	22	7.8	7.7
<i>Olanzapine and Samidorphan</i>	1,625	1	3	7	16	367	16.6	31.1
<i>Ibrexafungerp</i>	368	1	8	30	74	512	56.4	73.6
<i>Aducanumab-avwa</i>	260	1	27	27	31	300	42.2	49.3
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	63	1	1	1	2	35	2.4	4.6
<i>Cabotegravir</i>	470	1	17	28	42	174	31.8	22.5

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	1,533	1	3	10	26	421	23.5	39.8
Female	545	1	3	9	22	352	23.2	40.0
Male	988	1	4	10	27	421	23.6	39.7
Cabotegravir and Rilpivirine (co-packaged)	1,277	1	4	10	25	487	18.1	27.8
Female	285	1	4	11	27	242	18.9	24.7
Male	992	1	4	10	25	487	17.9	28.6
Voclosporin	174	1	3	10	21	318	23.2	44.8
Female	142	1	4	11	21	318	24.6	48.6
Male	32	1	3	9	22	77	17.0	20.1
Tepotinib	57	1	3	5	12	64	11.9	15.5
Female	33	1	3	4	12	61	10.0	13.7
Male	24	2	3	6	21	64	14.6	17.7
Umbralisib	31	1	2	5	15	116	12.5	22.6
Female	15	1	2	4	21	116	18.7	31.1
Male	16	1	2	5	10	25	6.8	6.5
Evinacumab-dgnb	42	4	27	27	34	240	34.4	33.9
Female	31	4	27	27	34	62	29.0	10.7
Male	11	25	27	27	34	240	49.4	63.5
Trilaciclib	0
Female	0
Male	0
Casimersen	26	1	6	13	15	103	16.5	20.8
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	26	1	6	13	15	103	16.5	20.8
Fosdenopterin	0
Female	0
Male	0
Melphalan Flufenamide	44	10	27	27	41	91	33.8	14.4
Female	21	21	27	27	41	75	34.6	13.3
Male	23	10	26	27	41	91	33.1	15.6
Tivozanib	293	1	3	6	15	130	13.5	20.3
Female	75	1	3	6	17	130	15.4	22.9
Male	218	1	2	6	14	123	12.8	19.4
Ponesimod	54	1	3	8	12	43	9.6	8.7
Female	37	1	3	6	12	43	9.1	9.2

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	17	1	6	9	11	31	10.6	7.8
Dasiglucagon	126	1	3	21	78	421	61.0	91.7
Female	73	1	3	16	56	361	49.8	79.7
Male	53	1	4	32	96	421	76.6	104.8
Viloxazine	3,193	1	3	8	19	469	18.3	31.6
Female	1,290	1	4	9	19	333	18.7	31.0
Male	1,903	1	3	8	19	469	18.0	32.0
Drospirenone and Estetrol	1,247	1	4	10	29	385	25.3	42.9
Female	1,246	1	4	10	29	385	25.3	42.9
Male	1	17	17	17	17	17	17.0	NaN
dostarlimab-gxly	79	19	20	20	21	135	25.5	16.5
Female	55	19	20	20	23	82	25.5	12.4
Male	24	19	20	20	20	135	25.7	23.7
Loncastuximab Tesirine-lpyl	242	3	20	20	22	145	23.5	11.2
Female	100	3	20	20	23	145	25.0	15.2
Male	142	12	20	20	21	62	22.4	7.1
Serdexmethylphenidate and Dexmethylphenidate	2,093	1	3	8	19	461	17.3	29.2
Female	848	1	3	8	19	254	17.6	28.7
Male	1,245	1	3	8	19	461	17.1	29.6
Pegcetacoplan	40	1	2	4	9	108	9.6	18.3
Female	20	1	1	4	8	20	5.5	5.3
Male	20	1	2	5	11	108	13.8	25.0
Amivantamab-vmjw	267	1	5	6	13	167	9.9	13.9
Female	195	1	5	6	13	167	9.3	12.7
Male	72	4	5	6	13	121	11.7	16.8
Piflufolstat F 18	2,161	1	113	159	210	459	166.8	71.3
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	2,161	1	113	159	210	459	166.8	71.3
Sotorasib	531	1	3	7	22	394	21.4	39.9
Female	325	1	3	7	22	394	20.6	41.0
Male	206	1	3	7	20	234	22.5	38.3
Infigratinib	14	1	2	6	8	22	7.8	7.7
Female	7	1	1	5	8	21	6.6	6.9
Male	7	1	2	6	21	22	9.0	8.8
Olanzapine and Samidorphan	1,625	1	3	7	16	367	16.6	31.1

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Sex

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	877	1	3	7	17	367	17.7	33.1
Male	748	1	3	6	16	362	15.3	28.6
Ibexafungerp	368	1	8	30	74	512	56.4	73.6
Female	367	1	8	30	75	512	56.5	73.6
Male	1	16	16	16	16	16	16.0	NaN
Aducanumab-avwa	260	1	27	27	31	300	42.2	49.3
Female	143	1	27	27	30	265	36.2	33.5
Male	117	20	27	27	31	300	49.5	62.9
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	63	1	1	1	2	35	2.4	4.6
Female	19	1	1	1	2	5	1.5	1.0
Male	44	1	1	1	2	35	2.8	5.5
Cabotegravir	470	1	17	28	42	174	31.8	22.5
Female	22	3	19	34	67	82	41.9	25.9
Male	448	1	17	27	40	174	31.3	22.3

NaN: Not a Number

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vericiguat	1,533	1	3	10	26	421	23.5	39.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	21	1	3	10	38	270	39.9	71.3
41-64 years	311	1	3	9	29	334	25.6	40.3
≥ 65 years	1,201	1	3	10	25	421	22.6	38.9
Cabotegravir and Rilpivirine (co-packaged)	1,277	1	4	10	25	487	18.1	27.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	1	5	16	22	33	15.4	11.0
25-40 years	183	1	4	12	25	121	19.1	21.2
41-64 years	781	1	4	10	26	487	18.2	29.6
≥ 65 years	302	1	4	9	25	242	17.5	26.7
Voclosporin	174	1	3	10	21	318	23.2	44.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	18	1	2	5	12	77	12.4	20.0
25-40 years	77	1	3	10	19	318	21.9	44.1
41-64 years	73	1	4	12	27	318	27.4	50.8
≥ 65 years	6	1	3	15	33	71	23.0	26.4
Tepotinib	57	1	3	5	12	64	11.9	15.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	5	1	2	3	3	4	2.6	1.1
≥ 65 years	52	1	3	5	14	64	12.8	16.0
Umbrisib	31	1	2	5	15	116	12.5	22.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	4	3	6	10	64	116	34.5	54.4
≥ 65 years	27	1	2	4	15	60	9.3	12.7
Evinacumab-dgnb	42	4	27	27	34	240	34.4	33.9
0-17 years	1	27	27	27	27	27	27.0	NaN
18-24 years	1	240	240	240	240	240	240.0	NaN
25-40 years	5	25	27	27	34	40	30.6	6.3
41-64 years	19	4	27	27	34	44	27.2	11.0
≥ 65 years	16	25	27	28	34	62	31.7	9.0

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Trilaciclib	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Casimersen	26	1	6	13	15	103	16.5	20.8
0-17 years	18	6	6	13	27	103	20.2	24.0
18-24 years	6	1	6	13	13	17	10.5	5.9
25-40 years	2	1	1	2	3	3	2.0	1.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Fosdenopterin	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Melphalan Flufenamide	44	10	27	27	41	91	33.8	14.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	7	19	26	27	34	45	29.3	8.2
≥ 65 years	37	10	27	27	41	91	34.7	15.3
Tivozanib	293	1	3	6	15	130	13.5	20.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	53	1	2	4	12	110	9.2	15.7
≥ 65 years	240	1	3	6	16	130	14.4	21.1
Ponesimod	54	1	3	8	12	43	9.6	8.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	1	1	1	1	1	1.0	NaN
25-40 years	17	1	4	9	13	33	11.3	9.0
41-64 years	32	1	3	7	11	43	9.0	8.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	4	3	5	7	13	18	8.8	6.5
Dasiglucagon	126	1	3	21	78	421	61.0	91.7
0-17 years	33	1	3	21	78	279	56.6	74.3
18-24 years	11	1	1	15	69	152	39.8	55.4
25-40 years	21	1	4	19	96	365	86.0	126.5
41-64 years	51	1	3	19	82	421	56.2	91.6
≥ 65 years	10	16	27	44	48	334	71.2	95.5
Viloxazine	3,193	1	3	8	19	469	18.3	31.6
0-17 years	2,354	1	3	8	19	469	18.3	32.7
18-24 years	259	1	4	9	19	160	18.0	26.4
25-40 years	316	1	4	8	17	291	15.9	26.5
41-64 years	241	1	4	9	26	200	21.2	33.1
≥ 65 years	23	1	4	10	29	51	16.2	15.9
Drospirenone and Estetrol	1,247	1	4	10	29	385	25.3	42.9
0-17 years	165	1	3	11	31	333	25.8	41.2
18-24 years	444	1	3	10	28	354	24.3	40.9
25-40 years	476	1	4	11	31	385	26.3	44.4
41-64 years	162	1	4	9	29	373	24.8	45.2
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
dostarlimab-gxly	79	19	20	20	21	135	25.5	16.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	20	20	21	21	21	20.5	0.7
41-64 years	20	20	20	20	21	135	32.0	29.8
≥ 65 years	57	19	20	20	20	48	23.5	7.6
Loncastuximab Tesirine-lpyl	242	3	20	20	22	145	23.5	11.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	42	42	42	42	42	42.0	NaN
25-40 years	4	21	23	24	26	27	24.0	2.4
41-64 years	20	12	20	20	21	62	22.3	9.8
≥ 65 years	217	3	20	20	21	145	23.5	11.4
Serdexmethylphenidate and Dexmethylphenidate	2,093	1	3	8	19	461	17.3	29.2
0-17 years	1,324	1	3	8	20	461	17.4	30.0
18-24 years	228	1	4	9	21	200	17.9	23.9
25-40 years	296	1	3	7	17	249	16.7	29.6

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	236	1	3	8	19	249	16.6	29.1
≥ 65 years	9	1	3	6	33	95	23.1	32.2
Pegcetacoplan	40	1	2	4	9	108	9.6	18.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	6	6	10	14	14	10.0	5.7
25-40 years	6	1	3	6	8	45	11.3	16.7
41-64 years	15	1	1	3	12	108	13.5	27.1
≥ 65 years	17	1	2	4	6	31	5.5	7.3
Amivantamab-vmjw	267	1	5	6	13	167	9.9	13.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	3	5	5	5	5	5	5.0	0.0
41-64 years	49	4	5	6	13	69	11.0	12.0
≥ 65 years	215	1	5	6	13	167	9.7	14.4
Piflufolastat F 18	2,161	1	113	159	210	459	166.8	71.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	156	10	109	154	208	387	161.5	71.7
≥ 65 years	2,005	1	114	159	210	459	167.2	71.3
Sotorasib	531	1	3	7	22	394	21.4	39.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	4	4	67	130	130	67.0	89.1
41-64 years	114	1	2	5	13	265	16.4	34.7
≥ 65 years	415	1	3	8	23	394	22.5	40.9
Infigratinib	14	1	2	6	8	22	7.8	7.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	5	5	6	6	6	5.5	0.7
41-64 years	5	1	1	4	5	22	6.6	8.8
≥ 65 years	7	1	2	6	21	21	9.3	8.4
Olanzapine and Samidorphan	1,625	1	3	7	16	367	16.6	31.1
0-17 years	6	3	3	4	5	6	4.2	1.2
18-24 years	105	1	3	8	17	172	18.4	29.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023, by Age Group

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	563	1	3	7	17	367	18.1	37.7
41-64 years	802	1	3	6	16	211	15.2	25.7
≥ 65 years	149	1	3	7	18	277	17.7	31.6
lbrefafungerp	368	1	8	30	74	512	56.4	73.6
0-17 years	2	1	1	13	25	25	13.0	17.0
18-24 years	44	1	20	34	77	341	65.5	76.5
25-40 years	171	1	5	26	69	512	53.7	76.7
41-64 years	145	1	11	37	76	464	56.8	68.7
≥ 65 years	6	20	21	32	56	260	70.2	93.9
Aducanumab-avwa	260	1	27	27	31	300	42.2	49.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	7	27	27	28	35	54	32.9	9.8
≥ 65 years	253	1	27	27	31	300	42.5	49.9
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn	63	1	1	1	2	35	2.4	4.6
0-17 years	50	1	1	1	2	35	2.6	5.2
18-24 years	6	1	1	1	2	3	1.5	0.8
25-40 years	4	1	1	1	1	1	1.0	0.0
41-64 years	1	3	3	3	3	3	3.0	NaN
≥ 65 years	2	1	1	1	1	1	1.0	0.0
Cabotegravir	470	1	17	28	42	174	31.8	22.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	29	1	22	29	47	174	36.2	32.5
25-40 years	223	1	17	28	53	118	32.8	21.4
41-64 years	172	1	19	28	39	136	32.2	22.6
≥ 65 years	46	1	5	22	30	88	22.3	18.4

NaN: Not a Number

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2021

	Censoring Reason												
	End of Exposure Episode ²		Occurrence of User-Defined Censoring Criteria ³		Evidence of Death ⁴		Disenrollment ⁵		End of Data ⁶		End of Study year ⁷		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Vericiguat</i>	6,531	6,270	96.0%	0	0.0%	200	3.1%	1,724	26.4%	1,649	25.2%	0	0.0%
<i>Cabotegravir and Rilpivirine (co-packaged)</i>	5,025	4,948	98.5%	0	0.0%	*****	*****	1,238	24.6%	1,177	23.4%	0	0.0%
<i>Voclosporin</i>	781	756	96.8%	0	0.0%	*****	*****	135	17.3%	131	16.8%	0	0.0%
<i>Tepotinib</i>	272	257	94.5%	0	0.0%	17	6.3%	41	15.1%	37	13.6%	0	0.0%
<i>Umbralisib</i>	130	123	94.6%	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Evinacumab-dgnb</i>	381	381	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
<i>Trilaciclib</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Casimersen</i>	511	511	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
<i>Fosdenopterin</i>	0
<i>Melphalan Flufenamide</i>	193	193	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Tivozanib</i>	1,241	1,185	95.5%	0	0.0%	58	4.7%	183	14.7%	163	13.1%	0	0.0%
<i>Ponesimod</i>	242	234	96.7%	0	0.0%	*****	*****	67	27.7%	63	26.0%	0	0.0%
<i>Dasiglucagon</i>	933	933	100.0%	0	0.0%	0	0.0%	83	8.9%	60	6.4%	0	0.0%
<i>Viloxazine</i>	14,747	14,136	95.9%	0	0.0%	*****	*****	2,897	19.6%	2,961	20.1%	0	0.0%
<i>Drospirenone and Estetrol</i>	5,609	5,077	90.5%	0	0.0%	0	0.0%	1,549	27.6%	1,682	30.0%	0	0.0%
<i>dostarlimab-gxly</i>	434	434	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
<i>Loncastuximab Tesirine-lpyl</i>	1,207	1,206	99.9%	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Serdexmethylphenidate and Dexmethylphenidate</i>	9,532	8,911	93.5%	0	0.0%	0	0.0%	2,007	21.1%	2,353	24.7%	0	0.0%
<i>Pegcetacoplan</i>	170	165	97.1%	0	0.0%	*****	*****	51	30.0%	46	27.1%	0	0.0%
<i>Amivantamab-vmjw</i>	2,967	2,967	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2021

	Censoring Reason												
	Total Number of Episodes	End of Exposure Episode ²		Occurrence of User-Defined Censoring Criteria ³		Evidence of Death ⁴		Disenrollment ⁵		End of Data ⁶		End of Study year ⁷	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Piflufolastat F 18</i>	45,605	45,605	100.0%	0	0.0%	0	0.0%	51	0.1%	49	0.1%	0	0.0%
<i>Sotorasib</i>	2,350	2,187	93.1%	0	0.0%	151	6.4%	362	15.4%	318	13.5%	0	0.0%
<i>Infigratinib</i>	50	46	92.0%	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Olanzapine and Samidorphan</i>	7,366	7,225	98.1%	0	0.0%	20	0.3%	2,103	28.6%	1,993	27.1%	0	0.0%
<i>Ibrexafungerp</i>	2,215	2,211	99.8%	0	0.0%	0	0.0%	*****	*****	12	0.5%	0	0.0%
<i>Aducanumab-avwa</i>	1,291	1,290	99.9%	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Asparaginase Erwinia Chrysanthemi (recombinant)-rywn</i>	1,012	1,012	100.0%	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
<i>Cabotegravir</i>	1,735	1,730	99.7%	0	0.0%	0	0.0%	203	11.7%	192	11.1%	0	0.0%

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the number of the reasons for censoring may be greater than the total number of episodes.

²Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

³Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁴Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁷Represents episodes censored due to user-specified study end date.

⁸Data presented by a dash or period is due to their inability to be calculated. This table may not use all data representations.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to May 31, 2021

Censoring Reason												
Total Number of Episodes	End of Exposure Episode ²		Occurrence of User-Defined Censoring Criteria ³		Evidence of Death ⁴		Disenrollment ⁵		End of Data ⁶		End of Study year ⁷	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Vericiguat		Cabotegravir and Rilpivirine (co-packaged)		Voclosporin		Tepotinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A
Had required coverage type (medical and/or drug coverage)	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395
Enrolled during specified age range	94,739,190	731	94,739,190	731	94,739,190	731	94,739,190	731
Had requestable medical charts	94,739,190	0	94,739,190	0	94,739,190	0	94,739,190	0
Met demographic requirements (sex, race, and Hispanic origin)	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762
Members with a valid index event								
Had any cohort-defining claim during the query period	3,623	93,791,805	2,235	93,793,193	390	93,795,038	167	93,795,261
Claim recorded during specified age range	3,623	0	2,235	0	390	0	167	0
Episode defining index claim recorded during the query period	3,623	0	2,235	0	390	0	167	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	3,212	411	1,910	325	324	66	141	26
Met inclusion and exclusion criteria	3,212	0	1,910	0	324	0	141	0
Had sufficient post-index continuous enrollment	3,212	0	1,910	0	324	0	141	0
Final cohort								
Number of members	3,212	N/A	1,910	N/A	324	N/A	141	N/A

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Umbralisib		Evinacumab-dgnb		Trilaciclib		Casimersen	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A
Had required coverage type (medical and/or drug coverage)	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395
Enrolled during specified age range	94,739,190	731	94,739,190	731	94,739,190	731	94,739,190	731
Had requestable medical charts	94,739,190	0	94,739,190	0	94,739,190	0	94,739,190	0
Met demographic requirements (sex, race, and Hispanic origin)	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	*****	*****	*****	*****	*****	*****
Claim recorded during specified age range	*****	*****	*****	0	*****	0	*****	0
Episode defining index claim recorded during the query period	*****	*****	*****	0	*****	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	*****	*****	*****	*****	*****	0	*****	*****
Met inclusion and exclusion criteria	*****	0	*****	0	*****	0	*****	0
Had sufficient post-index continuous enrollment	*****	0	*****	0	*****	0	*****	0
Final cohort								
Number of members	76	N/A	49	N/A	*****	N/A	30	N/A

***** Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Fosdenopterin		Melphalan Flufenamide		Tivozanib		Ponesimod	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A
Had required coverage type (medical and/or drug coverage)	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395
Enrolled during specified age range	94,739,190	731	94,739,190	731	94,739,190	731	94,739,190	731
Had requestable medical charts	94,739,190	0	94,739,190	0	94,739,190	0	94,739,190	0
Met demographic requirements (sex, race, and Hispanic origin)	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762
Members with a valid index event								
Had any cohort-defining claim during the query period	0	93,795,428	*****	*****	678	93,794,750	123	93,795,305
Claim recorded during specified age range	0	0	*****	0	678	0	123	0
Episode defining index claim recorded during the query period	0	0	*****	0	678	0	123	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	0	0	*****	*****	632	46	106	17
Met inclusion and exclusion criteria	0	0	*****	0	632	0	106	0
Had sufficient post-index continuous enrollment	0	0	*****	0	632	0	106	0
Final cohort								
Number of members	0	N/A	87	N/A	632	N/A	106	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Dasiglucagon		Viloxazine		Drospirenone and Estetrol		dostarlimab-gxly	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A
Had required coverage type (medical and/or drug coverage)	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395
Enrolled during specified age range	94,739,190	731	94,739,190	731	94,739,190	731	94,739,190	731
Had requestable medical charts	94,739,190	0	94,739,190	0	94,739,190	0	94,739,190	0
Met demographic requirements (sex, race, and Hispanic origin)	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762
Members with a valid index event								
Had any cohort-defining claim during the query period	858	93,794,570	9,009	93,786,419	4,313	93,791,115	*****	*****
Claim recorded during specified age range	858	0	9,009	0	4,313	0	*****	0
Episode defining index claim recorded during the query period	858	0	9,009	0	4,313	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	736	122	7,859	1,150	3,472	841	*****	*****
Met inclusion and exclusion criteria	736	0	7,859	0	3,472	0	*****	0
Had sufficient post-index continuous enrollment	736	0	7,859	0	3,472	0	*****	0
Final cohort								
Number of members	736	N/A	7,859	N/A	3,472	N/A	99	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Loncastuximab Tesirine-lpyl		Serdexmethylphenidate and Dexmethylphenidate		Pegcetacoplan		Amivantamab-vmjw	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A
Had required coverage type (medical and/or drug coverage)	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395
Enrolled during specified age range	94,739,190	731	94,739,190	731	94,739,190	731	94,739,190	731
Had requestable medical charts	94,739,190	0	94,739,190	0	94,739,190	0	94,739,190	0
Met demographic requirements (sex, race, and Hispanic origin)	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762
Members with a valid index event								
Had any cohort-defining claim during the query period	363	93,795,065	5,752	93,789,676	*****	*****	322	93,795,106
Claim recorded during specified age range	363	0	5,752	0	*****	0	322	0
Episode defining index claim recorded during the query period	363	0	5,752	0	*****	0	322	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	338	25	5,031	721	*****	*****	303	19
Met inclusion and exclusion criteria	338	0	5,031	0	*****	0	303	0
Had sufficient post-index continuous enrollment	338	0	5,031	0	*****	0	303	0
Final cohort								
Number of members	338	N/A	5,031	N/A	65	N/A	303	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Piflufolastat F 18		Sotorasib		Infigratinib		Olanzapine and Samidorphan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A
Had required coverage type (medical and/or drug coverage)	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395
Enrolled during specified age range	94,739,190	731	94,739,190	731	94,739,190	731	94,739,190	731
Had requestable medical charts	94,739,190	0	94,739,190	0	94,739,190	0	94,739,190	0
Met demographic requirements (sex, race, and Hispanic origin)	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762
Members with a valid index event								
Had any cohort-defining claim during the query period	46,260	93,749,168	1,456	93,793,972	*****	*****	4,752	93,790,676
Claim recorded during specified age range	46,260	0	1,456	0	*****	0	4,752	0
Episode defining index claim recorded during the query period	46,260	0	1,456	0	*****	0	4,752	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	43,225	3,035	1,296	160	*****	*****	4,064	688
Met inclusion and exclusion criteria	43,225	0	1,296	0	*****	0	4,064	0
Had sufficient post-index continuous enrollment	43,225	0	1,296	0	*****	0	4,064	0
Final cohort								
Number of members	43,225	N/A	1,296	N/A	32	N/A	4,064	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable


Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

	Ibrexafungerp		Aducanumab-avwa		Asparaginase Erwinia Chrysanthemi (recombinant)-rywn		Cabotegravir	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A	149,908,316	N/A
Had required coverage type (medical and/or drug coverage)	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395	94,739,921	55,168,395
Enrolled during specified age range	94,739,190	731	94,739,190	731	94,739,190	731	94,739,190	731
Had requestable medical charts	94,739,190	0	94,739,190	0	94,739,190	0	94,739,190	0
Met demographic requirements (sex, race, and Hispanic origin)	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762	93,795,428	943,762
Members with a valid index event								
Had any cohort-defining claim during the query period	1,805	93,793,623	360	93,795,068	*****	*****	884	93,794,544
Claim recorded during specified age range	1,805	0	360	0	*****	0	884	0
Episode defining index claim recorded during the query period	1,805	0	360	0	*****	0	884	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,569	236	348	12	*****	*****	741	143
Met inclusion and exclusion criteria	1,569	0	348	0	*****	0	741	0
Had sufficient post-index continuous enrollment	1,569	0	348	0	*****	0	741	0
Final cohort								
Number of members	1,569	N/A	348	N/A	67	N/A	741	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.


N/A: Not Applicable

Figure 1a. Patient Entry into Study by Month for Vericiguat in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on January 19, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1b. Patient Entry into Study by Month for Cabotegravir and Rilpivirine (co-packaged) in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on January 21, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1c. Patient Entry into Study by Month for Voclosporin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on January 22, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1d. Patient Entry into Study by Month for Tepotinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on February 3, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1e. Patient Entry into Study by Month for Umbralisib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on February 5, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1f. Patient Entry into Study by Month for Evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on February 11, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1g. Patient Entry into Study by Month for Trilaciclib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on February 12, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1h. Patient Entry into Study by Month for Casimersen in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on February 25, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1i. Patient Entry into Study by Month for Fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on February 26, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1j. Patient Entry into Study by Month for Melphalan Flufenamide in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on February 26, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1k. Patient Entry into Study by Month for Tivozanib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on March 10, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1I. Patient Entry into Study by Month for Ponesimod in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on March 18, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1m. Patient Entry into Study by Month for Dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023




The FDA approval date for this drug was on March 22, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1n. Patient Entry into Study by Month for Viloxazine in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on April 2, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 10. Patient Entry into Study by Month for Drospirenone and Estetrol in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on April 15, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1p. Patient Entry into Study by Month for dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on April 22, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1q. Patient Entry into Study by Month for Loncastuximab Tesirine-Ipyl in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on April 23, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1r. Patient Entry into Study by Month for Serdexmethylphenidate and Dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on March 2, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1s. Patient Entry into Study by Month for Pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on May 14, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1t. Patient Entry into Study by Month for Amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on May 21, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1u. Patient Entry into Study by Month for Piflufolostat F 18 in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on May 26, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1v. Patient Entry into Study by Month for Sotorasib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023




The FDA approval date for this drug was on May 28, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1w. Patient Entry into Study by Month for Infigratinib in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on May 28, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1x. Patient Entry into Study by Month for Olanzapine and Samidorphan in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023




The FDA approval date for this drug was on May 28, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1y. Patient Entry into Study by Month for Ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on June 1, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1z. Patient Entry into Study by Month for Aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023




The FDA approval date for this drug was on June 7, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1aa. Patient Entry into Study by Month for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023

The FDA approval date for this drug was on June 30, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1ab. Patient Entry into Study by Month for Cabotegravir in the Sentinel Distributed Database from January 1, 2021 to May 31, 2023



The FDA approval date for this drug was on December 20, 2021 as listed on the FDA website <https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention>

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 21, 2023)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	05/31/2023
DP02	01/01/2004	11/30/2022
DP03	01/01/2008	04/30/2023
DP04	01/01/2006	02/28/2023
DP05	01/01/2000	04/30/2023
DP06	01/01/2008	12/31/2022
DP07	01/01/2005	07/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	08/31/2022
DP10	01/01/2007	01/31/2023
DP11	01/01/2000	10/31/2022
DP12	01/01/2010	12/31/2022

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Proprietary and Non-proprietary Names of Medical Products Used to Define Exposures in this Request

Non-proprietary Name	Proprietary Name
	vericiguat
vericiguat	Verquvo
	cabotegravir and rilpivirine co-packaged
cabotegravir and rilpivirine (co-packaged)	Cabenuva
	cabotegravir
cabotegravir	Apretude
cabotegravir	cabotegravir
cabotegravir sodium	Vocabria
	voclosporin
voclosporin	Lupkynis
	tepotinib
tepotinib HCl	Tepmetko
	umbralisib
umbralisib tosylate	Ukoniq
	evinacumab-dgnb
evinacumab-dgnb	Evkeeza
	trilaciclib
trilaciclib dihydrochloride	Cosela
	casimersen
casimersen	Amondys-45
	fosdenopterin
fosdenopterin hydrobromide	Nulibry
	melphalan flufenamide
melphalan flufenamide hydrochloride	Pepaxto
	tivozanib HCl
tivozanib HCl	Fotivda
	ponesimod
ponesimod	Ponvory
ponesimod	Ponvory 14-Day Starter Pack
	dasiglucagon HCl
dasiglucagon HCl	Zegalogue Autoinjector
dasiglucagon HCl	Zegalogue Syringe
	viloxazine HCl
viloxazine HCl	Qelbree
	drospirenone/estetrol
drospirenone/estetrol	Nextstellis
	dostarlimab-gxly

Appendix B. List of Proprietary and Non-proprietary Names of Medical Products Used to Define Exposures in this Request

Non-proprietary Name	Proprietary Name
dostarlimab-gxly	Jemperli
	loncastuximab
loncastuximab tesirine-lpyl	Zynlonta
	serdexmethylphenidate
serdexmethylphenidate chloride/dexmethylphenidate HCl	Azstarys
	pegcetacoplan
pegcetacoplan	Empaveli
	amivantamab-vmjw
amivantamab-vmjw	Rybrevant
	piflufolastat F-18
piflufolastat F 18	Pylarify
	sotorasib
sotorasib	Lumakras
	infigratinib phosphate
infigratinib phosphate	Truseltiq
	olanzapine
olanzapine/samidorphane malate	Lybalvi
	ibrexafungerp citrate
ibrexafungerp citrate	Brexafemme
	aducanumab-avwa
aducanumab-avwa	Aduhelm
	asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)-rywn	Rylaze

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
cabotegravir and rilpivirine co-packaged			
C9077	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	Procedure	HCPCS
J0741	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	Procedure	HCPCS
cabotegravir			
J0739	Injection, cabotegravir, 1 mg	Procedure	HCPCS
evinacumab			
C9079	Injection, evinacumab-dgnb, 5 mg	Procedure	HCPCS
J1305	Injection, evinacumab-dgnb, 5 mg	Procedure	HCPCS
casimersen			
C9075	Injection, casimersen, 10 mg	Procedure	HCPCS
J1426	Injection, casimersen, 10 mg	Procedure	HCPCS
melphalan flufenamide			
C9080	Injection, melphalan flufenamide HCl, 1 mg	Procedure	HCPCS
J9247	Injection, melphalan flufenamide, 1 mg	Procedure	HCPCS
dostarlimab-gxly			
C9082	Injection, dostarlimab-gxly, 100 mg	Procedure	HCPCS
J9272	Injection, dostarlimab-gxly, 10 mg	Procedure	HCPCS
loncastuximab			
C9084	Injection, loncastuximab tesirine-lpyl, 0.1 mg	Procedure	HCPCS
J9359	Injection, loncastuximab tesirine-lpyl, 0.075 mg	Procedure	HCPCS
amivantamab-vmjw			
C9083	Injection, amivantamab-vmjw, 10 mg	Procedure	HCPCS
J9061	Injection, amivantamab-vmjw, 2 mg	Procedure	HCPCS
piflufolastat F-18			
A9595	Piflufolastat F-18, diagnostic, 1 mCi	Procedure	HCPCS
aducanumab-avwa			
J0172	Injection, aducanumab-avwa, 2 mg	Procedure	HCPCS
asparaginase Erwinia chrysanthemi			
J9021	Injection, asparaginase, recombinant, (Rylaze), 0.1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
Acute Myocardial Infarction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Alzheimers			
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnesic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Diabetes			
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

		Code	
Code	Description	Category	Code Type
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Depression			
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Rheumatoid Arthritis/Osteoarthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Stroke/ TIA			
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Prostate Cancer			
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Endometrial Cancer			
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
COPD and Bronchiectasis			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Glaucoma			
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

		Code	
Code	Description	Category	Code Type
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code		Description	Code Category	Code Type
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage		Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified		Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage		Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage		Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage		Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage		Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified		Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage		Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage		Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage		Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage		Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified		Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage		Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage		Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage		Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage		Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified		Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage		Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage		Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage		Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage		Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified		Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage		Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage		Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage		Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage		Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified		Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage		Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage		Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage		Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage		Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified		Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage		Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage		Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage		Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage		Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye		Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye		Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral		Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye		Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye		Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye		Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral		Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM

Osteoporosis

M80.00X	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.049 A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051 A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052 A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059 A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061 A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062 A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069 A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071 A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072 A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079 A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08X A	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AX A	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80X A	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811 A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812 A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819 A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821 A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822 A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829 A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831 A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832 A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.839 A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841 A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842 A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849 A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851 A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852 A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859 A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861 A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862 A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869 A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871 A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872 A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879 A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88X A	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AX A	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Drug Abuse or Dependence			
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

		Code	
Code	Description	Category	Code Type
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

		Code	
Code	Description	Category	Code Type
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Obesity (diagnosis/procedure)			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Smoking (diagnosis/procedure)			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Alcohol Abuse or Dependence			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code	
		Category	Code Type
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
History of Cardiac Arrest			
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
History of Coronary Angioplasty or Bypass			
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM

Appendix E. List of Proprietary and Non-proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-proprietary Name	Proprietary Name
Obesity (prescription)	
amino acids/multivit-minerals/dietary supplement/protein sup	Optifast 70
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
diethylpropion HCl	diethylpropion HCl (bulk)
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl	phentermine HCl (bulk)
phentermine HCl/topiramate	Qsymia
resveratrol/chromium pico/green tea/EGCG/caffeine/digestive3	Resveratrol Diet
Smoking (prescription)	
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate

Appendix E. List of Proprietary and Non-proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-proprietary Name	Proprietary Name
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, to assess utilization and uptake of the 2021, part 1 (Approved January 2021-June 2021) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Query period: 01/01/2021 - Most recent available data
Coverage requirement: Medical and Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index requirement: 0 days
Enrollment gap: 45 days
Age groups: 0-17, 18-24, 25-40, 41-64, 65+ years
Stratifications: Age group, Sex, Calendar Month
Restrictions: Male and Female
Distribution of index-defining codes: No
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	vericiguat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
2	cabotegravir and rilpivirine (co- packaged)	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	voclosporin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	tepotinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	umbralisib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
6	evinacumab-dgnb	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	trilaciclib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	casimersen	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	fosdenopterin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	melphalan flufenamide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
11	tivozanib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	ponesimod	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	dasiglucagon	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	viloxazine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
15	drospirenone and estetrol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	dostarlimab-gxly	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	loncastximab tesirine-lpyl	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
18	serdexmethylphenid ate and dexmethylphenidate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	pegcetacoplan	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
20	amivantamab-vmjw	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	piflufolastat F 18	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
22	sotorasib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	infigratinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
24	olanzapine and samidorphan	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	ibrexafungerp	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
26	aducanumab-avwa	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
27	asparaginase erwinia chrysanthemi (recombinant)-rywn	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
28	cabotegravir	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.
National Drug codes (NDC) are checked against First Data Bank's FDB MedKnowledge®
N/A: Not Applicable

Appendix G. Baseline Characteristics for this Request

Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Acute Myocardial Infarction (AMI)	1	IPP, IPS	-183	-1	n/a	1	N/A
Alzheimer's Disease and related conditions	2	Any	-183	-1	n/a	1	N/A
Atrial Fibrillation	3	IPP, IPS	-183	-1	n/a	1	N/A
	4	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	5	IPP, IPS OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Diabetes	6	IP*, IS*	-183	-1	n/a	1	N/A
	7	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	8	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Heart Failure	9	IP*, AV*, ED*, OA*	-183	-1	n/a	1	N/A
Hyperlipidemia	10	IP*, IS*	-183	-1	n/a	1	N/A
	11	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	12	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Hypertension	13	IP*, IS*	-183	-1	n/a	1	N/A
	14	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	15	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Depression	16	Any	-183	-1	n/a	1	N/A
Ischemic Heart Disease	17	Any	-183	-1	n/a	1	N/A

Appendix G. Baseline Characteristics for this Request

Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
Rheumatoid Arthritis/Osteoarthritis	18	Any	-183	-1	n/a	2	N/A
Stroke/Transient Ischemic Attack (TIA)	19	IP*	-183	-1	n/a	1	N/A
	20	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	21	IP* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Breast Cancer	22	IP*, IS*	-183	-1	n/a	1	N/A
	23	AV*, ED* OA*	-183	-1	n/a	2	N/A
	24	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Colorectal Cancer	25	IP*, IS*	-183	-1	n/a	1	N/A
	26	AV*, ED* OA*	-183	-1	n/a	2	N/A
	27	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Prostate Cancer	28	IP*, IS*	-183	-1	n/a	1	N/A
	29	AV*, ED* OA*	-183	-1	n/a	2	N/A
	30	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Lung Cancer	31	IP*, IS*	-183	-1	n/a	1	N/A
	32	AV*, ED* OA*	-183	-1	n/a	2	N/A
	33	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Endometrial Cancer	34	IP*, IS*	-183	-1	n/a	1	N/A
	35	AV*, ED* OA*	-183	-1	n/a	2	N/A
	36	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Acquired Hypothyroidism	37	IP*, IS*	-183	-1	n/a	1	N/A
	38	AV*, ED* OA*	-183	-1	n/a	2	N/A
	39	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Anemia	40	Any	-183	-1	n/a	1	N/A
Asthma	41	IP*, IS*	-183	-1	n/a	1	N/A
	42	AV*, ED* OA*	-183	-1	n/a	2	N/A
	43	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Benign Prostatic Hyperplasia	44	IP*, IS*	-183	-1	n/a	1	N/A
	45	AV*, ED* OA*	-183	-1	n/a	2	N/A
	46	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A

Appendix G. Baseline Characteristics for this Request

Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
Chronic Kidney Disease	47	IP*, IS*	-183	-1	n/a	1	N/A
	48	AV*, ED* OA*	-183	-1	n/a	2	N/A
	49	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
COPD and Bronchiectasis	50	IP*, IS*	-183	-1	n/a	1	N/A
	51	AV*, ED* OA*	-183	-1	n/a	2	N/A
	52	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Glaucoma	53	AV*, ED*, OA*	-183	-1	n/a	1	N/A
Osteoporosis	54	IP*, IS*	-183	-1	n/a	1	N/A
	55	AV*, ED* OA*	-183	-1	n/a	2	N/A
	56	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
<i>Other</i>							
Obesity: diagnosed or identified by weight management procedures	57	Any	-183	-1	n/a	1	N/A
Obesity: identified by weight management-related prescriptions	58	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	59	Any	-183	-1	n/a	1	N/A
Smoking: diagnosed or identified by smoking cessation procedures	60	Any	-183	-1	n/a	1	N/A

Appendix G. Baseline Characteristics for this Request

Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation period	Forced supply to attach to dispensing
Smoking: identified by smoking-related prescriptions	61	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	62	Any	-183	-1	n/a	1	N/A
Drug Abuse or Dependence	63	Any	-183	-1	n/a	1	N/A
History of Cardiac Arrest	64	Any	-183	-1	n/a	1	N/A
History of Coronary Angioplasty or Bypass	65	Any	-183	-1	n/a	1	N/A

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Secondary) uses the second diagnosis position.

N/A: Not Applicable

¹Care setting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.


Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital.

'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

Appendix H. Query Design Diagram for this Request



¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² 28 scenarios defined on initiation of NMEs approved in 2021 part 1 (one scenario per NME); Cohort entry date=first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date